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Investigations into the stability of growth factor induced-
vasculature and the effects of synthetic biomaterials on heart 
remodelling after myocardial infarction 
 
ABSTRACT 
 
In recent years, therapeutic neovascularization has emerged as a promising strategy to treat a 
number of cardiovascular pathologies, yet the creation of stable vasculature is still a major 
challenge for which no adequate solution currently exists. Numerous strategies, including 
delivery of growth factors and employment of biomaterial scaffolds, have been proposed to 
address this problem. However, these approaches have yet to be widely adopted or validated, 
perhaps because there is inadequate knowledge of the appropriate growth factor dosage rates 
and material compositions for such a purpose. This work was based on the hypothesis that 
optimization of growth factor delivery rate and duration, combined with a biomaterial scaffold, 
could lead to an improved strategy for therapeutic neovascularization. To test this hypothesis, a 
novel in vivo model system that allows for characterization of stability and mural cell investment 
of newly created vessels was designed. Using this model, the effects of numerous growth factors 
on vessel development were tested, with vascular endothelial growth factor-A165 (VEGF) 
emerging as the most potent initiator of neovascularization in initial experiments. Subsequent 
studies revealed that VEGF concentration plays a critical role in the nature and persistence of 
neovessels in a biomaterial scaffold. When VEGF was delivered at 150ng/day for 42 days, 
scaffold neovessels were found to be stable for up to 2.5 months after withdrawal of VEGF. At 
this timepoint, vessels induced by a 10-fold higher concentration of VEGF had regressed to 
levels comparable with PBS controls. Upon identifying advantageous delivery conditions for 
VEGF to induce therapeutic neovascularization, a rat myocardial infarction model was employed 
to investigate whether these findings might be applied in the setting of myocardial ischemia, as 
this remains one of the major pathologies hypothesized to benefit greatly from therapeutic 
neovascularization. In this model, VEGF delivery was combined with an injectable polyethylene 
glycol (PEG) hydrogel, which had previously been shown to effectively deliver VEGF in vivo. 
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Surprisingly, injection of non-degradable PEG hydrogels alone revealed that synthetic 
biomaterial injections into infarcted myocardium could result in retardation of post-infarct left-
ventricular remodelling. Importantly though, despite using a non-degradable material, the 
beneficial effects observed - complete prevention of wall thinning and significant (33.3% and 
43.3%) reductions in end-diastolic diameter increase at 2 and 4 weeks - did not persist until the 
3-month time-point. An additional hypothesis, that enzymatically degradable hydrogels could be 
a required compromise to overcome the inflammatory response observed with non-degradable 
PEG whilst still providing mechanical support, was not supported by further experiments. Finally, 
the potential of enzymatically degradable PEG hydrogels for the sustained delivery of growth 
factors to the myocardial infarct (injury) site and promotion of angiogenesis was tested. 
Prolonged VEGF delivery did not lead to improved left ventricular function after myocardial 
infarction. These findings suggest that not only are the time and mode of growth factor delivery 
critical variables that determine the efficacy of therapeutic angiogenesis, but also that the PEG 
hydrogel described may need further refinement to allow for its use as a growth factor delivery 
vehicle in context of myocardial ischemia. 
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1. INTRODUCTION 
 
Cardiovascular disease (CVD) is the most common cause of death in the industrialized world 
today.  In 2005, CVD accounted for 35.2% of all deaths in the United States1. Risk factor 
identification, an emphasis on disease prevention, the development of novel drugs and advances 
in invasive medical therapies have contributed to declining death rates from cardiovascular 
disease. Yet the socioeconomic burden of these diseases remains high. A drop off in mortality 
resulting from myocardial infarction (MI) observed in recent decades was paralleled by an 
increase in the incidence of heart failure (HF) 2, with up to one third of patients developing heart 
failure after a coronary attack. Furthermore, the rising epidemic of Diabetes Mellitus will 
contribute to a substantial increase in peripheral arterial disease over the next decades3-5. In all 
more than 80 million American adults presently suffer from one or more types of cardiovascular 
disease. The cost of CVD in 2008, estimated at $448.5 billion1, underlines that new therapies 
and effective strategies to prevent cardiovascular disease are urgently needed. Over the last 10 
years, promoting angiogenesis - the formation of new blood vessels - has emerged as one of the 
more promising concepts to treat cardiovascular disease6. While progress has been made in 
understanding basic mechanisms regulating therapeutic angiogenesis, the translation into clinical 
practice has been disappointing. A major obstacle remains the establishment of a stable mature 
neovasculature. The future success of therapeutic angiogenesis will depend on developing 
strategies to minimize the leakiness of newly generated vessels and to create a vascular bed that 
resists regression at least for months, if not years. 
  
1.1. History of Angiogenesis 
 
The 1971 New England Journal of Medicine publication by the late Judah Folkman stating that 
tumour growth is angiogenesis-dependent can be viewed as the beginning of the modern era of 
angiogenesis research 7. Folkman not only predicted that without developing a microvasculature 
most tumours would be restricted to a size of 1-2 millimetres and that tumours would be capable 
of secreting molecules promoting the growth of the microvasculature, he also anticipated the 
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discovery of angiogenesis inhibitors that would make it possible to prevent the arising of new 
capillary sprouts 7. Still, it required developing methods to culture endothelial cells8,9, assays to 
assess angiogenesis in vivo, and discovering the first angiogenic growth factor, basic fibroblast 
growth factor (bFGF/FGF2) in the 1970´s10, to silence many sceptics. The first successful use of 
anti-angiogenic therapy to treat a teenage patient suffering from progressive pulmonary 
haemangiomatosis was reported in 198811,12. Based on experimental evidence and its anti-
angiogenic properties elucidated in animal studies, Judah Folkman had suggested low-dose 
interferon-α after conventional therapies had failed. 
In 1989, another pro-angiogenic protein, vascular endothelial growth factor A (VEGF-A) 13 was 
discovered, and the first angiogenesis inhibitor, thrombospondin-114,15, was identified. While most 
research was initially directed towards limiting angiogenesis to prevent tumours from growing, 
the idea of promoting microvascular growth to improve perfusion and recover function in 
ischemic tissues appealed to cardiovascular researchers.  
The concept of using angiogenic factors was based on Folkman’s research on tumours and 
proposed as early as 1977. 15 years later, Yanagisawa-Miwa et al. 16 and Jeffrey M Isner’s group 
in 1994 were amongst the first to report the potential benefits of therapeutic angiogenesis17.  
 
1.2. Angiogenesis and Vasculogenesis 
 
Angiogenesis is instrumental during the growth and repair of organs. A transitory physiological 
angiogenic response can be observed during wound healing or during the female reproductive 
cycle18,19. An imbalance or chronic activation may on the other hand lead to cancer or the 
promotion of arthritis or proliferative retinopathy6. 
 
Historically discussed separately, it is becoming increasingly clear that during embryonic as well 
as during adult life, the two main mechanisms that contribute to neovascularization, 
vasculogenesis and angiogenesis20, are not mutually exclusive21. Vasculogenesis describes the 
de novo development of blood vessels from progenitor cells, the prime example being the 
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formation of the primary capillary plexus by differentiating angioblasts during embryonic 
development20. The growth of new blood vessels by sprouting and extension from the pre-
existing vasculature is referred to as angiogenesis (or sprouting angiogenesis) and can further be 
distinguished from non-sprouting angiogenesis, during which a vessel splits into two by forming a 
transcapillary pillar or posts of extracellular matrix (ECM)20. Vasculogenesis and angiogenesis 
simultaneously contribute to the expanding neovasculature during wound healing, tumour growth 
or inflammation21. 
 
A first hint that vasculogenesis might indeed occur and contribute to neovascularization in adult 
life stems from a 1997 study by Asahara et al.22, suggesting that a subset of CD34+ human 
endothelial progenitor cells could differentiate into cells that show characteristics comparable 
with endothelial cells. Young and his colleagues confirmed the hypothesis in 2002, when they 
showed that endothelial progenitor cells (EPCs) derived from the bone marrow integrate into the 
vasculature of newly born mice23. Both pro-24-27 and anti-angiogenic28,29 stimuli have since been 
shown to operate by affecting endothelial progenitor cells. EPCs not only play a significant role 
during pathological angiogenesis, they also contribute to vascular quiescence and homeostasis30 
and as a source of angiogenic factors modulate angiogenesis and vasculogenesis. 
 
1.3. Molecular mechanisms of angiogenesis 
 
The endothelial cell (EC) is the primary cell involved in angiogenesis31. Activation of the EC 
marks the beginning of the angiogenic response. ECs then acquire invasive, migratory and 
proliferative characteristics32,33.  
By blocking a stabilizing signal usually transmitted through the Angiopoietin-1 (Ang-1) – Tie-2 
axis, Angiopoietin-2 (Ang-2) plays a prominent role in destabilizing the vessel by promoting the 
detachment of pericytes and smooth muscle cells (SMCs)34. The VEGF and Notch signalling 
pathways orchestrate the EC sprouting and migration by breaking up cell adhesion proteins, 
such as vascular endothelial cadherin, claudins and occludin and loosening inter-endothelial cell 
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contacts35-37. ECs then invade and break down the extracellular matrix, migrate towards an 
angiogenic stimulus/gradient, proliferate and reorganize into a new vascular sprout38. While tip 
cells, a group of selected endothelial cells, instigate the new sprout and migrate towards a VEGF 
gradient 39-42, the activation of Notch receptor in the remaining stalk cells compromises the ability 
of those cells to respond to VEGF 43 by increasing the ratio of VEGFR1 to VEGFR2. As a 
consequence, stalk cells proliferate to form the body of the extending capillary. During vessel 
sprouting, the extracellular matrix undergoes extensive remodelling mediated by proteinases, 
including matrix metalloproteinases (MMPs) and plasminogen activators44-48. This delicate 
process is controlled by their respective inhibitors, the tissue inhibitors of matrix 
metalloproteinases (TIMPs) and plasminogen activator inhibitor (PAI-1) ensuring a balance 
between degradation of the extracellular matrix, thereby providing space for the sprouting vessel, 
while preventing excessive ECM breakdown that would lead to the removal of critical support and 
guidance signals and possibly vessel collapse44,49-52. Once the sprout has reached its final length, 
the endothelial cells differentiate, form a lumen and a new basement membrane is synthesized44. 
 
1.4. Stabilization of the neovasculature 
 
After the formation of a new vessel, the recruitment of mural cells helps to stabilize the immature 
vasculature53. Multiple molecular pathways regulate this process, referred to as arteriogenesis. 
One of the mechanisms characterized best is the recruitment of pericytes expressing the platelet-
derived growth factor receptor-β [(PDGFR)-β] by endothelial cells secreting platelet-derived 
growth factor-B (PDGF-B)54. Ang-1, secreted by perivascular cells, also plays a prominent role in 
vessel maturation55 by assisting the interaction of ECs with both mural cells and the extracellular 
matrix, as does TGF-β through promoting extracellular matrix deposition and differentiation of 
mesenchymal to mural cells 56-58. Recent evidence suggests that platelet-derived growth factor 
receptor β-positive (PDGFRβ+) perivascular progenitor cells (PPCs) can be recruited to sites of 
active vascular remodelling from the bone marrow that also contribute to vessel maturation 59,60. 
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1.5. Neovascular regression 
Creating stable vascular networks after growth factor delivery remains challenging and the 
strategies will likely differ from tissue to tissue. While prolonged exposure to a single growth 
factor (VEGF) has been shown to result in the creation of persisting neovessels in heart and 
liver61, overexpression of VEGF in the trachea was described to consistently lead to a regression 
of the induced neovasculature, independent of the duration of growth factor exposure62. 
Therefore, tissue-specific differences in the recruitment of supporting mural vascular cells likely 
exist. In some tissues prolonged exposure to a single growth factor may allow the establishment 
of signalling gradients necessary to recruit supporting vascular mural cells while in others a 
diverse set of angiogenic growth signals may be required for the recruitment of support cells to 
achieve vascular stability. Apart from supporting mural cells, neovessel stability may benefit from 
the early establishment of blood flow, as exposure to mechanical shear stress during laminar 
blood flow has been identified as a critical regulator of EC apoptosis63. Transduction of these 
mechanical stresses has been described to culminate in the activation of pro-survival signalling 
pathways, such as PI3K/Akt64-66, while a reduction in shear stress has been linked to elevated 
levels of MMPs (e.g. MMP-2, MMP-9, MT1-MMP) 67-69, which may critically modify EC 
interactions with the extracellular matrix. Increasing evidence suggests that while membrane-
type MMPs control EC tube formation46,70-73, an important function of secreted MMPs, such as 
MMP-1, MMP-9 and MMP-10, is regulating vascular regression74,75. The extracellular matrix is 
thus not only inherently involved in the regulation of the initiation of angiogenesis and lumen 
formation, but also in promoting vascular stability44. 
 
Recent evidence suggests that clinical trials to promote neovascularization and the recovery of 
ischemic tissues after injury may have been hampered by the inability to create a stable vascular 
network76. Developing more efficient approaches will likely depend on acquiring a deeper 
understanding of the mechanisms involved in both promoting a mature vascular phenotype and 
governing neovascular regression.   
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1.6. Growth factors and angiogenesis  
As growth factors are a central focus of this study, their involvement in angiogenesis is reviewed 
in some detail in the following section. 
 
1.6.1. VEGF A  
Vascular endothelial growth factor A was first identified by Senger and colleagues77 in 1983. 
Found in the supernatant of a guinea pig tumour cell line, it was originally named vascular 
permeability factor (VPF) due to its striking ability to enhance vascular permeability. A few years 
later, in 1989, Ferrara and colleagues successfully isolated this protein from the supernatant of 
bovine pituitary cells13 giving it its current name, vascular endothelial growth factor. Subsequent 
sequencing would later disclose the two proteins to be identical.  
 
To date, the human VEGF family encompasses 5 members: Placental growth factor (PlGF), 
VEGF-A, VEGF-B, VEGF-C and VEGF-D78. As part of the VEGF/PDGF super-gene family79, 
these growth factors share a number of characteristic features: their homodimeric structure, 
conservation of 8 cysteines at distinct positions and three disulfide bonds (S-S) that form three 
loops within the peptide. 
 
The name-giving attribute of VEGF-A is its potent stimulatory effect on vascular endothelial cells. 
By promoting vascular endothelial cell growth, survival, migration and the formation of tubules 80-
82, VEGF-A has emerged as a major conductor of the angiogenic response, for example during 
cyclical angiogenesis in female reproductive organs19. VEGF-A increases vascular permeability, 
promotes monocyte chemotaxis83 and is involved in the recruitment of vascular endothelial 
growth factor receptor 1+ (VEGFR1+) inflammatory cells [VEGFR1+-haematopoietic stem cells 
(HSCs)]. The important interaction between VEGF and the chemokine stromal-cell derived 
factor-1, whose receptor CXCR4 is expressed on endothelial progenitor cells (EPCs), raises the 
possibility that co-mobilisation of EPCs and HSCs and recruitment to areas of active 
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neovascularisation is essential for angiogenesis 24,84 and the remodelling of the extracellular 
matrix 25,85,86.  
 
VEGF-A isoforms mainly differ in their heparin-binding ability, which is an important determinant 
of their bioavailability. Whereas VEGF-A 121 is freely diffusible, the isoforms 189 and 206 are 
almost entirely bound to the extracellular matrix or cell surfaces78. VEGF-A 165 shows more 
balanced properties and is significantly available in both the free as well as the heparin-bound 
form.  
 
VEGF exerts its effects by binding to a family of tyrosine kinase receptors, VEGFR1, -2 and -378. 
The receptors consist of an extracellular ligand-binding domain, arranged in 7 immunoglobulin-
like domains, apart from VEGFR3, in which 1 domain is replaced by a disulfide bridge, a 
transmembrane spanning region and the intracellular portion containing the tyrosine kinase 
domain. While VEGF-A binds to VEGFR1 and -2, PlGF and VEGF-B exclusively bind to 
VEGFR1, VEGF-C and VEGF-D mediate their actions via VEGFR2 and VEGFR378. 
 
Knockout studies have revealed essential roles during development for both VEGF-A and its 
receptors. Inactivation of a single VEGF-A allele results in embryonic lethality between days 11 
and 1287. VEGFR1, also known as Flt-1, is indispensable for the normal development of blood 
vessels during embryogenesis88,89. Mice lacking VEGFR2 die between day 8.5 and 9.5 in utero 
owing to an inadequate vasculogenic response and failure to form blood-islands90. 
 
VEGF-A transmits its main mitogenic, angiogenic (chemotactic and pro-survival signal) and 
permeability-enhancing effects via VEGFR2 (human form also known as KDR, mouse: Flk-1)78. 
VEGFR1 has been shown to compete with VEGFR2 for VEGF-A, and by acting as a trap for 
VEGF-A, a role for VEGFR1 as a regulator for the pro-angiogenic effects - induced by VEGF-A 
through VEGFR2 - has been suggested91,92. Soluble VEGFR1 has previously been shown to be 
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responsible for the avascularity of the cornea93. VEGFR3 (Flt-4) is primarily located on lymphatic 
endothelial cells and is essential for lymphatic endothelial cell development and function94.  
 
After VEGF binds to the extracellular binding domain, the receptor molecules dimerize thereby 
activating the intracellular tyrosine kinase78. The two main signal transduction pathways activated 
via VEGFRs are the Phospholipase Cγ (PLCγ) pathway95 and the PI3K pathway96. The PI3K 
pathway is switched on downstream of VEGFR2 and-396. Through the activation of Akt, also 
known as protein kinase B, this pathway mediates EC survival97. It is also involved in controlling 
the actin cytoskeleton and thus important for EC migration and vascular tube formation. 
Interestingly, binding of different ligands to the VEGFRs initiates selective phosphorylation site 
patterns and differential downstream signalling (VEGF-A98 and PlGF99 after binding to VEGFR1).  
The transmission of signals via the VEGFRs can be switched off either by dephosphorylation100 
(by phosphotyrosine phosphatases) or by internalization and/or degradation of the receptor96. 
Apart from the VEGFRs 1-3, a few co-receptors exist, n mely neuropilins and heparan sulfate 
(HS) proteoglycans (HSPGs), which adjust downstream VEGF signalling. Neuropilin-1 more 
efficiently presents VEGF165 to VEGFR2 thereby promoting the transduction of its signal101. 
 
Via the transcription factor hypoxia inducible factor 1 (HIF-1α), oxygen tension is a major 
regulator of VEGF gene expression102. A binding site for HIF-1α has been discovered in the 
promoter region of the VEGF gene103. Several growth factors have also been shown to up-
regulate VEGF expression, amongst them EGF (endothelial growth factor), TGF-α, TGF-β, 
keratinocyte growth factor (KGF), IGF-1 (insulin-like growth factor), FGF and PDGF104-106. 
Inflammatory cytokines like IL-1-α and IL-6107,108 or oncogenic mutations109-111(ras, wnt-signalling 
pathway) may also alter VEGF gene expression. 
 
To date, VEGF-A represents one of the most investigated growth factors for therapeutic 
angiogenesis and besides FGF remains the only one previously tested in phase III clinical trials. 
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1.6.2. VEGF-C 
Vascular endothelial growth factor C signals via VEGFR2 and -394,112 and is critically involved in 
the development of the lymphatic vasculature. At active sites of lymphatic vessel development, 
VEGF-C is expressed along with VEGFR3113,114. Gene targeting studies have substantiated the 
importance of VEGF-C for the development of the lymphatic vasculature, showing that mice 
lacking VEGF-C die between day 15.5 and 17.5 in utero due to severe tissue oedema resulting 
from their failure to develop lymphatic vessels113. In tumour models, cells overexpressing VEGF-
C have been associated with increased lymphangiogenesis and a higher potential to invade the 
lymphatic system115-117. 
 
It has also been demonstrated that VEGF-C is capable of inducing a strong angiogenic 
response. Cao and colleagues reported that VEGF-C stimulates the proliferation and chemotaxis 
of porcine ECs118. A pro-survival effect on ECs and a potential to enhance migration have also 
been described115. In a mouse cornea angiogenesis ass y, VEGF-C delivery generated capillary 
sprouts at a high density comparable to VEGF-A118. When the lymphatic vasculature was also 
examined, VEGF-C was shown to create a comparable number of both blood and lymphatic 
vessels119. Due to the decreased leakiness of the neovasculature compared to VEGF-A induced 
neovessels, the study authors even suggested VEGF-C as a potential alternative angiogenic 
growth factor to its family member119. In a variety of other animal models such as the chicken 
embryo chorioallantoic membrane118,120,121 and a mouse ischemic hindlimb model122, the pro-
angiogenic properties of VEGF-C have been confirmed. Other reports have challenged these 
findings120,121,123 and the extent to which VEGF-C may increase neovascularization remains 
controversial. 
 
In a recent report, Benest and co-workers adapted a rat mesenteric angiogenesis model for 
lymphangiogenesis124. One of their most interesting findings was that the presence of lymphatic 
tissue is critical when considering the pro-angiogenic properties of VEGF-C, showing an inverse 
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correlation between blood and lymphatic vessel density. In the vicinity of a lymphatic vascular 
network, the pro-angiogenic effects of VEGF-C were significantly reduced124. 
 
1.6.3. PLGF  
Placental growth factor, a highly expressed growth factor in the placenta, was discovered in 1991 
by Maria Graziella Persico125. PlGF binds and activates VEGFR1 to induce downstream 
signalling125,126. PlGF knockout mice, though born without any obvious abnormalities in the 
vascular system, demonstrate an impaired angiogenic response after ischemia127. Furthermore, 
studies have shown that as a result of reduced angiogenesis PlGF-/- mice have a hindered ability 
to develop adipose tissue in a murine model of diet-induced obesity128.  
 
Reports indicate that PlGF-induced vessels possess a more stable phenotype than vessels 
created by VEGF-A delivery. A possible explanation offered has been the ability of PlGF to target 
not only ECs127, but also smooth muscle cells, and macrophages, the three main cell types 
involved in the growth of collaterals31,129. Luttun and colleagues have shown that these cell types 
all express higher levels of the PlGF-binding receptor Flt-1 during collateral growth130.  
 
PlGF has been postulated to shape angiogenesis in diverse ways131. Apart from its direct effect 
on ECs via VEGFR1, PlGF has also been shown to compete VEGF-A off of VEGFR-1, allowing 
VEGF-A to bind and signal through VEGFR2 instead132. By binding to VEGFR1, PlGF is also 
believed to regulate the sensitivity of cells towards the VEGF/VEGFR2 axis. In inflammatory 
cells, monocytes or smooth muscle cells residing in wound or tumour stroma, PlGF may 
potentially influence angiogenesis by upregulating VEGF133.  
 
Some of the mechanisms involving PlGF in the regulation of pathological angiogenesis have 
recently been described. Tumour angiogenesis and vascular leakage are impaired in PlGF -/- 
mice. A critical way for PlGF to enhance tumour angiogenesis127 is the mobilization of 
haematopoietic progenitor cells from the bone marrow134. Interestingly, synergistic effects 
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existing between PlGF and VEGF have also been demonstrated to exhibit a profound effect on 
pathological angiogenesis, as PlGF was shown to promote pathological angiogenesis by 
triggering crosstalk between VEGFR-1 and VEGFR-299,127,130. 
 
Even though PlGF has not been as thoroughly investigated as VEGF, it has demonstrated its 
usefulness for therapeutic angiogenesis in a number of experimental settings130. In ischemic 
myocardium, PlGF has been reported to induce angiogenesis and arteriogenesis more efficiently 
than VEGF without triggering typical side effects seen with VEGF, such as the generation of 
haemangiomas130. PlGF-treated animals recovered better in an ischemic hindlimb model than 
animals in the VEGF-treated group, mainly by exerting a more powerful effect on collateral side 
branch growth130. With PlGF, Carmeliet’s group was further able to create a stable vasculature 
that persisted for more than a year130. In yet another report, Kolakowski and colleagues 
confirmed PlGF’s potential to promote angiogenesis in the heart135. Delivery of 1µg PlGF into the 
heart 2 weeks after myocardial infarction led to improved cardiac function measured via maximal 
LV pressure, maximal dP/dt, and ejection fraction, and PlGF was further shown to increase the 
thickness of the border zone wall and reduce dilation of the left ventricular cavity after MI135.  
 
1.6.4. Ang-2 
Angiopoietins and their main receptor, the tyrosine kinase Tie-2, are closely involved in the 
creation of new vessels and in determining their long-term fate136. Apart from promoting EC 
survival, sprouting and migration, the angiopoietin-Tie-2 axis has been shown to be involved in 
the recruitment of pericytes137,138 whilst also mediating anti-permeability and anti-inflammatory 
effects139. Tie receptors are mainly expressed by ECs. Angiopoietin-1 (Ang-1) and angiopoietin-2 
(Ang-2) transmit distinct actions via the Tie2 receptor, which is reflected in their expression 
patterns. Ang-1 is expressed by perivascular cells and in a paracrine way preserves the 
quiescent state of the mature vasculature55,140. By activating Tie-2 and thereby initiating the 
activation of the downstream signalling pathway PI3K, Ang-1 promotes endothelial cell survival, 
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motility, tube formation and sprouting140-143. Ang-2, the antagonistic ligand for Tie-2, is 
synthesized by ECs themselves, stored in Weibel-Palade bodies, and released upon 
stimulation144. It has a fundamental role in the initiation of angiogenesis by destabilizing the 
endothelium34,145 and loosening the contacts between endothelial and perivascular cells34,146-148. 
Hypoxia has been identified as an important stimulus for the up-regulation of Ang-2 mRNA149. 
Other stimuli controlling the expression levels of Ang-2 include growth factors like VEGF150 and 
bFGF150, angiotensin II151, leptin152 and TNF-α153.  
 
Further evidence underlying the importance of angiopoietins and the Tie receptors during 
angiogenesis stems from gene targeting studies. Tie-2-/- mice die between day 9.5 and 12.5 in 
utero due to deficiencies in the development of the vascular system leading to vessel rupture, 
haemorrhage and impaired heart function57,154. These mice further have a reduced number of 
endothelial and perivascular cells, implicating Tie-2 with both the survival of ECs and the 
generation of a more stable vasculature. The phenotype of Ang-1-/- mice resembles that of Tie-2-
deficient mice155, while Tie-1 knockout mice die after day 13.5 due to shortcomings in the 
vascular system, apparent by haemorrhages and oedema57,156.  
 
Contrary to vessels induced by VEGF alone, Ang-1, when co-delivered with VEGF, has been 
shown to generate leakage-resistant blood vessels, emphasizing the role of Ang-1 in the 
maturation of the vasculature157. Of note, in the presence of VEGF, Ang-2 supports the growth of 
blood vessels and sprouting angiogenesis, while effectively blocking the maturation signals 
mediated by Ang-1145. In the absence of VEGF, Ang-2 leads to endothelial cell death and 
regression of the neovasculature145. 
 
1.6.5. PDGF-BB 
Platelet-derived growth factor was first purified in 1979158,159. Initially two PDGF genes were 
discovered, PDGF-A and PDGF-B, which were shown to homo- or heterodimerize into the active 
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forms PDGF-AA, PDGF-AB or PDGF-BB160. In 2000 and 2001, two more members of the PDGF-
family, PDGF-CC161, and PDGF-DD162,163 were described. A key difference between the early 
members and PDGF-CC and PDGF-DD is that the latter ones are released in a latent form and 
proteolytic cleavage of an amino-terminal CUB domain is required to activate these growth 
factors164.  
Two PDGF receptor subunits exist, PDGFRα and PDGFRβ165. When PDGF binds to its receptor, 
each PDGF monomer unites with a receptor subunit to stabilize the PDGFR-complex166. PDGF-
BB shows a high affinity for both PDGFRα and PDGFRβ and is thus considered the universal 
ligand for all three receptors: PDGFRαα, PDGFRββ and PDGFRαβ165.  
 
PDGF-BB plays a crucial role in the recruitment of pericytes to the neovasculature, thereby 
promoting its stability and the switch to a more mature phenotype167,168. PDGFRβ+-perivascular 
progenitor cells in tumours have been shown to control the differentiation of pericytes and 
influence vascular survival59.  
 
Both PDGF-BB and PDGFRβ null mutants demonstrate substantial microvascular bleeding and 
die at later stages of gestation169-171. A diminished recruitment of vascular smooth muscle cells 
and pericytes has been identified as the underlying defect167.   
PDGF has emerged as a prominent target for therapeutic angiogenesis. Not only has PDGF a 
role in the recruitment of vascular progenitor cells59, but Li and colleagues have also 
demonstrated that by means of recruiting endothelial and pericyte precursors PDGF-CC is 
required for the revascularization for ischemic limb and heart tissues172. PDGF-BB delivery has 
furthermore been demonstrated to preserve myocardial contractility after myocardial infarction by 
both decreasing cardiomyocyte apoptosis and increasing vascular density and regional 
perfusion173,174.  
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1.6.6. bFGF (FGF2) 
The first angiogenic growth factor successfully isolated in 1984 by Judah Folkman and co-
workers, basic fibroblast growth factor (bFGF) shows strong heparin-binding properties175,176. 
bFGF primarily is bound within the basement membrane in vivo177. While bFGF may be 
mobilized178 from the ECM, it can also activate endothelial cells in its bound form179-181. bFGF is a 
strong angiogenic factor that stimulates DNA synthesis, migration and plasminogen activator 
production in endothelial cells182,183. To date, bFGF is the only growth factor other than VEGF 
that has been used in advanced human clinical trials to promote therapeutic angiogenesis184,185.  
 
Apart from endothelial cells, bFGF also stimulates smooth muscle cells and fibroblasts, making it 
less selective than VEGF186. It binds to a tyrosine kinase receptor family, fibroblast growth factor 
receptors 1-4 (FGFR1-4)187. Interestingly, FGFR expression may be increased on tumour 
endothelial cells188. After bFGF binding, its receptor dimerizes and autophosphorylates tyrosine 
residues located in its intracellular domain187. Importantly, for successful activation of the FGFR 
by bFGF, the growth factor also needs to bind to heparan-sulfate proteoglycans (HSPGs)178 to 
stabilize the complex between the receptor and the ligand. PI3K189 and the ERK1/2190,191 
pathways have been associated with transmitting the angiogenic signals of bFGF. A soluble form 
of the extracellular part of FGF1 (aFGF) exists that may bind bFGF and thereby prevent its 
binding to the target receptors192. Thrombospondin-1, an endogenous angiogenesis inhibitor, 
may similarly regulate bFGF function192.  
 
bFGF has been shown to play an important role in tumour and inflammatory-mediated 
angiogenesis182. It promotes tumour cell proliferation and survival193, and has been linked to 
promoting tumour cell migration and differentiation towards a more invasive phenotype194-196. 
Inhibition of bFGF signalling has been demonstrated to shrink tumours and reduce their 
vascularization197. The requirement of the monocyte chemoattractant protein-1/CC chemokine 
receptor 2 axis for bFGF-induced neovascularization is exemplary of the contribution of 
inflammatory cells to angiogenesis198. It has been suggested that short-term exposure to bFGF 
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may act as a pro-inflammatory and pro-angiogenic signal, whereas long-term exposure may 
communicate anti-inflammatory effects182.  
 
There is extensive cross talk between bFGF and a number of growth factors. Hepatocyte growth 
factor has been shown to increase bFGF levels in external auditory canal choleastoma cell 
cultures199. The combination of PlGF and bFGF synergistically enhanced bovine retinal 
endothelial cell proliferation, survival and migration200. Insulin-like growth factor works in concert 
with bFGF to increase endothelial cell proliferation and survival200. When co-delivered with 
granulocyte colony-stimulating factor, bFGF had a more pronounced angiogenic effect in a 
mouse ischemic hindlimb model201. A synergistic effect on neovascularization has also been 
reported for PDGF-BB and bFGF, as well as for the combination of VEGF and bFGF. It has been 
suggested that bFGF may induce neovascularization indirectly by activating the VEGF/VEGFR 
system202,203-206. By simultaneously delivering PDGF-BB and bFGF, Cao and colleagues were 
able to generate long-lasting vessels in the mouse corneal micropocket assay, concluding that 
the recruitment of mural cells contributed to vessel stability. When subsequently testing the 
combination in the hind-limb ischemia model, they found an enhanced stimulation of collateral 
growth and increased perfusion207.  
 
1.6.7. BDNF 
Brain-derived neurotrophic factor (BDNF) belongs to a family of structurally related neurotrophins 
that, during their development, support the growth, survival and differentiation of neurons, in both 
the central and peripheral nervous system208-213. Other members include nerve growth factor, 
neurotrophin-3, neurotrophin-4/5, neurotrophin-6 and neurotrophin-7214-217. Synthesized as 
precursors, neurotrophins require proteolytic cleavage for activation218. Neurotrophins bind to two 
types of receptors, p75NTR and TrkA, TrkB and TrkC, which bind BDNF and neurotrophin-3 
selectively219. An important role for BDNF in controlling the fate of the cardiac microvasculature 
during development has been revealed through genetic studies 220.  
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The pro-angiogenic effects of BDNF have been well documented. In an ischemic hindlimb model, 
Kermani and colleagues found higher levels of BDNF in the ischemic tissue221, pointing towards 
a critical contribution of BDNF post injury. They further demonstrated that overexpression of 
BDNF has VEGF-like effects on increasing capillary density and enhancing blood flow221. 
Interestingly, the authors not only observed that the activation of TrkB on endothelial cells 
contributes to the pro-angiogenic effects but also that exogenous BDNF acted as a chemotactic 
factor recruiting CD11+myeloid cells and Sca1+ hematopoietic cells221, leading them to conclude 
that those cells potentially home to the injury site and may contribute to the maturation of the 
neovasculature. Kim et al. reported that brain-derived endothelial cells express BDNF and that 
BDNF is able to activate TrkB and p75NTR, which are also expressed on the endothelial cells219. 
When exposed to exogenous BDNF, transformed rat brain endothelial cells showed increased 
survival, which was mediated through the TrkB receptor and downstream phosphatidylinositol 
(PI) 3-kinase-Akt signalling. BDNF-treatment also elicited an angiogenic response, confirmed by 
tube formation and cellular sprouting219. 
 
In multiple myeloma (MM), a disease that is associated with increased angiogenesis of the bone 
marrow, remission has been linked to reduced BDNF levels222,223. Hu and colleagues have 
shown that BDNF-signalling through the TrkB receptor is indeed one of the mechanisms 
responsible for the observed increase in angiogenesis224. When co-culturing multiple myeloma 
cells and human umbilical vein endothelial cells (HUVECs), the authors demonstrated migration 
and network formation of the endothelial cells and these effects were blocked by an anti-BDNF 
antibody. Anti-BDNF antibody delivery further stopped tumour growth, induced tumour necrosis 
and reduced tumour vessel density, underlining the importance of BDNF in this particular 
tumour224. 
 
In combination with bFGF, BDNF has shown potential for use in therapeutic angiogenesis225. 
Prolonged release from gelatin hydrogels resulted in enhanced left ventricular function and 
angiogenesis, measured by means of left ventricular ejection fraction, regional myocardial blood 
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flow and vessel density, respectively225. Interestingly, in an ischemia-reperfusion model, border 
zone myocytes have been known to express BDNF226. Pro-angiogenic effects of BDNF have also 
been recorded in a rat spinal cord injury model227. 
 
1.6.8. SDF-1 
Over the last few years the chemokine stromal-cell derived factor-1 (SDF-1), also known as 
CXCL12, has emerged as an essential factor regulating neovascularization228. Its receptor, 
CXCR4 is expressed on a variety of cells participating in angiogenesis, such as hematopoietic 
cells, endothelial progenitor cells or smooth muscle cell progenitors228. An important axis early in 
development, both SDF-1 and CXCR4 null mice lack the interconnecting vessels that form 
between the primary capillary plexus and the superior mesenteric artery in the small intestine229. 
SDF-1 has been shown to promote endothelial cell proliferation, differentiation, tube formation 
and to improve survival of endothelial progenitor cells230,231.  
 
While SDF-1 alone induces angiogenesis in the matrigel plug assay, a more dramatic angiogenic 
response has been described after co-delivery with VEGF-A232,233. Recent reports have further 
established an important partnership between SDF-1 and VEGF-A in the regulation of the 
angiogenic response after ischemic injury. Both SDF-1 and VEGF-A are capable of mobilizing 
cell populations residing in the bone marrow, CXCR4+ and VEGFR2+ cells, respectively. 
Furthermore, the retention and incorporation of cells recruited by VEGF-A upregulation into sites 
of active neovascularization has been shown to be dependent on SDF-184.  
 
SDF-1 is upregulated in ischemic tissues234-240. It has been hypothesized to be an important 
factor responding to hypoxia by initiating the angiogenic response and thereby limiting tissue 
damage241-243. In prostate cancer cells, the levels of a variety of angiogenic factors have been 
shown to be SDF-1 dependent, including VEGF, IL-6, IL-8 and TIMP-2244. In these cells, SDF-1 
was further shown to limit the synthesis of angiostatin, a prominent angiogenesis inhibitor244. 
Also, by promoting MMP production, SDF-1 facilitates remodelling of active angiogenic sites and 
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neovessel formation25,84,245. SDF-1 dependent recruitment of CXCR4+PDGFR+ckit+ smooth 
muscle progenitor cells has furthermore been shown to ensure the stability of the newly formed 
vasculature246. 
 
After myocardial ischemia, SDF-1 has been demonstrated to reduce cardiomyocyte death247, 
decrease infarct size248, promote neovessel formation247,249, CXCR4+ckit+ stem cell recruitment 
and, most importantly, improve cardiac function247,249. 
 
1.6.9. HGF 
Hepatocyte growth factor (HGF), a heparin-binding growth factor250, combines a unique set of 
features, making it a promising candidate for biological revascularization and myocardial infarct 
therapies251. HGF has been shown to promote both angiogenesis252-255 and myocardial 
hypertrophy, whilst inhibiting apoptosis and fibrosis256-258.  
 
HGF levels are considerably elevated after acute myocardial infarction259. Yasuda and co-
workers reported that in humans high HGF levels in the infarct area correlate with reduced 
ventricular dilation and enhanced cardiac function, thus suggesting a cardioprotective role of 
HGF260. In various animal models of ischemia-reperfusion, HGF has been shown to beneficially 
affect infarct size and cardiac function, confirming this hypothesis. Miyagawa and colleagues 
reported that HGF gene therapy ameliorates adverse ventricular remodelling and improves 
cardiac function in a mouse MI model261. Intramyocardial injection of an adenovirus encoding 
HGF preserved myocardial function and geometry, promoted angiogenesis and led to significant 
reductions in apoptosis262. In another report, HGF gene therapy significantly reduced the 
ischemic area and increased capillary density and regional myocardial perfusion in a pig 
myocardial infarct model263. The authors further observed a significant decrease in the fibrotic 
area in the HGF group and improved cardiac function and increased wall thickness when a high 
dose of HGF (4mg) was administered263.  
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Diabetes remains one of the most common underlying causes necessitating revascularization 
therapies. It is therefore important to note that intramuscular injection of a HGF plasmid into the 
ischemic hindlimb of diabetic rats significantly increased blood flow and capillary density in a 
dose-dependent manner264.  
 
In combination these promising studies have led to the initiation of clinical studies to explore the 
angiogenic effects and safety of HGF treatment in the setting of peripheral arterial disease265,266.  
 
1.7. Angiogenesis assays 
The major breakthrough that permitted the development of angiogenesis assays was the 
establishment of cell culture techniques for vascular endothelial cells. While in vitro assays are 
more easily accessible, more cost effective and easier to quantify, a number of important 
shortcomings exist in comparison with in vivo assays. Most importantly, endothelial cells in 
culture remain in an activated state, whereas endothelial cells in vivo are activated only under 
special circumstances, e.g. during the estrus cycle, or during pathological conditions such as 
inflammation, tumour growth or wound healing267-269. Continued cell passaging may induce the 
activation of cellular receptors or the loss of cell surface antigens, negatively affecting the 
reproducibility of experiments. Furthermore, in vitro angiogenesis studies are typically performed 
on pure endothelial cell cultures, and thus interactions with supporting perivascular cells or the 
effects of systemic factors cannot be studied. In vitro assessment of endothelial cell proliferation 
is typically performed either by cell counting (manually or, if available, via flow cytometer) or – to 
obtain a more accurate measure – by quantifying DNA synthesis (via flow cytometric analysis of 
the cell cycle or incorporation of radioisotopes). Evaluation of endothelial cell migration 
comprises the measurement of chemokinesis and chemotaxis, the random and directed 
migration of cells, respectively. Chemokinesis may be quantified using time-lapse microscopy 
while chemotaxis towards a concentration gradient is typically determined with transwell or 
Boyden chamber culture systems. The tube formation assay represents a more advanced in vitro 
angiogenesis assay that determines the potential of endothelial cells to form tubes, which can 
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often be enhanced in a three-dimensional model system, such as matrigel, fibrin or collagen. 
Organ culture assays such as the aortic ring assay, in which the outgrowth of endothelial cells is 
quantified, reflect the in vivo situation more closely, as endothelial cells interact with surrounding 
smooth muscle cells, pericytes and the supporting matrix.   
The complex regulatory mechanisms that regulate angiogenesis are best studied in vivo.  
Used for more than 60 years, the chorioallantoic membrane (CAM) assay was the first assay 
developed for the in vivo assessment of neovascularization270,271. A major advantage of this 
assay is its ready availability. Delivering tissues and reagents to be tested for their angiogenic 
potential is technically relatively easy and the angiogenic response can be assessed using 
standard histological techniques. An important downside to consider is that while the assay may 
be performed on chick embryos aged 5 to 14 days, the responsiveness to angiogenic stimuli 
varies considerably during this timespan. Due to the extensive capillary bed of the chorioallantoic 
membrane, it can be challenging to distinguish the pro-angiog nic effects of a given tested 
substance272. Furthermore, quantification of the neovasculature may be complicated by a 
commonly observed inflammatory response seen around day 8 after delivery of a variety of 
biologics273. Technically more challenging but similar to the CAM assay is the mesenteric window 
assay274,275. Importantly, in this assay, angiogenesis is tested on mammalian tissue, the small gut 
mesenteric window of rodents. In addition, this assay can be performed on adult laboratory 
animals and it allows one to distinguish between and quantify capillaries, arterioles and venules.  
The corneal angiogenesis assay is currently considered as the gold standard of in vivo 
angiogenesis assays. As the cornea is essentially avascular, the ingrowth of the peripheral limbal 
vasculature after implantation of pro-angiogenic tissues of biologics into a corneal pocket can be 
easily assessed. While surgically challenging and time consuming, the corneal angiogenesis 
assay allows monitoring of the effects of pro- and anti-angiogenic stimuli over extended periods 
of time, if delivered via osmotic pumps or slow-release polymers. However, due its avascularity, 
the immune-privileged cornea represents a somewhat atypical site to assess physiological 
angiogenesis and therefore findings from this assay need to be carefully interpreted and may not 
always be adaptable to other tissues.  
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The matrigel plug assay presents an alternative to the in vivo assays mentioned above. Liquid 
matrigel is mixed with the test substance and, upon subcutaneous injection into the animal, 
solidifies at body temperature to form a plug that can easily be explanted and processed for 
histological analysis. A number of important limitations of this assay exist. The dynamics of 
neovascularization cannot be non-destructively tracked during the course of the experiment. 
Moreover, striking regional differences in neoangiogenesis were uncovered after implantation of 
matrigel plugs into various subcutaneous sites276-280. In recent years, the use of chamber assays 
has become more popular. The rabbit ear, mouse or rat dorsal skinfold or the cranium have been 
used as implantation sites. In these in vivo assays, intravital microscopy is used to track 
neovascularisation in real time after removal of a piece of the skin or part of the skull281. While a 
great advantage of the chamber assay is the continuous monitoring of neoangiogenesis, these 
experiments are technically challenging and imaging may be complicated by suboptimal optical 
properties as a result of the thickness of the tissue examined. In total, the described assays have 
contributed significantly to a general increase in mechanistic insight into the process of 
neovascularization. However, these assays have been established to study the formation of 
neovessels and assess the angiogenic potential of growth factors; yet prevention of vascular 
regression is also a critical component of therapeutic neovascularization. In their current format, 
the ability of these assays to monito  neovascular regression is limited, thus modifications may 
be required to parse the effects of factors on vascular stability and regression.  
 
 
1.8. Summary 
Therapeutic angiogenesis has emerged as a novel concept to enhance blood flow in ischemic 
tissues. In recent years, numerous growth factors have been demonstrated to contribute to 
angiogenesis. A major obstacle that has yet to be overcome is the instability of growth factor-
induced neovasculature. Thus far little is known about the factors that determine the long-term 
fate of growth factor-induced neovasculature. Due to tissue-specific differences, previous studies 
have shown conflicting results. Whereas delivery of single growth factors has resulted in the 
development of a stable neovasculature in some tissues, treatment with the same growth factor 
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regimen can result in rapid neovessel regression in others. Timing and dosage likely are 
important variables that regulate vascular stability, as are interactions between co-delivered 
growth factors. While these factors appear crucial in explaining the failed translation of 
therapeutic angiogenesis from bench to bedside, our understanding of which mechanisms 
contribute to making neovessels unstable is incomplete, partly due to the lack of appropriate in 
vivo animal models. A deeper insight into this process is required to exploit the potential of 
therapeutic angiogenesis.    
 
 
2. HYPOTHESES 
Part of the work described in this thesis is the development of a novel in vivo angiogenesis model 
that addresses some of the deficiencies in existing models. Using this model and a rat model of 
myocardial infarction, this thesis tests the following hypotheses: 
 
1. Stability of growth-factor induced neovasculature is highly dosage-dependent 
2. Stability of growth-factor induced neovasculature is enhanced by controlled co-delivery of 
specific factors 
3. Targeted delivery of an angiogenic growth factor (VEGF-A) via an injectable biomaterial 
implant induces a neovasculature that exhibits long-term stability and improves cardiac 
remodelling and functional recovery after myocardial infarction. 
 
3. RESULTS: Angiogenesis chapter 
 
3.1. Establishment of a subcutaneous in vivo angiogenesis model 
In order to track the angiogenic potential of growth factors and to test the long-term stability of 
newly formed vessels induced by recombinant growth factor delivery, an in vivo angiogenesis 
model was designed (see chapter 10.1.1, 10.1.3.). The in vivo angiogenesis assay described 
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here allows for the precise delivery of growth factors to a scaffold and the quantification of vessel 
growth into the scaffold during and after growth factor delivery. Neovascularization constructs 
were produced in our laboratory with the generous help of Dr. Deon Bezuidenhout and Mr. 
Johann Eygelaar. Using spherical microbeads, a revised phase inversion technique was 
employed to generate polyurethane with well-defined porosity282.  On the luminal surface, 
polyurethane tubes used in the experiments were lined with expanded tetrafluoroethylene 
(ePTFE). This modification allowed for ready tissue-ingrowth into the porous polyurethane but 
prevented complete closure of the lumen enabling growth factor-delivery to the polyurethane 
graft via an attached osmotic pump. Osmotic pumps allowed for the establishment of a stable 
growth factor gradient within the polyurethane graft for extended periods. Depending on the 
length of the experiment, a variety of osmotic mini-pumps were used for growth factor delivery. A 
schematic of the vascularization device is depicted in Fig.1, a photograph in Fig.2.  
 
 
 
 
 
Fig.1. (A) Schematic representation of the vascularisation devices, showing porous polyurethane (1), 
ePTFE cell barrier (2), plug (3), polyethylene tube assembly (4), silk ligatures (5), and osmotic pump 
(6). The scanning electron micrographs show the cross-section (B), as well as the lumenal (C) and 
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The main purpose of these studies was to identify growth factors that significantly contribute to 
angiogenesis in this model, to characterize the stability of the neovasculature and to identify 
mechanisms/parameters that contribute to vascular stability. 
 
 
 
3.2. Basal levels of vascular ingrowth into the vascularization device 
In an initial pilot experiment the basal level of vascular ingrowth into the vascularization device 
after subcutaneous implantation was determined. Vascularization devices were either implanted 
alone or attached to phosphate buffered saline-delivering osmotic mini-pumps. Vascularization 
devices were explanted after 10 days and the angiogenic response was visualized by staining 
with an antibody targeting CD31.  
 
3.2.1. Results 
As expected, the ePTFE barrier prevented ingrowth of organized tissue into the luminal space of 
the porous polyurethane tube. A small number of individual cells were found within the ePTFE 
barrier (data not shown).  
Subcutaneous implantation of neovascularization devices resulted in 2.11±0.14% of the total 
graft area being vascularised after 10 days (see Fig. 3, n=4). Delivering phosphate buffered 
saline via an attached osmotic mini-pump had no significant effect on neovessel formation 
(2.4±0.27%, n=6, p>0.05, representative image shown in Fig.4).  
Fig.2. Photograph of the vascularization device           
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3.2.2. Discussion 
Delivery of phosphate-buffered saline did not have an effect on neovascularisation in this assay 
and is well suited as a negative control for comparison with angiogenic growth factors. For 
ensuing experiments, growth factors were diluted in phosphate-buffered saline. Importantly, 
image analysis of neovascularization revealed that vascularisation density within polyurethane 
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Fig.3. Graph shows baseline vascularization of a polyurethane graft after subcutaneous implantation for 
10 days. Delivery of PBS via an attached osmotic mini-pump does not affect neovascularization. 
Fig.4. Immunohistochemical staining of CD31 positive vessels in devices explanted after delivery of 
PBS for 10 days. The ePTFE barrier (black arrow) successfully prevented tissue ingrowth into the 
lumen of porous polyurethane tubes. 
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grafts was highly reproducible after PBS delivery, allowing comparison of the angiogenic 
potential of growth factors tested in different sets of experiments.    
 
3.3. Dynamics of VEGF-induced neovascularization  
The vascular endothelial growth factor family plays a particularly prominent role in angiogenesis. 
Though angiogenesis is most probably controlled by a complex interaction of growth factors at 
both temporal and spatial levels31,283, signalling by vascular endothelial growth factor-A165 (VEGF-
A165; for the remainder of the thesis referred to as VEGF) is an essential and rate-limiting step in 
physiological angiogenesis78.  
Therefore, to test whether VEGF promotes neovascularization into polyurethane grafts, VEGF 
was delivered at 1500ng/day for 5 days. Vascular grafts were explanted after 5 days (n=5) and 
neovascularisation was subsequently visualized by staining with a CD31-antibody.  
 
3.3.1. Results, day 5 
VEGF delivery resulted in significantly higher neovessel formation in comparison with PBS at 5 
days. At day 5, 4.83±0.85% of the total graft area was vascularised in the VEGF group as 
compared to 1.84±0.12% in the PBS control group (p<0.01, 1.62 fold increase, n=5).   
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   Fig.5. As early as 5 days 
after the initiation of 
VEGF delivery, a 
significant 1.62 fold 
increase in angiogenesis 
is observed (*p<0.01, 
n=5). 
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To investigate whether prolonging the delivery of VEGF could further increase 
neovascularisation, 1500ng/day of VEGF were delivered for a total of 10 days before harvest of 
the vascular grafts on day 10 (PBS: n=6, VEGF: n=4). Neovascularisation was again visualized 
by staining with a CD31-antibody. 
 
3.3.2. Results, day 10 
At day 10, 8.76±1.37% of the total graft area was vascularised after VEGF-delivery in 
comparison with 2.4±0.13% in controls (p<0.001, 2.65 fold increase, n=4(VEGF), n=6 (PBS), see 
Fig.6). Delivery of VEGF for an additional 5 days increased neovascularisation by 81%, nearly 
doubling the number of neovessels present in the vascularization device. Representative images 
for polyurethane grafts after PBS and VEGF delivery explanted at day 10 are shown in Fig.7. 
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Fig.6. Prolonged VEGF delivery for 10 days instead of 5 enhances neovessel formation even further 
(2.65 fold over PBS controls at day 10 (*p<0.001, n=4) in comparison with 1.62 fold at day 5 (p<0.01, 
n=5).  
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3.3.3. Conclusion 
Taken together, these experiments show that the delivery of VEGF significantly increases 
angiogenesis in the neovascularisation device. Neovessel formation was significantly increased 
after continuously delivering VEGF for 5 days. Yet, prolonged delivery of VEGF for an additional 
5 days had an even more pronounced effect on neovascularisation, almost doubling the number 
of CD31+-vessels in the polyurethane graft. In combination, these experiments show that 
continuous delivery of VEGF steadily increases neovascularization until day 10.  
 
3.4. Promotion of angiogenesis by the vascular endothelial growth factor 
family  
3.4.1. Rationale 
The vascular endothelial growth factor family currently comprises 5 family members. While 
VEGF, VEGF-C and PlGF have all been shown to enhance angiogenesis, these growth factors 
establish a neovasculature with distinct features. In comparison with VEGF, Placental growth 
Fig.7. Immunohistochemical staining of CD31 positive vessels in devices explanted after delivery of 
PBS(a) or 1500ng/day VEGF(b) for 10 days. A dramatic increase in neovascularization is observed 
after VEGF delivery. 
 a b 
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factor (PlGF) has been shown to induce a neovasculature that is more stable in nature and better 
resembling the physiological phenotype. This is most likely based on the ability of PlGF to not 
only stimulate endothelial cells127 but also vascular smooth muscle cells and macrophages31,128.  
To determine whether placental growth factor is a more potent angiogenesis stimulus than VEGF 
in this assay, neovascularization devices were implanted subcutaneously and 1500ng/day PlGF, 
were delivered via attached osmotic pumps for 10 days (n=6). Furthermore, to determine, 
whether the promotion of neovascular formation after VEGF delivery is dosage-dependent, 
150ng VEGF/day were delivered for 10 days (n=6). After explantation, neovessel formation was 
assessed via CD31-staining. 
 
3.4.2. Results 
Both VEGF and PlGF significantly increased neovascularization after 10 days in comparison with  
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Fig.8. Daily delivery of either 150ng VEGF (*p<0.01) or 1500ng PlGF (§p=0.001) significantly enhances 
neovascularization after 10 days by 132% and 76.1%, respectively (n=6). No significant difference in 
angiogenic potential was observed between delivering 150ng VEGF/day and a 10-fold higher PlGF 
dosage. 
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PBS controls. In PBS grafts, 2.84±0.29% of the total graft area was vascularised. 10-day delivery 
of 150ng/day VEGF increased neovascularization by 132% (to 6.61% of the total graft area, 
p<0.01), while the delivery of 1500ng/day PlGF increased angiogenesis by 76.1% (to 5%, 
p=0.001), as shown in Fig.8. 
 
3.4.3. Conclusion 
These data indicate that VEGF acts as a more potent stimulus for vessel formation in the 
subcutaneous rat model than PlGF, as lower VEGF concentrations induced angiogenesis as 
effectively as the highest PlGF dosages examined (p=0.148). Furthermore, this experiment 
provided initial evidence that VEGF-induced angiogenesis into the neovascularization device is 
dosage-dependent based.  
 
3.5. Vascular endothelial growth factor-C and short-term neovascularization 
While vascular endothelial growth factor C has traditionally been considered a lymphangiogenic 
factor, additional evidence suggests that it acts as an angiogenic stimulus119,124. The ability of 
VEGF-C to induce neovascularization was therefore tested in the subcutaneous rat model. 
VEGF-C was delivered for 10 days via osmotic pumps at 150ng/day or 600ng/day, respectively, 
and subsequently neovascularization was assessed by immunohistochemical analysis of CD31.   
 
3.5.1. Results 
After osmotic delivery of 150ng VEGF-C per day 2.59±0.2% (n=6) of the polyurethane graft area 
was vascularized, while delivery of 600ng VEGF-C per day resulted in a vascularization area of 
2.74±0.21% (n=6). Neither 10-day delivery of 150ng/day nor 600ng/day VEGF-C had a 
significant effect on neovascularization in comparison with PBS controls (2.4±0.13%, n=6), 
[p=0.2 (PBS, VEGF-C (600ng/day)); p=0.45 (PBS, VEGF-C (150ng/day))].  
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A possible effect of VEGF-C delivery on lymphatic vessels could not be excluded, as repeated 
attempts to establish an immunohistochemistry protocol were unsuccessful. 
 
 
 
3.6. Angiogenic potential of brain-derived neurotrophic factor (BDNF) and 
hepatocyte growth factor HGF 
Apart from the VEGF family, numerous growth factors such as hepatocyte growth factor253,254,262-
264 (HGF) and brain-derived neurotrophic factor219,221,225 (BDNF) have been shown to be potent 
inducers of angiogenesis.  
To determine, whether BDNF or HGF induce angiogenesis at levels similar to VEGF or even 
exceed VEGF-induced neovascularization in the subcutaneous wound healing model, 1µg/day of 
HGF or BDNF, respectively, were delivered via osmotic pump for 10 days. Neovessel formation 
was assessed by immunohistochemical staining for CD31. 
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Fig.9. No significant pro-angiogenic effects are observed after the delivery of 150ng/day VEGF-C, 
600ng/day VEGF-C or PBS for 10 days. 
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3.6.1. Results 
BDNF delivery significantly increased neovascularization by 29.6% compared to PBS controls 
(from 2.4±0.13 to 3.11±0.65%, p<0.05, n=6 (BDNF, PBS)). Nevertheless, compared to VEGF-
induced neovessel formation after 10 days, the observed increase was minimal. Due to the high 
variability seen in explanted grafts after delivery of 1µg/day HGF, no significant effects on altering 
the intrinsic angiogenic response after 10 days (2.94±1.12%, p>0.05, n=6) were seen. 
 
 
 
3.6.2. Conclusion 
Quantification of neovascularization revealed that while HGF and PlGF significantly enhanced 
angiogenesis in comparison with PBS controls, VEGF was the most potent pro-angiogenic factor 
(of those tested) when delivered alone. Angiogenesis is controlled by numerous growth factors, 
and growth factor-interaction is important during neovessel formation. Therefore, to determine 
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Fig.10. In comparison with VEGF, BDNF treatment only led to a modest increase in neovascularization 
after 10 days (29.6% increase over PBS controls, *p<0.05, n=6). No significant increase in 
angiogenesis was observed after delivering 1µg/day HGF for 10 days. 
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whether short-term neovascularisation could be further increased, the effects of delivering 
multiple pro-angiogenic growth factors either simultaneously or subsequently were tested next. 
 
3.7. Synergistic angiogenic effects of growth factors 
Simultaneous delivery of multiple growth factors may be required to increase neovascularization 
to achieve therapeutic levels. In concert, bFGF and PDGF have previously been shown to have 
synergistic effects on promoting angiogenesis207. Furthermore, cross talk between vascular 
endothelial growth factor and angiopoietins is essential for the regulation of neovascular 
formation and vascular stability145,157. Angiopoietin-2 plays a particularly important role in the 
initiation of angiogenesis; during this phase it is required to destabilize vessels by promoting 
pericyte and vascular smooth muscle cell detachment, before vascular endothelial growth factor 
stimulates endothelial cell invasion, proliferation and migration34. 
 
Therefore to test whether a) the combination of bFGF and PDGF has synergistic effects on 
promoting angiogenesis and b) whether, in the presence of Ang-2, VEGF-A induces 
neovascularization more effectively, 1) bFGF and PDGF and 2) Ang-2 and VEGF-A, respectively, 
were delivered simultaneously. Neovascularization devices were explanted after 10 days and 
neovessel formation was assessed by immunohistochemical analysis of CD31. 
 
3.7.1. Results – bFGF/PDGF 
Quantification of CD31-positive vessels revealed that the simultaneous delivery of 1200ng/day 
bFGF and PDGF for 10 days had no stimulatory effect on angiogenesis in our rat model. In 
comparison with controls, the vascularized area remained unchanged at 2.69±0.4% as compared 
to 2.4±0.14 in PBS controls (p>0.05, n=5 for both groups). 
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Ang-2/VEGF 
2 distinct VEGF dosages (50ng/day and 150ng/day) were tested for their ability to enhance 
angiogenesis in concert with Ang-2 (15ng/day) after continuous delivery for 10 days. Two 
hypotheses were tested in this experiment: namely, whether a) the combination of VEGF at a low 
dosage (50ng/day) with Ang-2 (15ng/day) enhances neovessel formation; and b) whether the 
simultaneous delivery of VEGF (150ng/day) and Ang-2 (15ng/day) synergistically leads to a more 
pronounced increase in neovascularization.     
 
3.7.2. Results - Ang-2/VEGF 
Sole delivery of 50ng/day VEGF or 15ng/day Ang-2, respectively, did not significantly increase 
neovascularization compared to PBS controls (n=6 for all groups). To the contrary, 150ng 
VEGF/day, simultaneous delivery of 50ng VEGF and 15ng Ang-2/day and simultaneous delivery 
of 150ng VEGF in combination with 15ng Ang-2/day all led to significant increases in 
angiogenesis in the vascularization device at day 10, by 57, 48 and 80%, respectively. Yet, 
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Fig.11. Simultaneous delivery of bFGF and PDGF at 1200 ng/day for 10 days did not induce 
angiogenesis in the subcutaneous graft model (p>0.05, n=5). 
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despite observing a trend towards an increase in angiogenesis when vascular endothelial growth 
factor at either dose (particularly for the lower dose of VEGF) was co-delivered with angiopoietin-
2, these differences were not significant when compared with VEGF delivery alone (see Fig.12). 
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Fig.12. 150ng VEGF/day, simultaneous delivery of 50ng VEGF and 15ng Ang-2/day and 
simultaneous delivery of 150ng VEGF in combination with 15ng Ang-2/day promoted neovessel 
formation at 10 days (*p<0.05 vs PBS). No pro-angiogenic effect was seen after delivery of 15 
ng/day Ang-2 or 50ng/day VEGF (#p>0.05). A strong trend towards a synergistic effect was 
observed when Ang-2 was co-delivered with low VEGF dosages (p=0.11 when compared with sole 
delivery of VEGF (50ng/day), n=6) 
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3.7.2.1.	  Conclusion	  -­‐	  Ang-­‐2/VEGF	  
While the study was underpowered to show a significant synergistic effect on neovessel 
formation by the simultaneous delivery of VEGF-A and Ang-2, the observed trend is in 
conjunction with the current literature284. In combination with previous experiments, though, the 
results suggested that increasing the dose of VEGF-A is a more effective way to increase 
angiogenesis into vascularization devices in comparison with co-delivery of Ang-2. 
 
3.8. Simultaneous delivery of diverse VEGF family members for the 
stimulation of neovascularization  
VEGF-A, VEGF-C and PLGF activate a diverse set of vascular endothelial growth factor 
receptors78. While VEGF-A binds to both VEGFR1 and -2, its downstream angiogenic effects are 
transmitted through VEGFR-2. PlGF exclusively binds to VEGFR1, while VEGF-C mediates its 
actions via VEGFR2 and-3. By competing with VEGF-A for binding to VEGFR-1 and thereby 
allowing it to bind more to VEGFR-2, PlGF has been proposed to increase pro-angiogenic 
signalling132. Furthermore, while it has been suggested that angiogenic therapy may be improved 
by simultaneously stimulating blood and lymphatic vessel growth285, this hypothesis has not yet 
been tested. To determine whether the concurrent delivery of VEGF-A, VEGF-C and PlGF has 
synergistic effects on neovascular development, 150ng/day of each growth factor were delivered 
concurrently over a period of 10 days. Neovessel formation was assessed by 
immunohistochemical analysis of CD31. 
 
3.8.1. Results 
Simultaneous delivery of VEGF-A, VEGF-C and PlGF vascularized 6.39±0.87% of the total graft 
area after 10 days (n=6), corresponding to a statistically significant 128% increase in 
vascularization with respect to PBS controls (2.8±0.31%, see Fig.13). Nevertheless, since 
comparable results were achieved by the sole delivery of 150ng/day VEGF-A for 10 days 
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(6.61±0.95%, n=6), simultaneous delivery of the three VEGF family members did not further 
promote neovessel formation at this timepoint. 
 
 
 
 
3.9. Discussion – Growth factor delivery for stimulation of angiogenesis 
VEGF-A, PlGF and BDNF significantly increased neovascularization after being continuously 
delivered for 10 days, with VEGF inducing the most prominent increase in neovessel formation. 
Furthermore, a trend towards synergistically promoting angiogenesis was observed for VEGF 
and Ang-2, in accordance with previous reports in the literature. An increase in sample number 
likely would have confirmed this effect. Since increasing VEGF dosage more effectively induced 
an increase in neovessel formation, this avenue was no longer pursued. For some other growth 
factors (HGF, VEGF-C) their previously described angiogenic potential could not be confirmed in 
this subcutaneous wound-healing model. Multiple potential explanations for this discrepancy 
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Fig.13. The concurrent delivery of 150ng/day of VEGF-A, VEGF-C and PlGF significantly enhanced 
vascularization at 10 days (*p>0.01, n=6). In comparison with sole delivery of 150ng VEGF/day, no 
additional pro-angiogenic effects were seen by co-delivering VEGF-C and PlGF.  
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exist. Growth factor stability has been a major concern in therapeutic angiogenesis approaches. 
The initial experiments with a diverse set of angiogenic growth factors clearly indicate that at 
least some of the growth factors were stable for extended periods of time when delivered with an 
osmotic minipump.  In addition, an extensive analysis of growth factor stability was performed for 
VEGF, which is believed to be one of the most unstable growth factors17 in the body. Both 
saphenous vein endothelial cell proliferation assays and enzyme-linked immunosorbent assays 
were performed to confirm VEGF stability up to day 42. These data are presented in chapter 
3.10.2., along with experiments describing the effects of continuous VEGF delivery for up to 42 
days on neovascularization. A high variability in levels of neovascularization was observed after 
HGF delivery. An increase in sample number may therefore have allowed for discernment of a 
more subtle effect of HGF on increasing neovessel formation. The lack of a pro-angiogenic effect 
observed after HGF treatment may also reflect specific differences that exist between 
angiogenesis assays, such as delivery method and site. Increases in angiogenesis were reported 
after adenoviral injection into the myocardium262,263 as well as after HGF plasmid delivery into the 
ischemic hindlimb of diabetic rats264. VEGF-C also did not promote angiogenesis into 
neovascularisation devices. Despite analysing its angiogenic potential after delivery at 2 different 
dosages, it is possible that the correct dosage was not delivered and that a further increase in 
VEGF-C may have been necessary to induce subcutaneous angiogenesis. Timing and duration 
of VEGF-C delivery are likely important variables determining its effects on neovascularization 
and both may have contributed to the negative finding. Other possible explanations include 
tissue-specific differences in growth factor metabolism in comparison with models described 
previously, in which an increase in angiogenesis was observed, and differences in the 
mode/route of growth factor delivery. The combination of bFGF/PDGF was previously shown to 
synergistically enhance angiogenesis in an ischemic hind-limb model. Cao et al used 
micropellets, growth factor loaded heparin-sepharose beads and slow-release polymers in a 
mouse corneal micropocket assay, a matrigel assay and a rat hindlimb ischemia model, 
respectively207. The release kinetics for each of the described methods are not described in 
further detail in this manuscript and may differ substantially. While osmotic mini pumps were 
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used to deliver bFGF and PDGF-BB in a rabbit model of hindlimb ischemia in the same report207, 
it should be noted that collateral formation and blood flow were measured to show synergistic 
effects of bFGF and PDGF-BB, and not an increase in capillary density. Analysis of downstream 
signalling pathway activation may be of interest in determining why the simultaneous delivery of 
VEGF, VEGF-C and PlGF did not significantly alter neovascularization in comparison with VEGF 
treatment alone. Overall, the data obtained after delivery of VEGF were the most robust, 
reproducibly leading to dramatic increases in neovascularization after 5 and 10 days. Initial 
experiments with varying dosages indicated a dosage-dependent effect on neovessel formation. 
As VEGF dynamics appeared to be the most interesting finding in the context of this assay that 
deserved more extensive study, a detailed characterisation of VEGF was carried out. PlGF 
emerged as another protein that induced significant neo-angiogenesis and since this growth 
factor has been associated with increased vascular stability, the response to PlGF was 
investigated for its ability to generate stable vessels. 
 
3.10. Scaffold neovascularisation after VEGF stimulation is dosage 
dependent  
Vascular endothelial growth factor (VEGF) has been extensively studied for short-term vessel 
ingrowth in tissue regeneration applications to stimulate vascularisation of polymeric scaffolds286-
289. Initial experiments indicated that, at the 10-day timepoint, VEGF enhances angiogenesis in 
the vascularization device in a dosage dependent fashion. Yet, little is known about the long-term 
fate of the neovasculature induced by VEGF stimulation. To test the hypothesis that the 
concentration of VEGF plays a critical role in the nature and persistence of vasculature formed in 
a tissue regenerative scaffold, the effects of different concentrations of VEGF on the 
vascularisation of a porous scaffold in the short-, intermediate- and long-term were evaluated. 
For up to 6 weeks, 15, 150 and 1500ng VEGF/day were delivered to polyurethane scaffolds by 
osmotic pumps. The stability of the vessels created as well as their mural cell investiture and 
perfusion was quantified. 
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3.10.1. Continuous delivery of VEGF for 10 days 
The level of neovascularisation within a porous polyurethane scaffold as visualized by staining 
with an antibody against CD31 is shown in Fig.14 A–D. Delivery of 15ng/day in this model had no 
impact but the two higher dosages of 150 and 1500ng/day dramatically increased vessel 
ingrowth area relative to the control by 159±39 and 286±90%, respectively, corroborating the 
previous findings for these dosages (Fig. 14E). Regions containing a very high density of small 
vessels and putative endothelial sacs were observed in explants from the highest VEGF dosage 
regime but not in the other dosages (Fig 14D).  
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3.10.2. Continuous delivery of VEGF for 20, 30 and 42 days 
To determine the stability of VEGF at 37 °C over the maximum delivery period, the VEGF 
solution used to load the pumps was incubated for 42 days at 37 °C and then used to stimulate 
endothelial cell growth (see chapter 10.1.5.). The incubated VEGF resulted in a 15% increase in 
cell number after 2 days compared to media alone (p<0.05) with fresh recombinant VEGF 
producing a similar increase. Furthermore, the VEGF content within an implanted polyurethane 
device that had VEGF pumped at 1500ng/day (as determined by ELISA, described in chapter 
10.1.5.) was found to be similar after 10 and 42 days implantation (226±21 and 257±11ng, 
respectively). The delivery of VEGF for periods greater than 10 days was then investigated for 
the two higher dosages. After 20 days the ingrowth was similar to that at 10 days with increases 
of vessel area within the polyurethane of 120±47 and 273±185% for the 150 and 1500ng/day 
dosages, respectively (Fig.15A). No endothelial sacs were observed at this time point. At 30 days 
the situation again was unchanged with regards to the delivery of 150ng/day VEGF (161±65% 
increase) but the maximum dosage regime now had a lower increase (125±113%) than the 
medium dosage. Additionally, this increase was not significant with respect to the control (p>0.2). 
The lack of significance derived from maximum dosage explants either having highly elevated 
vessel ingrowth similar to that observed in the two previous time points for this dosage or a gross 
appearance and amount of vessels identical to that in the control explants (Fig. 15B, C). At 42 
days explants of the 1500ng/day group also had two distinct appearances with the majority 
indistinguishable from the control and the remainder having considerably increased vessel 
Fig.14. Immunohistochemical staining of CD31 positive vessels in devices explanted after delivery of 
(A) 0, (B) 15, (C) 150 and (D) 1500ng VEGF/day for 10 days. Arrowhead indicates a CD31 positive 
vessel and white arrow indicates ePTFE cell barrier in Fig.14A. *in Fig.14D indicates a putative 
endothelial sac. Bar represents 50 µm (E). The area of vascularisation was determined as a percentage 
of the total area available for tissue ingrowth in the polyurethane wall. There was a significant increase 
in vascularisation relative to the control after delivery of 150 and 1500ng VEGF/day for 10 days (n=4). 
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ingrowth. Again, the medium dosage had a significant though substantially decreased increase 
(48±15%) in vessel density whilst the increase in response to the maximal dosage was again 
insignificant. The average vessel diameter was then determined for the medium and maximal 
VEGF and control groups at the two earliest time points. Vessel diameter at 10 days was found  
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to increase from 14.7±1.84µm for the control group to 20.1±1.17µm f r the medium dosage 
(p<0.05) and again to 23.9±1.55µm for the maximal dosage (p<0.05 maximum vs. medium dose) 
(Fig. 15D). By 20 days, the vessel diameters were very similar and the differences observed 
were not significant (15.4±0.2, 16.0±0.84, and 16.3±1.30µm for control, medium VEGF, and 
maximal VEGF groups, respectively). 
 
3.10.3. Vessel persistence after discontinuing VEGF delivery 
After VEGF had been delivered through the polyurethane device for 42 days at 150 and 
1500ng/day, the osmotic pump was removed and the device left in position for a further 80 days. 
The vessel density showed an overall decline but the medium dosage group still had an elevation 
over the control (46±11% increase, p<0.05) (Fig.16). The maximal dosage group’s vessel density 
was not significantly increased above the control. 
Fig.15. Constant delivery of VEGF resulted in concentration dependent differences in vascularisation 
levels. (A) The area of vascularisation was significantly increased by delivery of 150ng VEGF/day for 
20, 30 and 42 days. A significant increase was only observed for 20 days of delivery at 1500ng 
VEGF/day (*p< 0.05 vs. control, n=5–6). (B, C) Immunohistochemical staining for CD31 of two explants 
that had received VEGF at 1500ng/day for 30 days shows the dramatic differences in outcome. Bar 
represents 50µm. (D) Analysis of the average vessel diameter after 10 and 20 days of VEGF delivery 
showed that supply of VEGF for 10 days at 150ng/day increased the average diameter relative to the 
control and at 1500ng/day increased vessel size relative to both the control and the 150ng VEGF/day 
dosage. After 20 days delivery, the average diameter for both VEGF groups had reduced to that of the 
control (*p< 0.05 vs. control, δp< 0.05 vs. 150ng VEGF/day, n=4). 
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3.10.4. Mural cell coverage of vessels 
As mural cell coverage has been extensively implicated in the stability of vessels, the investiture 
of the newly formed vessels with desmin-positive cells was assessed (Fig.17A). The vessels 
induced by the medium VEGF dosage had a similar coverage of desmin-positive mural cells to 
that found on those in the control group (Fig.17B). However, the vessels resulting from the 
maximal concentration of VEGF showed a significant reduction (29.2±6.6%) in coverage after 20 
days of delivery. All groups showed an increase in coverage (51.3±2.9%) at 4 months relative to 
the 42 days time point. 
Fig. 16. A persistent increase in vascularisation levels after termination of VEGF supply is dependent 
on the concentration of VEGF delivered. VEGF was delivered for 42 days and devices were explanted 
80 days after pump removal. The delivery of VEGF at a dose of 150ng/day showed a significantly 
increased vasculature in the graft compared to the control (n=7). 
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Fig. 17. Analysis of mural cell coverage of endothelial cells. (A) Micrograph showing fluorescently 
labelled CD31 (red), desmin (green) and nuclei (blue). The yellow stain results from the overlay of a 
desmin positive cell and a CD31 positive endothelial cell. Bar represents 50 µm. (B) The percentage of 
endothelial cells directly in contact with a desmin positive cell was quantified as described in Section 2. 
Delivery of VEGF at 1500ng/day for 20 days resulted in a significant decrease in endothelial cell 
coverage (*p<0.05 vs. control, n=4–7). 
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3.10.5. Vessel perfusion 
When the vessels that had grown into the polyurethane scaffold were identified by physiological 
perfusion with a biotinylated L. esculentum lectin, it was observed that vessels that had been 
exposed to VEGF for 20 days had substantially more intense staining than the control group with 
the high dosage group appearing the brightest (Fig.18A–C). Vessels within the scaffold still 
stained positive for lectin at the terminal time point but the intensity was much diminished for the 
VEGF groups and there was no discernible difference between them and the control group (data 
not shown). 
 
 
Fig. 18. Analysis of vessel perfusion as determined by Lycopersicon esculentum lectin binding. The 
bound biotinylated lectin was detected by Cy3-streptavidin (red) after 20 days of delivery of VEGF at 
(A) 0, (B) 150 and (C) 1500ng/day. The intensity of staining increased with increasing VEGF 
concentration. 
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3.10.6. Discussion 
VEGF was stable and its concentration in the device maintained at a consistent level for the 
entire period of VEGF supply. High concentrations of VEGF induced maximal, but transient, 
vessel growth into porous PU scaffolds, as spontaneous regression occurred even with 
continued growth factor delivery over a period of 6 weeks. In contrast, medium concentrations of 
VEGF (150ng/day) induced not only a constant increase in vascularisation during delivery, but 
also resulted in elevated and functional vascularity for 2.5 months after termination of VEGF 
delivery.  A delivery of VEGF at 15ng/day was found to be insufficient to generate an increase in 
this angiogenesis model at 10 days whilst 1500ng/day VEGF generated an even more extreme 
increase than the medium dosage at this time point. As most tissue engineering projects would 
desire as rapid a connection with the host vasculature as possible, the low dosage was not 
further investigated. The response to the high dosage would suggest that the burst release 
observed for many biopolymers286 might not be deleterious but rather advantageous as long as it 
is not sustained for an extended period. This caveat stems from the finding that the high dosage 
eventually resulted in dramatic regression of the neovascularisation that started somewhere 
between 20 and 30 days of VEGF delivery. The precise timing of the delivery of VEGF may also 
be important as is evidenced by the study of Gosain and colleagues290 where in a similar manner 
to that reported here, VEGF was delivered by osmotic pumps to polyvinyl alcohol sponge discs. 
However, the delivery of VEGF only began 17 days after disc implantation, when the 
concentration of endogenous VEGF generated during wound healing started to decrease and it 
was found that the delivered VEGF did not prevent the regression of vessels. The exact reason 
for the persistence of an elevated vascularisation for the medium dosage of VEGF is not clear 
and is almost certainly multi-factorial in nature. This view derives in part from observations on the 
nature of the vessels generated. The medium dose led at all time points to vessels that 
morphologically closely resembled those in the control group, though they were larger at 10 
days, whilst the maximum dose at 10 days had regions densely filled with smaller vessels, 
putative endothelial sacs and an average vessel size that was even greater than those in the 
medium dosage. It is interesting that while both VEGF dosages still had induced substantially 
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larger areas of vessel ingrowth at 20 days the average vessel size had decreased to that of the 
control group and there were very few endothelial sacs present. The reason and mechanism(s) 
for this decrease in size are unclear but must reflect either a very dynamic period of regression of 
large vessels and sprouting of new smaller vessels or intussusception of the larger vessels. 
VEGF clearly can induce sprouting and has also been implicated in the regulation of 
intussusception291. The high dose also exhibited a significant decrease in endothelial cell contact 
with mural cells at 20 days. Again, the medium dose showed no such decline in vessel coverage. 
The mural cells are assumed to most likely be pericytes and possibly a subset of smooth muscle 
cells as these cell types have been shown to express the intermediate filament desmin292. The 
association of pericytes with endothelial cells has been variously reported to either be correlated 
with stabilization of blood vessels293 or not294. Though this study was not designed to comment 
on this discrepancy, an image analysis assay was established that determines the level of 
endothelial cell ensheathment by pericytes. This is analogous to the assay designed for whole 
retinal mounts established by Chan-Ling and co-workers292, which was found to predict stability 
of newly developed vessels in the retina. Interestingly the pericyte coverage increased for all 
groups at the final time point when it might be expected that the vessels that are present would 
be stable. Finally the VEGF treated implants had a substantial increase in perfusion as 
determined by lectin binding in the earlier stages with the high dose having the most pronounced 
increase. L. esculentum lectin binding could rather be altered by differing expression of its ligand 
(N-acetyl-D-glucosamine) on the endothelial surface and not by a change in perfusion. However, 
it has been demonstrated that binding of L. esculentum was uniform on normal and inflamed 
vessels295. Additionally decreased lectin binding in peritubular capillaries in diseased kidneys was 
found to correlate with decreased perfusion as determined by intravitral microscopy analysis of 
red blood cell velocity296. Though a cause for the increased perfusion was not determined, it may 
result from increased nitric oxide (NO) levels as VEGF causes the increased production of NO 
via upregulation of endothelial nitric oxide synthase297 and NO has been determined to increase 
perfusion in several areas of the body, most probably through its vasodilation of resistance 
vessels298. It is therefore tempting to suggest that the precipitous regression observed for the 
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high dose regime results from a confluence of the above factors. The vascularised area 
generated within the scaffold by this dosage was massively elevated over the normal tissue 
response (even 50–75% higher than the medium dosage) and this elevation was coupled with an 
increased perfusion. This would probably have resulted in supply far outstripping metabolic 
demand and caused a dramatic pruning of the newly formed vessels299. The extent of pruning 
may have been exacerbated by the irregular nature and inadequate pericyte coverage of the 
vessels. The medium dose, however, may avoid this fate by generating vessels that do not cross 
critical thresholds of difference from physiological vessels. This finding suggests that a single 
growth factor can induce stable vessels into a scaffold but further work needs to be done to 
elucidate the minimal delivery period. In conclusion, the concentration of VEGF delivered plays a 
central role in determining the nature of neovessels, which in turn critically influences the stability 
of generated vascular constructs. 
 
3.11. Regression of VEGF-induced neovasculature is preceded by the 
termination of vessel perfusion 
While high VEGF dosages (1500ng/day) were highly efficient at inducing neovessels in the short 
term, the time course experiments suggested that there could be a precipitous regression of 
vessels after exposure to VEGF at such a high dosage. It was therefore thought worthwhile to 
examine the kinetics of regression of vessels that had been induced by this dosage in more 
detail. Early experiments revealed that that VEGF-induced neovascularization reached its 
maximum around day 10 after implantation. To study the dynamics of vascular regression after 
termination of VEGF delivery, 1500ng/day VEGF were delivered via osmotic pumps for 10 days; 
osmotic pumps were removed at day 10 and subsequently the vascularization devices were 
explanted at the time of and 1, 2, 4, 10 or 20 days after pump removal, respectively. The level of 
neovascularisation within the scaffolds was visualized by staining with an antibody against CD31 
and physiological perfusion was assessed with biotinylated L. esculentum lectin.  
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3.11.1 Vessel persistence after discontinuing VEGF delivery 
During the initial 48 hours after termination of VEGF delivery vascular density remained 
unchanged (Fig.19). Between day 10+2 and 10+4 a sharp increase in vascular regression was 
observed and by day 10+4 the number of vessels had decreased by 75.9% in comparison to day 
10 (Fig.19). Regression of the neovessels continued at a rapid rate and by day 10+10 the  
 
 
neovasculature had regressed completely (-191.4%) to levels comparable with PBS controls 
harvested at this timepoint. A further decrease was observed on day 10+20 (-254.2% in 
comparison with 10-day levels). 
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Fig.19. After termination of VEGF delivery at 10 days (1500ng/day), the induced neovasculature 
appeared stable for 2 days (#p>0.05 compared with 10 day vascular area after VEGF delivery, n=4-6) 
before regressing rapidly (*p<0.01, **p<0.001 both compared with 10 day VEGF-induced 
vascularization, n=4-6). At day 20, 10 days after pump explantation, no significant difference in 
vascularization between VEGF grafts and PBS controls was observed (p=0.11, n=4). 
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3.11.2. Vessel perfusion 
Assessment of physiological kidney perfusion confirmed successful delivery of biotinylated L. 
esculentum lectin in all animals (n=3 for each timepoint). Perfusion at day 1 post pump-removal 
Fig.20. Immunohistochemical staining of neovascular devices for CD31 performed on day 1 (a), 2 (b), 4 
(c) and 19 (d) after removal of VEGF-delivering osmotic pumps. As early as day 2 (b) a substantial 
decrease of CD31+-vessels (in blue) is seen. 4 days after termination of VEGF-delivery (c) the 
neovasculature has entirely regressed to control levels. 
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(10+1) remained unchanged in vascularization devices in comparison with grafts explanted 
immediately after pump removal at day 10 (see Fig.21a). Vascular perfusion was still observed 2 
days after pump removal albeit at a diminished rate (shown in Fig.21b), but by day 4 after 
termination of VEGF delivery the perfusion had almost entirely stopped (see Fig.21c). At days 
10+4, 10+10 and 10+20, there were no discernible difference in perfusion between VEGF-
treated groups and PBS controls. 
 
 
Fig.21. Vessel perfusion as determined by L. esculentum lectin binding. Successful perfusion with lectin 
in each animal was confirmed by detecting bound biotinylated lectin with Cy3-streptavidin in kidneys 
harvested at the time of sacrifice. Kidney perfusion was similar at each timepoint and representative 
images are shown in respective inserts (framed in white). 1 day after termination of VEGF delivery 
vascularization devices remain highly perfused (Fig.21a). 48 hours after stoppage of VEGF delivery a 
profound decrease in perfusion in vascularization devices was observed (Fig.21b). Perfusion of 
neovessels has almost entirely stopped by day 10+4 (Fig.21c). 
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3.11.3. Discussion 
The dynamics of vascular perfusion and regression were assessed. Experiments confirmed that 
short-term delivery of high VEGF dosages does not result in a stable neovasculature. Within 48 
hours after termination of VEGF delivery, a dramatic decrease in vascular perfusion was 
observed (Fig. 21b). 96 hours after VEGF removal perfusion had come to a complete halt 
(Fig.21c). Regression of the neovasculature occurred at a slower rate [following approximately 
48 hours after perfusion] (see Fig. 20). First significant signs of vascular regression became 
apparent 4 days after termination of VEGF delivery and 10 days after stoppage of VEGF 
delivery, neovessels had completely regressed and there was no significant difference in 
comparison with PBS controls. 
While the mechanisms underlying vascular regression are currently poorly understood, a number 
of hypotheses exist that attempt to explain this phenomenon. While it is possible that the 
deferred regression of vessels resulted from a slow clearance of VEGF from the 
neovascularisation site, turnover of VEGF in the body h s been shown to be rapid17 and thus this 
explanation seems unlikely. It is plausible that a lack of metabolic demand precedes the stop in 
vascular perfusion and initiates the pursuing vascular regression58. Growth factor interactions 
have been shown to be instrumental in regulating neovessel stability. As the previous study had 
shown that the concentration of VEGF has substantial effects on the maturation of neovessels, it 
is intriguing to hypothesize that super-physiological growth factor concentrations may prevent the 
establishment of stabilizing signals mediated by supplementary endogenous growth factors. As a 
result, this could block the recruitment of stabilizing perivascular cells to the newly forming 
vessels. 
 
4. INTRODUCTION: Attempts to prevent vascular regression 
As stable vasculature is a prerequisite for many therapeutic angiogenesis approaches, it was felt 
that further attention should be paid to stabilizing the rapid and dramatic increases in 
neovascularization observed for the high VEGF dosage. Even though it was shown that a 
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moderate dosage could sustain a stable vasculature, many therapies will benefit from a more 
rapid connection to the host vasculature.  
A number of strategies have been suggested to promote vessel stability. In the body, the survival 
of many capillary beds throughout the body is dependent on the continuous presence of 
VEGF294,300. Numerous reports have suggested that vascular stability depends on the temporal 
and spatial interplay of a diverse set of growth factors that help recruit stabilizing perivascular 
cells. While SDF-1 has been identified as an important regulator initiating angiogenesis in 
ischemic tissues234-240, SDF-1-dependent recruitment of CXCR4+PDGFR+ckit+ smooth muscle 
progenitor cells has also been shown to promote neovascular stability246. PlGF has been 
associated with superior vascular stability130 in comparison with VEGF likely due to targeting 
endothelial cells127, smooth muscle cells and macrophages, all of which are instrumental in the 
growth of collaterals31,129. Synergistic effects existing between PlGF and VEGF exhibit a profound 
effect on pathological angiogenesis, as PlGF was shown to promote pathological angiogenesis 
by triggering crosstalk between VEGFR-1 and VEGFR-299,127,130. Furthermore, tumour vessels 
resistant to VEGFR2 have been described to regress upon treatment with an antibody targeting 
PlGF (α-PlGF)301. As crosstalk between VEGF and PlGF appears to be important in controlling 
vessel stability, these results suggest that a strategy based on simultaneous delivery of these 
angiogenic factors may be worth exploring for therapeutic angiogenesis. 
Finally, signals derived from ECM turnover play an important role during angiogenesis. MMPs 
help regulate extracellular matrix remodelling to provide space during vascular sprouting44-48. As 
critical support and guidance signals are mediated through the ECM, a shift in the balance of 
MMPs and their inhibitors (TIMPs) has been suggested to contribute to determining vascular 
fate, namely vessel collapse versus vessel stability, after establishment of an immature vascular 
bed44,49-52. 
Therefore to test the aforementioned hypotheses, the long-term fate of VEGF-induced 
neovessels was assessed after simultaneous and sequential delivery of VEGF, SDF-1 and PlGF. 
Furthermore the effects of an MMP-modulating agent on neovessel stability were tested.  
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4.1. Are low VEGF dosages essential to protect neovessels from 
regression? 
Previous experiments have shown that neovascular stability is dependent on the VEGF dosage.  
High VEGF-dosages give rise to neovessels that are prone to regression after termination of 
growth factor delivery. It has been demonstrated that the survival of many capillary beds 
throughout the body is dependent on the continuous presence of very low levels of VEGF294,300. 
In order test the hypothesis that minimal levels of VEGF are needed to maintain vascular stability 
and prevent neovessel regression, osmotic pumps were exchanged at day 10, and 15ng 
VEGF/day were delivered for an additional 10 days subsequent to 10-day delivery of 1500ng 
VEGF/day. After harvesting neovascularization devices, neovessel formation was assessed by 
immunohistochemical staining for CD31. 
 
4.1.1. Results 
Sequential delivery of 15ng/day VEGF did not successfully prevent or retard the regression of 
VEGF-induced neovessels. 10 days after the termination of high VEGF delivery (1500ng/day), 
vascularization in the treatment group was 3.15±0.33% and did not differ significantly from PBS 
controls (2.54±0.29%, n=6, p=0.2, Fig.22). Historical comparison with highly reproducible data 
obtained after delivering 1500ng VEGF/day for 10 days and harvesting neovascularization 
devices at 10 and 20 days, respectively, was performed (for this and ensuing experiments). In 
comparison with grafts that only had VEGF delivered for 10 days before being explanted at day 
20 (10+10) no differences were observed (3.5±0.09%, n=4, p=0.43). A 223.8% reduction was 
observed on day 20 in comparison with vascularization levels at day 10. Delivery of VEGF 
dosages in the range of 15ng/day is therefore not sufficient to promote stabilization of the vessels 
created and this strategy fails to halt the regression seen after terminating the delivery of VEGF 
at high dosages. 
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4.2. Does the VEGF-SDF-1 axis contribute to creating vascular stability in 
therapeutic angiogenesis? 
The interaction between SDF-1 and VEGF is critical in regulating the angiogenic response after 
ischemic injury. SDF-1 has emerged as a major factor regulating the retention and incorporation 
of progenitor cells recruited by VEGF-A up-regulation into sites of active neovascularization84 and 
in particular the SDF-1 dependent recruitment of CXCR4+PDGFR+ckit+ smooth muscle 
progenitor cells has been shown to enhance the stability of the newly formed vasculature246. 
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Fig.22. Immunohistochemical analysis of CD31-positive vessels in devices explanted after 20 days. 
To allow for comparison, historical data depicting vascularization levels seen after 10 days of 
delivering 1500ng/day VEGF is shown (*, black bar). Delivery of 15ng/day VEGF does not prevent or 
slow down the regression of VEGF-induced neovessels.   
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In order to test the hypothesis that via recruitment of stabilizing progenitor cells SDF-1 enhances 
the stability of VEGF-induced neovessels in the subcutaneous angiogenesis assay 150ng SDF-
1/day were administered for a period of 10 days subsequent to administering 1500ng VEGF/day 
for 10 days. At day 20 the vascularization devices were explanted and processed for histological 
analysis. 
 
4.2.1. Results – Sequential delivery of VEGF and SDF-1 
Immunohistochemical analysis for CD31+-vessels was performed. Vascularization in the 
treatment group was 2.92±0.11% and did not differ significantly from controls (2.82±0.3%, n=6, 
p=0.3). Historical comparison with vascularization seen after 10-day delivery of 1500ng 
VEGF/day shows that the neovasculature has entirely regressed (-249.3%).  
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Vascularization area measured after sequential delivery of 1500ng VEGF/day and 150ng SDF-
1/day was not significantly different compared to levels seen after sole delivery of 1500ng 
VEGF/day for 10 days (when devices were explanted on day 20). Thus, the subsequent 
administration of SDF-1 did not promote the stability of VEGF-induced neovascularization. 
 
While the sequential delivery of VEGF and SDF-1 did not have an effect on vascular stability and 
was unsuccessful in preventing the regression of neovessels, simultaneous delivery of both 
growth factors may be needed for vessel maturation. Evidence supports that SDF-1 and VEGF 
enhance neoangiogenesis synergistically when delivered simultaneously. In the matrigel plug 
assay, co-delivery with VEGF-A232,233 resulted in a more significant increase in angiogenesis than 
sole delivery of SDF-1. Furthermore the ability of SDF-1 to promote matrix metalloproteinase 
production and assist during vessel formation by facilitating the remodelling of active angiogenic 
sites has been described25,84,245.  
 
To test the hypothesis that simultaneous delivery of VEGF-A and SDF-1 enhances angiogenesis 
and promotes vascular stability, VEGF-A and SDF-1 were co-delivered for 10 days. Osmotic 
pumps were explanted after 10 days and at day 20 after device implantation, vascularization 
devices were harvested and neovessel formation was assessed by immunohistochemical 
staining for CD31. 
 
4.2.2. Results – Simultaneous delivery of VEGF and SDF-1 
Image analysis performed on vascularization devices harvested on day 20 revealed that 
Fig.23. Analysis of CD31+vessels after harvesting vascularization devices at day 20. The sequential 
delivery of VEGF-A and SDF-1 does not create a more stable vascular bed in comparison with sole 
delivery of 1500ng VEGF/day. (p>0.05). 10 days after termination of VEGF-A delivery the 
neovasculature has completely regressed to levels seen in the PBS control (p=0.3, n=6).  
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simultaneous delivery of 1500ng VEGF-A/day and 150ng SDF-1/day resulted in a vascularization 
area of 3.03±0.28% (see Fig.24). This did not differ significantly from controls solely delivering 
150ng SDF-1/day (2.48±0.19%, n=6, p=0.076). Importantly, no effect on vascular stability was  
 
 
 
 
observed, when VEGF and SDF-1 were delivered in tandem. As previously observed after 
delivering 1500ng/day VEGF for 10 days, growth-factor-induced neovessels had entirely 
regressed by day 20 (-236.6%, historical comparison). 
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Fig.24. Immunohistochemical analysis of CD31+ vessels shows that the simultaneous delivery of 
VEGF-A and SDF-1 for 10 days has no synergistic effects on enhancing the stability of newly formed 
vessels. Immunohistochemical analysis revealed that the neovascularization at day 20 is not 
significantly different in neovascularization devices administered with VEGF alone. 
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4.3. Is regression of VEGF-induced neovasculature MMP-mediated? 
Matrix metalloproteinases are critically involved in both the creation and remodelling of 
neovessels and in the degradation of immature vasculature46,70-73,74. MMPs have been described 
as potential contributors to neovascular regression74,75, that may be targeted for therapeutic 
purposes. In three-dimensional collagen matrices Saunders et al. were able to show that 
suppression of EC-derived TIMP-2 and pericyte-derived TIMP-3 expression using siRNA resulted 
in capillary tube regression in an MMP-dependent manner302. These data directly implicated 
TIMP-2 and TIMP-3 in the pericyte-mediated enhancement of neovascular stability. Similar 
inhibition of regression was also observed with GM6001, an MMP-inhibitory small molecule. 
 
In order to investigate a potential role of MMPs in vascular stability and the degradation of VEGF-
induced neovasculature, GM6001 was delivered to block MMP activity after creation of the 
capillary bed. After delivering 1500ng VEGF/day over the course of 10 days, osmotic pumps 
were exchanged and GM6001 was administered at 2.5, 25 or 250mM, respectively, for an 
additional 10 days. The devices were harvested for histological analysis on day 20 and the 
vascularization area was assessed by immunohistochemical analysis with an antibody targeting 
CD31. 
 
4.3.1. Results 
Vessel ingrowth area after 20 days was 2.71±0.41%, 3.68±0.52% and 3.01±0.52% for GM6001 
delivered at 2.5, 25 and 250mM, respectively (n=5-6, see Fig.25). No significant difference in 
vascularization was observed between the different dosages of GM6001 (p=0.36 25vs250mM; 
p=0.65 2.5vs250mM; p=0.2 2.5vs25mM GM6001). Furthermore, when compared with sole 
delivery of 1500ng VEGF/day vascularization measured on day 20 did not differ significantly at 
any dosage (VEGF 10+10: 3.5±0.09%, p=0.17 (GM6001 (2.5mM) vs. VEGF 10+10), p=0.78 
(GM6001 (25mM) vs. VEGF 10+10), p=0.44 (GM6001 (250mM) vs. VEGF 10+10)). When 
compared to vessel ingrowth area induced by 1500ng VEGF/day around it’s peak on day 10, 
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vascularization on day 20 was reduced by 276.4%, 177.2% and 238.8% after administration of 
GM6001 at 2.5, 25 and 250mM, respectively. 
While this result cannot exclude an important role for specific MMPs in regulating the fate of 
immature vessels, it shows that broad inhibition of MMPs with GM6001 does not prevent 
unstable VEGF-induced vessels from regressing.   
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Fig.25. Vascularization area was assessed by analysis of CD31+-vessels on day 20. VEGF-induced 
neovasculature is not stabilized by sequential delivery of the MMP-inhibitory small molecule (GM6001) 
at dosages ranging from 2.5 to 250mM.  
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4.4. Does PlGF create a more stable vasculature than VEGF?                                              
Does the simultaneous delivery of VEGF-A, VEGF-C and PLGF promote 
vascular stability? 
PlGF-induced vessels have been described as possessing a more stable phenotype than 
vessels created by VEGF delivery. A possible explanation offered has been the ability of PlGF to 
affect not only endothelial cells127, but also smooth muscle cells, and macrophages, the three 
main cell types involved in the growth of collaterals31,129. While the simultaneous delivery of 
VEGF-A, VEGF-C and PlGF did not further promote short-term neovascularization in comparison 
with VEGF-A delivery alone, vascular stability may still be enhanced after concurrent stimulation 
of the lymphatic vasculature285.  
 
In order to investigate whether PlGF is superior in promoting vascular stability in comparison with 
VEGF, 1500ng PlGF/day were delivered for 10 days.  After an additional 10 days, the 
neovascularization devices were explanted and neovessel stability was assessed by 
immunohistochemical staining for CD31. 
To test whether the combinatorial delivery of VEGF-A, VEGF-C and PlGF induces a more stable 
vasculature, 150ng/day of each growth factor were delivered simultaneously over a period of 10 
days, and after explanting the neovascularization devices on day 20, the effects on neovessel 
stability was determined by CD31 staining. 
 
4.4.1. Results - PlGF 
As previously shown, the delivery of 1500ng/day VEGF enhanced short-term neovascularization 
significantly more than the delivery of 1500ng/day PlGF (Fig.26). Vessel ingrowth area on day 10 
after continuous growth factor delivery was 8.76±1.12% in neovascularization devices after 
VEGF delivery compared with 5.00±0.39% if PlGF was administered (p=0.013, n=4-6). When 
vascular stability of the induced neovasculature was assessed on day 20, 10 days after 
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termination of growth factor delivery, vessel ingrowth area for both treatments was not 
significantly different, as vascularization area for PlGF and VEGF-grafts was measured at 
3.26±0.3 and 3.5±0.09%, respectively (p=0.55, n=4-6). While only 53% of neovessels seen on  
 
 
 
day 10 regressed after PlGF-administration, VEGF-grafts showed a three-fold higher regression 
of vessels on day 20 (-150%). Regardless, just as seen for VEGF, vessel ingrowth area 
measured on day 20 was not significantly different in PlGF-grafts when compared with PBS 
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Fig.26. Immunohistochemical analysis of CD-31+-vessels after delivery of 1500ng/day PlGF or VEGF, 
respectively, was performed. On day 10 (+), vascularization was significantly higher in 
neovascularization devices after VEGF administration in comparison with PlGF (*p<0.05). When 
devices were explanted on day 20, 10 days after termination of growth factor delivery (§), no significant 
difference was seen between the two treatment groups (p<0.05) and PBS controls (data not shown), 
indicating that neither VEGF nor PlGF can create a stable vasculature after delivered at high dosages. 
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controls (p=0.57, n=4-6, data not shown). Thus, when administered at high dosages 
(1500ng/day), PlGF did not promote a more stable neovasculature than VEGF. 
 
4.4.2. Results – Simultaneous delivery of VEGF-A, VEGF-C, PlGF 
Previous experiments had shown that when delivered continuously over 10 days, the 
simultaneous delivery of 150ng/day of VEGF-A, VEGF-C and PlGF did not further enhance 
short-term neovascularization in comparison with only delivering 150ng VEGF/day (6.39±0.87%  
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Fig.27. To assess the effects of simultaneous short-term delivery (10 days) of VEGF-A, VEGF-C and 
PlGF (150ng/day each), neovascularization devices were harvested 10 days after stoppage of growth 
factor delivery. Quantification of vessel ingrowth area showed that neovascular stability is not enhanced 
after combined delivery. Vessel regression was not prevented until day 20 and vascularization area 
was indistinguishable from PBS controls (p>0.05). 
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compared with 6.61±0.95%, respectively; p>0.05, n=6, see Fig.13). After stoppage of growth 
factor delivery on day 10 neovascularization devices were harvested on day 20 to assess the 
effects of simultaneously delivering VEGF-A, VEGF-C and PlGF on vessel stability. At this 
timepoint, 3.00±0.21% of the graft was vascularized, demonstrating that the combined short-term 
delivery of these three VEGF-family members does not promote vessel maturation and stability.  
 
4.5. Discussion – Strategies to prevent regression of VEGF-induced 
neovasculature 
A number of strategies to promote vascular maturation and long-term vascularization were 
previously described in the literature. Importantly, these previous studies were designed to test 
the potential of growth factors and combinations thereof to promote long-term neovascularization 
rather than examining factors that modulate maturation as opposed to regression in therapeutic 
angiogenesis after successful establishment of a new capillary bed. The potential of PlGF to 
promote vessel maturation and to create a stable vasculature has been described as superior in 
comparison with VEGF31,127,129. This finding was not observed using our angiogenesis assay (see 
Fig. 26). Again, timing and mode of delivery, growth factor dosage and tissue specificity are the 
most likely candidates that may explain this discrepancy. A strong case for the importance of 
growth factor dosage and the duration of growth factor administration can be made in light of 
previous findings. When testing the effects of short-term delivery of PlGF on vessel stability, a 
dosage of 1500ng/day PlGF was chosen. Findings from the more comprehensive investigation 
into the long-term stability of VEGF-induced neovasculature suggest that the high PlGF dosage 
may have been the underlying cause for this negative result. When PlGF was co-administered 
with VEGF-A and VEGF-C at 150ng/growth factor/day for 10 days, the neovasculature had also 
regressed by day 20 (see Fig.27).  As VEGF-A successfully promoted long-term vessel stability 
when delivered at 150ng/day for 6 weeks, these experiments collectively suggest that short-term 
delivery (10 days) of the tested growth factors (VEGF-A, PlGF) is not sufficient to create a stable 
vasculature. 
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As the underlying mechanisms regulating vascular regression after pro-angiogenic therapy with 
high dosages of VEGF (1500ng/day) are currently not well understood, three independent 
hypotheses suggested in the literature were tested: a) that newly created capillary beds are 
dependent on continuous VEGF-supply294,300; b) that the stability of VEGF-induced vessels is 
SDF-1-dependent84,246; and c) that matrix metalloproteinases promote vascular regression after 
termination of VEGF-administration74,75. Neither one of these strategies did successfully prevent 
vessel regression, as vessel ingrowth area was indistinguishable from controls on day 20 (see 
Figs. 22-25). The nature of these findings is likely multifactorial as well. SDF-1 and GM6001 may 
not have reached therapeutic levels necessary to prevent the regression of VEGF-induced 
neovasculature; higher levels of VEGF could be necessary to promote EC survival in order to 
shift the balance between maturation and regression. Furthermore, a more complex in vivo 
setting may have contributed to prevent the successful inhibition of MMP-dependent capillary 
tube regression previously demonstrated in vitro302.  
Importantly, differences may exist between the regulatory mechanisms that control vascular 
stability and regression during physiological, pathological and therapeutic angiogenesis 
(depending on the growth factor regimen selected). Future therapeutic angiogenesis strategies 
will require the development of growth factor-specific assays that enable the identification of 
regulators determining vascular reg ession.  
 
4.6. Identification of potential candidates that regulate the regression of 
VEGF-induced neovasculature 
Factors contributing to an unstable vasculature (prone to regression) are largely unknown and 
the process of vascular regression remains incompletely understood. An observation in earlier 
experiments revealed that after 30 days of high VEGF delivery around 50% of the grafts were still 
highly vascularized, whilst neovessels in the other half of the grafts had completely regressed to 
levels comparable with PBS controls.  
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To identify factors that contribute to vascular stability and regression after VEGF delivery, a 
quantitative real-time PCR-based rat angiogenesis gene array was performed. Advanced primer 
design in the RT2 Profiler PCR Array System guarantees that every single q-RT-PCR reaction 
creates highly specific amplicons for each gene without co-amplifying non-specific byproducts. 
As each single reaction is optimized for standard condition, a panel of pathway-specific genes 
can be assayed simultaneously. Importantly the high reproducibility of these arrays has 
previously been demonstrated allowing comparison between samples run on different q-RT-PCR 
plates. 2 neovascularization devices per rat were implanted subcutaneously into 4 rats and 
VEGF was continuously delivered for 30 days at 1500ng/day. Vascularization devices were then 
harvested and RNA was isolated to allow the determination of the expression levels of 
angiogenic growth factors, growth factor inhibitors, adhesion molecules, proteases, and 
transcription factors.  
 
4.7.1. Results - Immunohistochemistry      
4 rats were used for this study. A total of 8 neovascularization devices were implanted. After 
harvest on day 30, the vascularization devices were cut in half. One half was used for RNA 
isolation, while the other one was processed for histological analysis of neovascularization by 
immunohistochemical analysis of CD31. 
Image analysis confirmed the previous finding that continuous delivery of high VEGF dosages 
(1500ng/day) for 30 days results in neovascular regression 50% of the time (shown in Fig.28). 
Interestingly, this effect was rat-specific, as in each of the 4 animals both grafts were either highly 
vascularised or showed vascular regression to levels indistinguishable from controls.  
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4.7.2. RNA quality control 
After isolation, high RNA quality was confirmed using a bioanalyzer at the Centre for Proteomic 
and Genomic Research (CPGR, located at the University of Cape Town), before proceeding with 
reverse transcription and sample preparation for the qRT-PCR-based gene array (see. Fig.29).  
 
 
Fig. 28. Vascularization devices were harvested after 30 days of continuous VEGF delivery 
(1500ng/day). Immunohistochemical analysis of CD31+-vessels confirmed that devices were either 
highly vascularised (4/8, 50%, Fig.28a) or showed postangiogenic vascular regression (4/8, 50%, 
Fig.28b).  
Fig.29. Representative electropherogram used to analyze the quality of RNA preparation is shown. 
Sharp peaks without shoulders for the 18S (left peak) and 28S (right peak) ribosomal RNA confirm high 
quality of total RNA.  
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4.7.3. Rat angiogenesis RT2 Profiler PCR Array 
The expression profiles of 84 angiogenesis-related genes were determined. Significant 
differences were found for 24 genes when comparing neovascularization devices with a stable 
vasculature with grafts showing complete vascular regression (p<0.05, see table 1). Of these 24 
genes, 17 were downregulated (14 by more than 2-fold) after vascular regression, while 7 genes 
were upregulated (6 by more than 2-fold). As expected, the regression of VEGF-induced 
neovasculature – from roughly 10% vascularization area to 2% (5-fold) – was concomitant with 
the significantly reduced expression of genes expressed by endothelial cells. Angiopoietin-2 (-
4.35 fold), vascular endothelial cadherin (-3.35 fold), vascular endothelial growth factor receptor-
1 (-4.23 fold), vascular endothelial growth factor receptor-2 (-5.46 fold), endothelial TEK tyrosine 
kinase (-4.35 fold), endothelial PAS domain protein 1 (-4.38 fold), endothelial differentiation gene 
1 (-2.26 fold) and platelet/endothelial cell adhesion molecule 1 (-1.95 fold) were down-regulated. 
After neovascular regression, a significant up-regulation of Chemokine (C-X-C motif) ligand 2 
(MIP-2, 12.17 fold), MMP3 (7.77 fold), Interleukin 1β (4.19 fold), TIMP1 (2.97 fold), Serpin 
F1/PEDF (2.89 fold), Ephrin A5 (2.56 fold) and Transforming growth factor β2 (1.97 fold) was 
observed. Levels of collagen type IV α3 (Tumstatin, 5.83 fold), collagen type XVIII α1 
(Endostatin, 4.63 fold), laminin α5 (2.53 fold), transforming growth factor α (2.41 fold), jagged 1 
(2.23 fold), fibroblast growth factor 1 (2.15 fold), plasminogen (2.05 fold), connective tissue 
growth factor (1.87 fold) and inhibitor of DNA binding 3 (1.71 fold) were significantly reduced. 
Trends towards a significantly reduced expression of fibroblast growth factor receptor 3 (-3.41 
fold, p=0.059), vascular endothelial growth factor C (-2.53 fold, p=0.068), prostaglandin-
endoperoxide synthase 1 (-2.38 fold, p=0.097), platelet-derived growth factor α (-2.39 fold, 
p=0.13) and platelet-derived growth factor β (-2.06 fold, p=0.11) were seen, while vascular 
endothelial growth factor A gene expression tended to be upregulated (+2.75 fold, p=0.12). 
 
4.7.4. Discussion 
Numerous angiogenic stimuli and factors controlling vascular stability have been identified, yet 
little is known about regulators that determine the fate of growth factor-induced neovessels. Two 
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prominent angiogenesis inhibitors were significantly upregulated in vascular grafts after 
neovascular regression, namely serpin F1 (better known as pigment epithelium-derived factor, 
PEDF, 2.89 fold up-regulation) and chemokine ligand 2 (CXCL2, also known as gro-β, 12.17 fold 
upregulation). Strong evidence exists supporting a critical interaction between VEGF and PEDF 
in regulating angiogenesis. Clinical studies have shown that loss of PEDF in combination with an 
increased expression of VEGF is a major stimulus for retinal angiogenesis303. Elevated levels of 
PEDF suppress VEGF-induced growth and migration of retinal endothelial cells while also 
inhibiting retinal neovascularization304. While this role for PEDF in inhibiting angiogenesis in the 
eye has been well established, PEDF has recently emerged as a critical regulator of 
microvascular density in prostate cells, pancreas305 and the liver306. Counterbalancing VEGF 
levels after castration, PEDF was shown to critically regulate prostate regression, thereby 
establishing an interaction between PEDF and vascular endothelial growth factor in this organ. 
The most direct evidence implicating PEDF in the regression of VEGF-induced neovasculature, 
though, stems from a study showing that adenoviral delivery of PEDF induces regression of 
ocular neovascularization in rho/VEGF mice307. CXCL2, expressed by monocytes308 that are 
highly present in granulation tissue, was shown to dose-dependently inhibit growth factor-
induced capillary endothelial cell proliferation309, and to inhibit angiogenesis in a chicken 
chorioallantoic membrane assay. Furthermore, CXCL2 delivery successfully slowed Lewis lung 
tumour growth by halting tumour-induced neoangiogenesis.  MMP-3 and TIMP-1 upregulation 
(by 7.77 and 2.97 fold, respectively) may contribute to vascular regression by either modulating 
extracellular matrix turnover (and thereby releasing angiogenesis inhibitors) or by preferential 
splicing of vascular endothelial growth factor310. 
Growth factor interactions have long been known to significantly contribute to vascular 
stability59,157,207. Amongst others, fibroblast growth factor, angiopoietins and platelet-derived 
growth factor B have been shown to modulate long-term vascularization in concert with VEGF. 
Neovascular regression was coupled to significant reductions in gene expression levels of the 
pro-angiogenic factors FGF-1, connective tissue growth factor, jagged-1 and TGF-α. In addition 
the expression of EGF, PDGFα, PDGFβ, VEGF-C and FGFR3 was markedly reduced (albeit not 
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significant). These findings suggest that a lack of supporting growth factors or an impaired 
establishment of growth factor gradients may contribute to the untimely vascular regression. 
Another group of proteins that may contribute to the instability of VEGF-induced vasculature are 
the inhibitors of DNA binding 1 (Id 1) and 3 (Id 3). These proteins are highly expressed in 
endothelial cells of tumour infiltrating blood vessels311 and it has previously been described that 
tumour growth and angiogenesis is impaired in Id1-Id3 double knockout mice312. In samples 
showing a regressed neovasculature, Id3 was significantly downregulated (-1.71 fold, p<0.05), 
while a strong trend was observed for Id1 (-2.1 fold, p=0.098). Interestingly, Id1 was recently 
identified as a selective marker of endothelial progenitor cells313. It is therefore intriguing to 
hypothesize that the number of endothelial progenitor cells contributes to the stability of VEGF-
induced neovasculature. This draws further support from the finding that regression of VEGF-
induced neovessels was a rat specific event, as in all 4 animals the neovascularization levels 
were similar in both implanted grafts. 
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Table 1. Results from rat angiogenesis RT2 Profiler PCR Array 
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4.7.5. Conclusion 
The results obtained from quantitative real-time PCR-based rat angiogenesis gene array studies 
implicate numerous factors in the regression of VEGF-induced neovasculature in our 
subcutaneous wound healing model and are of interest for further investigation. To substantiate 
these preliminary findings, these experiments need to be repeated to increase the number of 
replicates and protein levels of the differentially regulated genes need to be analysed by western 
analysis or immunohistochemistry to confirm the changes seen in gene expression levels. While 
these are clearly the confirmatory experiments needed, these studies were not performed due to 
time constraints. 
 
 
5. SUMMARY: Angiogenesis chapter  
Therapeutic angiogenesis has evolved into a promising strategy to treat ischemia-induced cell 
death, which underlies various cardiovascular pathologies. Developing strategies to create a 
mature and stable vasculature has been challenging due to a lack of suitable in vitro and in vivo 
models. Therefore a novel in vivo angiogenesis model that allows for characterization of stability 
and mural cell investment of newly created vessels was designed. Amongst a number of growth 
factors tested, vascular endothelial growth factor-A165 (VEGF) emerged as the most potent 
initiator of neovascularization in initial experiments. Subsequent studies showed that VEGF 
concentration plays a critical role in the nature and persistence of neovessels in a biomaterial 
scaffold. When VEGF was delivered at 150ng/day for 42 days, scaffold neovessels were found to 
be stable for up to 2.5 months after withdrawal of VEGF. At this timepoint, vessels induced by a 
10-fold higher concentration of VEGF had regressed to levels comparable with PBS controls. 
Using the angiogenesis assay, a timeline was established illustrating that, when delivered at the 
highest dosage of 1500ng/day, termination of VEGF delivery resulted in diminished perfusion of 
the neovasculature within 48 hours, followed by rapid regression of the vascular network. A 
series of experiments testing the potential of PlGF and various growth factor combinations 
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(VEGF+SDF-1, VEGF-A+VEGF-C+PlGF) to promote neovascular stability and/or to prevent 
neovascular regression revealed that apart from the growth factor dosage, the duration of growth 
factor delivery is a critical determinant of long-term vessel stability. As previous strategies 
described to enhance vessel maturation did not prevent the rapid regression of the 
neovasculature induced by high VEGF dosages, a gene expression array was performed, 
identifying serpin F1, CXCL2, PEDF, and inhibitors of DNA binding as potential fate regulators of 
VEGF-induced neovessels. Their exact roles and underlying mechanisms will have to be tested 
in future experiments. 
Overall, the major finding of the performed angiogenesis experiments was the identification of 
advantageous delivery conditions for VEGF to induce long-term therapeutic neovascularization. 
As myocardial ischemia remains one of the major pathologies hypothesized to benefit greatly 
from therapeutic neovascularization, the hypothesis that these findings might be applied in the 
setting of myocardial ischemia was tested next.  
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6. INTRODUCTION: Myocardial Infarction 
An estimated 8 million Americans have previously suffered a myocardial infarct. According to 
recent statistics, 770 000 will present with a new coronary attack this year, an equivalent of 1 
every 26 seconds, and about every minute someone will die from a MI1. Though early 
mortality after myocardial infarction has decreased over the past 20 years, the prevalence of 
heart failure is on the rise and studies have shown a close relationship between these two 
phenomena2. Today, 5.3 million Americans are suffering from heart failure1, a syndrome 
characterized by reduced cardiac output, increased pressures in the venous system and 
various molecular abnormalities causing a progressive deterioration of the ailing heart314,315.        
                                                                   
Myocardial infarction is viewed as the most severe manifestation of ischemic heart disease 
(IHD), resulting in extensive cardiomyocyte death316. In more than 90% of cases, a reduced 
coronary blood flow due to atherosclerotic coronary arterial obstruction leads to a mismatch 
between supply of oxygenated blood and nutrients and demand of the heart [for oxygen and 
nutrients] and in parallel an inadequate removal of metabolites316. Acute myocardial infarction 
and unstable angina are commonly referred to as acute coronary syndromes, being 
frequently caused by a sudden plaque change317. These plaque changes, such as superficial 
erosion, ulceration, fissuring, rupture, or deep haemorrhage abruptly transform a stable 
atherosclerotic plaque to an unstable and life-threatening atherothrombotic lesion, putting at 
risk the cardiomyocytes downstream of the blocked artery. 
 
6.1. Definition of myocardial infarction  
Clinical features, electrocardiography, biochemical markers, imaging techniques and 
[histo]pathology are typically used to uncover myocardial necrosis and support the diagnosis 
of myocardial infarction318. In most cases, a myocardial infarct is preceded by longstanding 
atherosclerosis of a coronary artery. According to the response-to-injury hypothesis319, this 
inflammatory process starts out as a reaction to endothelial dysfunction. A number of stimuli 
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are capable of damaging endothelial cells; amongst the more prominent are tobacco 
toxins320, oxidized low density lipoprotein321, reactive oxygen species322 and high blood 
pressure323. The ensuing inflammatory process of the vascular wall promotes binding of 
circulating monocytes to the activated endothelial cells and their ensuing migration into the 
subendothelial layer319. Upon maturation to macrophages, these cells act as scavengers, 
taking up oxidized LDL and transforming into foam cells319, which eventually rupture and 
deposit oxidized cholesterol onto the artery wall. The subsequent migration of smooth muscle 
cells from the media into the intima and their proliferation and fibrous transformation play a 
crucial part in rebuilding the plaque319.  
 
Atherosclerotic lesions range from fatty dots and streaks to fibroatheromas and complicated 
lesions. Whereas the vessel wall remodels outwards during the early phases, an expanding 
atherosclerotic plaque eventually results in the narrowing of the vessel lumen. The highest 
mortality from myocardial ischemia is typically seen in previously asymptomatic patients with 
acute plaque changes [before the plaque narrows the lumen] that lead to a complete 
obstruction of the coronary vessel, while the development of collateral vessels associated 
with recurrent minor ischemic episodes prior to myocardial infarction is associated with 
significantly lower in-hospital death and cardiogenic shock324,325.  
 
Myocardial ischemia is typically initiated by the change of an atherosclerotic plaque to an 
unstable lesion. Disruption of the plaque, e.g. by rupture, then leads to the activation of 
circulating thrombocytes and the coagulation cascade upon exposure of the highly 
thrombogenic subendothelial basement membrane and the lipid-rich centre of the plaque, 
thereby initiating the formation of an acute thrombus326. Within minutes the thrombus may 
then evolve and lead to the occlusion of a coronary artery and downstream myocardial 
ischemia. Contractility of the non-perfused segment of the heart is lost rapidly, within the first 
minute327,328. Irreversible cardiomyocyte death is first observed after 20 to 40 minutes327,328. In 
the case of a complete blockage of the coronary artery, the development of a transmural 
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myocardial infarct ensues with the necrosis stretching across the full thickness of the 
ventricular wall.  
 
6.2. Course of events after acute myocardial infarction, compensatory 
mechanisms, post-infarction remodelling and progression to heart failure 
Immediately after the coronary occlusion, there is a sharp drop in the contractility of the heart. 
Subsequently, less blood is ejected during the ensuing systole. A regular venous return thus 
produces an increased filling volume of the heart at the end of diastole. In agreement with the 
law of Starling, the higher end-diastolic volume, which corresponds to a higher preload, leads 
to an increase in contractility and subsequently to an increased stroke volume during the 
following systole329. 
In addition to the Frank-Starling mechanism, another important response to the hemodynamic 
changes that occur during MI is the activation of the neurohumoral system, aimed at 
upholding the blood pressure and thus ensuring the perfusion of vital organs329. At the root of 
the heart’s short-term adaptive changes lies the activation of the sympathetic nervous 
system330. Increased adrenergic signalling and the stimulation of the renin-angiotensin-
aldosterone system contribute to cardiac stimulation (increased inotropy, lusitropy, 
chronotropy and dromotropy), vasoconstriction (increased afterload) and fluid retention 
(increased preload). Secondly, the neurohumoral axis also initiates a proliferative response 
that promotes the initiation of a compensatory hypertrophy of the heart315,330. Collectively, the 
changes occurring on a molecular, cellular and structural level within the myocardium are 
known as ventricular remodelling. Together, they initially help a decreased number of 
cardiomyocytes, which are exposed to higher wall stresses according to the law of La Place, 
to carry an increased workload.  
 
The ventricular remodelling occurring in the aftermath of a myocardial infarction has been 
suggested to be the result of a combination of increased pressure- and volume-load331 and is 
characterized by thinning of the infarcted wall and an enlargement of the ventricular chamber. 
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The importance of this rebuilding process has emerged over the last 10 years, as various 
reports described that heart dimensions act as a meaningful surrogate marker for morbidity 
and mortality and have also proven their value in monitoring disease progression. Cardiac 
remodelling after a myocardial infarct is independently associated with a poor prognosis332, 
and even fairly minor increases in ventricular volume are linked to a major independent 
increase in the risk of death in those patients333. Currently, the underlying mechanisms of this 
process on a cellular and molecular level are incompletely understood.  
 
It has been suggested that early molecular and cellular changes in hypertrophied hearts that 
present compensatory mechanisms to adapt to elevated stresses/requirements post-MI 
depend on preferential activation of a set of signalling pathways promoting cell survival334. 
Cytoskeletal proteins have been linked to functioning as biomechanical sensors that transmit 
the increased loading conditions into a signal enhancing protein synthesis in 
cardiomyocytes335,336. The balance between adaptive mechanisms and detrimental changes, 
though, is fragile and not completely understood. During ventricular remodelling, the increase 
in cardiomyocyte size is not met by a comparable increase in capillary density, effectively 
increasing the distance between capillaries in the myocardium337. Furthermore, in the 
hypertrophied heart wall tension is elevated and higher metabolic demands need to be 
met338,339. Amongst other mechanisms responsible for pathological remodelling is a shift in 
the ratio of MMP´s and TIMP´s towards MMPs leading to an increased extracellular matrix 
turnover, which directly contributes to progressive LV dilation340,341. An enhanced formation of 
reactive oxygen species (ROS) and the activation of the neurohumoral pathway further 
increase the risk of cardiomyocyte death – in part via angiotensin II-mediated water retention 
and increased volume load on the heart which induce more stretch-induced abnormalities342. 
Eventually, the capacity of the infarcted heart to adjust to the combined volume- and 
pressure-load on non-infarcted areas of the myocardium is exhausted and leads to full onset 
of heart failure331. 
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6.3. Mechanical properties of infarcted myocardium and their impact on 
ventricular function 
The mechanical properties of the infarcted myocardium undergo characteristic changes after 
ischemic injury and 4 separate phases can be distinguished: a) acute ischemia (minutes to 
hours), b) the necrotic phase (hours to days 5-7), c) the fibrotic phase (between day 5 to 21) 
and d) the remodelling phase (21+ days)343. During acute ischemia, the infarcted myocardium 
loses its ability to generate force and contribute to systolic contraction, basically turning into a 
passive, viscoelastic material328,344,345. After a few hours, the infarct begins to stiffen346,347 and 
the oedema responsible for that effect mainly controls the mechanical features until the end 
of the necrotic phase around day 7348. By increasing the stiffness, the oedema is 
hypothesized to prevent further expansion of the infarct. This theory is supported by studies 
showing that anti-inflammatory drugs like steroids349,350, indomethacin351,352 and ibuprofen353, 
which reduce oedema, will lead to infarct expansion. Over the next month, during the fibrotic 
phase, collagen deposition354-356 is the main influence on the mechanical characteristics of the 
infarcted area, further stiffening the infarct. During post-infarct remodelling, collagen 
crosslinking appears to be a critical variable affecting the infarct regions´ mechanical 
properties357 and the scar remains stiffer than ischemic myocardium during the acute phase.  
 
These changes in mechanical properties of the infarct region have a substantial impact on the 
remote areas of the heart and affect the function globally. Various scenarios may occur as a 
consequence, the most disastrous of which is myocardial rupture, which typically occurs 
during the first week358,359. Bulging or stretching of the infarct squanders some of the energy 
created by the viable myocardium. Stiff infarcts tend to show less systolic dysfunction360 than 
compliant infarcts, which misuse a significant amount of energy360-363, thereby reducing the 
heart´s efficiency and putting it at a higher risk of pump failure. The downside of overly stiff 
infarcts is that they may impact ventricular function by impairing360 diastolic filling and 
restricting the ability to adjust left ventricular stroke volume by means of the Frank-Starling 
mechanism364. Another possible consequence after MI is infarct expansion365 and dilation of 
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the ventricle. The mechanism underlying this complication is slippage of the diminished 
cardiomyocyte population366. As a result of ventricular dilation, a higher wall stress is 
necessary to achieve a given cavity pressure, since a smaller amount of the force generated 
by the cardiomyocytes is directed toward the centre of the ventricle. By continuously 
operating at a higher wall stress, the cardiomyocytes must perform additional internal work to 
stretch the heart, less external work is available for the ejection and cardiac efficiency is 
reduced. By being coupled to the infarcted region, adjacent myocardium is also affected and 
the functional border zone shows a decreased contractility despite normal perfusion during 
the acute phase of the infarct367.  
 
The relationship between regional myocardial contractility, wall stress and bioenergetics was 
recently described in a porcine model of myocardial infarction368. Increased wall stress in the 
infarct border zone was found to result in higher regional energy demand and bioenergetic 
abnormalities, leading to a decrease in myocardial bioenergetics efficiency368. As properties 
of the healing infarct influence mechanical variables (stress, strain, work) of the non-infarcted 
myocardium that give rise to adaptive stimuli369 they are critical determinants for the 
remodelling of the ventricle that occurs after myocardial infarction331. Post-infarct ventricular 
remodelling may therefore precipitate the development of heart failure by driving the dilation 
of the cavity and the associated build-up in wall stress.  
 
6.4. Current therapy for the prevention of heart failure – HF as a 
biomechanical model  
Left-ventricular remodelling after myocardial infarction (MI) is a key component of heart failure 
and it has long been postulated that it may result from increased wall stress. While there have 
been advances in the medical therapy of heart failure, the only definite treatment currently 
known is heart transplantation, which suffers from a chronic shortage of organ donations. 
After early reperfusion, first line medical treatment of myocardial infarcts now consists of 
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angiotensin-converting enzyme (ACE)-inhibitors, angiotensin receptor blockers (ARB) and β-
adrenergic antagonists (β-blockers). These medications break the vicious cycle of 
neurohumoral activation, vasoconstriction and water retention, decrease pre- and afterload 
and establish more favourable ventricular energetics. At least in part, the reduction of 
morbidity and mortality after myocardial infarcts by ACE-inhibitors, β-blockers and ARBs has 
been credited to the attenuation and partial reversal of the remodelling of the injured heart370-
378. While heart failure can be stabilized using these treatment regimens, heart failure 
progresses in the majority of cases, even though this may occur more slowly379. The 
neurohumoral model of heart failure therefore does not entirely explain disease 
progression380,381. An increasing amount of evidence indicates that deterioration of HF may 
occur independently of activation levels of the neurohumoral axis. Thus, there is a high 
likelihood that a biomechanical component also drives progression of heart failure382. 
 
6.5. Biomaterials for treatment of ischemic myocardium 
With the high prevalence of HF, substantial research has been devoted towards developing 
novel treatments with an emphasis on cell delivery. Questions have arisen as to whether the 
improved LV pump function observed in many cell delivery approaches has been solely a 
result of cellular paracrine signalling, causing myocardial regeneration, neovascularization383 
or decreased apoptosis384, or whether changes found in ventricular function may purely or in 
part be a mechanical consequence of increasing the thickness of the LV wall 385,386. 
Therefore the potential of biomaterial delivery into the ischemic heart to tackle post-infarct 
remodelling and progression into heart failure has begun to be explored. 
 
Biomaterials have to meet numerous requirements to be considered potential candidates for 
tissue regenerative approaches. Most importantly, the materials need to be non-cytotoxic, 
non-immunogenic, non-infectious and when degradable, they must break down into non-toxic 
products387. Successful treatment of ischemic myocardium will further rely on selecting 
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biomaterials with adequate physical properties, such as mechanical strength, elasticity and 
viscosity. For additional protein delivery, non-covalent binding interactions and potential to 
control protein release will be of utmost importance.  
 
Natural biomaterials such as collagen, fibrin, alginate and matrigel are amongst the materials 
used thus far to treat MI, and initial results have given reason for cautious optimism. Kofidis et 
al. reported that matrigel injections into an infarcted mouse heart increased wall/scar 
thickness and prevented deterioration of cardiac function. When delivered in combination with 
embryonic stem cells, matrigel injections significantly improved cardiac function388. In rats, 
collagen injections increased scar thickness and improved left ventricular stroke volume and 
ejection fraction389. Fibrin delivery was shown to increase the survival of co-delivered 
myoblasts, decrease infarct size and promote neovascularization390. In yet another report, 
alginate injections 7 days after myocardial infarction resulted in increased scar thickness and 
further attenuated left ventricular remodelling and cardiac dysfunction391. Furthermore, even 
after alginate injections into 60 day-old infarcts, an increase in scar thickness and functional 
improvement of the heart was observed391-393. In summary, increased wall/scar 
thickness388,389,391, attenuation of adverse LV remodelling391, decreased infarct size390 and 
improvement of functional parameters388,389,391 have all been described to result from 
treatment of MI by natural biomaterials. 
Beneficial effects after synthetic biomaterial injections, which offer the advantage of 
enhanced control over characteristics such as degradation and mechanical properties, have 
also begun to be described. Performed concurrently with the work described in this thesis, 
studies showed that injection of self-assembling methoxy polyethylene glycol–poly 
(caprolactone)-(dodecanedioic acid)–poly(caprolactone)-methoxy polyethylene glycol 
(MPEG–PCL–MPEG) triblock polymer into rabbit and rat infarcts led to significant 
improvements in left-ventricular remodelling and function 4 weeks after treatment394,395. 
Reduced LV dilation and preserved contractility were reported after injection of a synthetic 
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thermoresponsive poly(NIPAAm-co-AAc-co-HEMAPTMC) hydrogel, up to 8 weeks after 
injection into 2-week-old infarcts396. 
While these initial results are promising, our current mechanistic understanding for the 
observed effects is insufficient. In a recent publication, Wall and colleagues used a finite 
element modelling approach in an attempt to shed light on some of the mechanisms 
responsible for LV improvement after material/cell injections into the heart386. They 
demonstrated that the injections help to normalize elevated wall stresses with stiffer materials 
showing greater benefit, improving ejection fraction and the stroke volume/end-diastolic 
volume relationship. 
 
6.6. Polyethylene glycol (PEG) hydrogels 
As novel synthetic biomaterials are being developed at a rapid rate, polyethylene glycol 
hydrogels have emerged as a frontrunner for the study of basic biologic processes and the 
development of tissue engineering-based therapies. A major advantage of synthetic 
biomaterials such as PEG over their natural counterparts is their easy purification, a reduced 
potential for immunogenicity and pathogen transmission and enhanced control over material 
properties allowing the tailoring to specific tissue requirements, and thus optimal exploitation 
of the injured tissue’s regenerative potential. Important features of polyethylene glycol 
compared to other synthetic biomaterials include its high degree of inertness, which 
translates into superior biocompatibility and its lack of adhesiveness for cells, thus making it a 
prime candidate for the incorporation of bioactive molecules397. Furthermore, polyethylene 
glycol is easy to handle, allowing transformation from liquid to solid state in situ398. Due to the 
high water content of PEG hydrogels, their properties are comparable to soft tissue. The high 
water content is critically important in ensuring proper exchange of waste and nutrients and 
aids in preserving the bioactivity of hydrophilic drugs399. The high structural similarity of PEG 
hydrogels to extracellular matrix imitates a physiological environment for cells entrapped 
within the hydrogel, enabling three-dimensional organization, macromolecular transport and 
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playing an important role in promoting physiological cell differentiation. Collectively, these 
characteristics make polyethylene glycol an attractive candidate for in vivo tissue engineering.  
 
Polyethylene glycol hydrogels have been developed that are formed by Michael-type 
conjugate addition reaction of PEG macromers with thiols400-402. [Based on chemistry, a 
variety of methods exist to initiate gelling403; as PEG hydrogels used for the ensuing studies 
were formed using Michael-type addition reaction, this method is explained in more detail.]  
Named after its discoverer, Arthur Michael, a Michael addition involves the formation of a 
chemical bond between a nucleophile, which donates a pair of electrons and is referred to as 
the Michael donor, and an electrophilic olefin, the Michael acceptor (an unsaturated chemical 
compound that contains one or more carbon-to-carbon double bonds). As the chemical 
reaction inducing PEG hydrogel formation uses non-enolate nucleophiles, namely thiols, as 
electron donors, this reaction is typically referred to as Michael-type addition reaction404. In 
biological systems, cysteine residues in proteins are taken advantage of, as the thiol group on 
the side chain of cysteine typically acts as the Michael donor. Hydrogel formation based on a 
Michael-type addition reaction between thiol and acrylate or vinylsulfone groups, respectively 
has often been described as ideally suited for biomedical applications, as thiols are absent in 
the bloodstream404.  
 
Due to advantageous condition reactions between thiols and acrylates or vinylsulfones, 
potential Michael addition reactions with amines are rare404-406. Importantly, the Michael-type 
addition reaction can be carried out at physiological pH without requiring organic solvents402. 
Upon mixing of PEG-macromers with a thiol-containing cross-linker, hydrogel formation of 
two takes place during gradual copolymerization. For studies carried out for this thesis, 20kD-
8arm Vinyl sulfone (VS)-PEG macromers were used, functionalized with VEGF165 for some 
studies. Crosslinking was either perfomed with dithiothreitol402  or with thiol groups cysteine-
containing peptides by conjugate addition, as previously described400. Gelling of PEG 
hydrogels is completed quickly without producing any toxic byproducts and most of its 
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degradation products are of neutral charge399. Generally, the molecular weight of degradation 
products is low enough to readily allow glomerular filtration and to prevent an immunological 
host response399. A major advantage of hydrogel formation via Michael-type addition reaction 
in terms of protein delivery is the lack of free radical formation, which potentially damages 
drugs and proteins bound to the hydrogel399. Apart from Michael-type addition reactions a 
wide range of crosslinking methodologies exist for PEG hydrogels that induce gel formation 
upon photopolymerization or after exposure to physiological temperatures. Increased free 
radical formation and more technically challenging crosslinking initiation, e.g. requiring a light 
source, make these techniques less suitable for in vivo tissue engineering399 
 
Whilst biomaterial degradability is desired in most tissue engineering applications, a non-
degradable hydrogel may be useful to provide mechanical support in tissues with low 
regenerative potential. Crosslinking VS-PEG with dithiothreitol (DTT) allows the formation of 
PEG hydrogels that are stable for up to 13 weeks after myocardial injection407.  
Crosslinking PEG-macromers with bis-cysteine peptides allows the integration of biological 
functionality into the hydrogel network400. The integration of cellular recognition sites, 
bioactive molecules and cell-responsive degradation sites allow the creation of an ECM-
mimicking matrix289,408. Michael-type addition preserves the chemistry of protein drugs, as no 
potentially harmful basic catalyst or UV light is required during the hydrogel formation402. 
Additionally, incorporation of matrix metalloproteinase-sensitive sequences into PEG 
hydrogels has successfully been shown to regulate cell-invasion by MMP-secreting cells thus 
controlling the rate of hydrogel degradation408,409. Extending on these studies, it was shown 
that this principle could also be applied to allow for cell-demanded release of bioactive 
molecules289. Overall, the advanced interaction between host tissue and synthetic 
biomaterials, such as PEG, have significantly advanced the field of tissue engineering, 
effectively assuming the role of a transitional extracellular matrix that is gradually replaced by 
regenerating tissue, which subsequently restores tissue-specific physiological functions. PEG 
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crosslinking chemistry thus provides high flexibility in tailoring mechanical properties and drug 
release kinetics depending on target tissue410,411.  
 
In vitro experiments have established polyethylene glycol as a material widely used for 3D 
cell culture and, amongst others, pancreatic beta cells and neural cells have been 
successfully cultured and expanded in PEG hydrogels412,413. Despite mainly consisting of 
water (commonly more than 90%), polyethylene glycol hydrogels can be engineered to 
possess a mesh size in nanometer range400, making the pore diameter of PEG hydrogels far 
smaller than that of either fibrin or collagen matrices, and smaller in magnitude than cellular 
migratory processes414-416. Therefore local (hydrolytic or proteolytic) breakdown of these gels 
dictates cellular migration. PEG hydrogels have thus emerged as model systems to study the 
effects of integrin-binding motifs and proteases on cellular migration by incorporating cell- 
binding sites such as RGD and by differentially crosslinking hydrogels with hydrolytically or 
proteolytically degradable peptide sequences104,105. The incorporation of proteolytic 
sequences (plasmin, MMPs) furthermore allows the introduction of an in vivo feedback 
system whereby the rate of hydrogel degradation and the release of incorporated proteins 
during tissue regeneration, is dictated by the secretion of proteinases from migrating host 
cells. Polyethylene glycol hydrogels have extensively been tested for their potential to deliver 
biologics and cells to promote tissue regeneration417-419. Lutolf et al. have previously shown 
that the incorporation of integrin-binding sites and MMP-degradable substrates allow invading 
inflammatory cells to dictate the release of bound bone morphogenetic protein-2408. In this 
study, PEG hydogels were shown to provide a temporary platform that promotes the 
regeneration of bony tissue by host cell activation (which participate in the generation of new 
ECM), resulting in complete closure of the rat cranium defect. 
 
PEG hydrogels formed by Michael-type addition reaction have been used extensively for 
controlled, local delivery of drugs and therapeutics. These hydrogels allow spatial and 
temporal control over growth factor presentation and release420-425, mimicking an important 
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role of the ECM, as some molecules are more effective when presented as a bolus, others 
when released slowly over time. Important aspects of controlling protein and drug release are 
the increased preservation of the therapeutics bioactivity and a decreased risk of adverse 
side effects399.  In order to optimize targeted drug delivery a variety of different loading 
techniques, e.g. entrapment or tethering (covalent, enzymatic, hydrolytic) may be 
combined399. Affinity hydrogels that are based on the heparin-binding capability of numerous 
growth factors are an interesting alternative422,423,426, as well as integration of biologics using 
the prodrug technique, whereby linker degradation hydrolytically427,428 or 
enzymatically289,429,430 releases the drug in its active form. Thus, PEG hydrogels are 
potentially well suited to deliver bioactive therapeutic molecules in the setting of myocardial 
infarction. Such delivery may be particularly useful in treating MI by stimulating therapeutic 
angiogenesis. 
 
6.7. Therapeutic angiogenesis for myocardial ischemia 
Therapeutic angiogenesis aims at establishing a stable, functional vascular network in tissues 
with an inadequate vasculature, thereby enhancing tissue perfusion and function431. Options for 
patients with ischemic heart disease (IHD) are limited and after myocardial infarction only 
directed towards restricting the damage. Medical treatment for IHD intends to reduce the oxygen 
demand of the myocardium432. Surgical options include revascularization by either angioplasty or 
coronary bypass grafting. While the promotion of angiogenesis with platelet-derived growth 
factor-BB (PDGF-BB) has been used to treat chronic wounds433 in animals and translation to the 
bedside has been successful, therapeutic angiogenesis as a treatment option for ischemic 
vascular disease has suffered from repeated setbacks. A great deal has been learned from 
studying the biology of tumour angiogenesis, some of the molecular and cellular mechanisms of 
the angiogenic response have been elucidated, however therapeutic neovascularization has yet 
to demonstrate the functional benefits previously shown in numerous animal experiments16,17,434. 
The inability to promote vessel maturation76 followed by the subsequent regression of neovessels 
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induced by angiogenic therapy has been identified as a major obstacle that therapeutic 
angiogenesis has yet to overcome to allow clinical translation. 
 
The original study showing that in a canine model of myocardial infarction the intracoronary 
delivery of basic FGF (bFGF) successfully increased neovascularization, improved the 
systolic function of the heart and limited infarct size was carried out by Yanasigawa-Miwa and 
colleagues16. Subsequently, numerous reports validated the theory that enhancing the 
angiogenic response by delivering a single growth factor is possible. Using a rabbit hind limb 
ischemia model, Takeshita et al. demonstrated that a single intra-arterial bolus injection of 
recombinant VEGF leads to a significant increase in capillaries and augmentation of collateral 
vessels and as a result an improved perfusion compared to controls17. The intramuscular 
injection of naked plasmid DNA encoding vascular endothelial growth factor165 (VEGF165), 
VEGF-C and recombinant hepatocyte growth factor (HGF) in the same model yielded similar 
results435,122,253. Banai and colleagues reported increased angiogenesis in the ischemic 
myocardium after intracoronary administration of VEGF434. Work showing that an 
intracoronary injection of a recombinant adenovirus expressing human fibroblast growth 
factor-5 (FGF-5) ameliorated blood flow abnormalities and restored function in an ischemic 
pig heart added more evidence supporting the hypothesis that the delivery of a single growth 
factor might be sufficient for therapeutic angiogenesis436.  
 
Despite the likelihood that any single factor would not induce the optimal angiogenic 
response, these early results were encouraging and warranted the first clinical trials for 
patients not eligible for traditional revascularization.  
 
6.8. Clinical trials for therapeutic angiogenesis 
To date bFGF and VEGF are the only growth factors tested in clinical trials for their potential 
to promote biological revascularization. The initial report was published by Jeffrey Isner´s 
group in 1996. Delivery of 2000 micrograms of human plasmid phVEGF165 via the hydrogel 
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polymer coating of an angioplasty balloon in a patient with severe peripheral vascular disease 
led to an increase in collateral vessels after 4 and 12 weeks, which was accompanied by 
increased resting and maximum flows437. 2 years later, Schumacher and colleagues reported 
that the injection of recombinant FGF-1 during coronary artery bypass surgery promoted 
angiogenesis in the setting of coronary artery disease438. In a control group injected with 
inactivated FGF-1, neovascularization was not evident. Several phase I studies followed, 
reporting improved stress perfusion detected with magnetic resonance imaging (MRI) or 
single photon emission computed tomography (SPECT) after treatment with recombinant 
FGF-2184,439,440 and VEGF441,442 and proving that the treatment was well tolerated. Phase I 
studies evaluating the potential use of plasmids443 and adenoviruses444 to deliver VEGF or 
FGF-4445 also demonstrated that the approach is safe. Larger Phase II trials further testing 
the potential of recombinant FGF-2185 and VEGF446 as well as adenoviral delivery of FGF-4447 
confirmed the safety of pro-angiogenic therapy, but these studies failed to show significant 
improvements in the treatment groups. Instead they revealed the presence of a large placebo 
effect and emphasized that randomized, controlled studies are needed. Possible explanations 
offered for the negative results included a diminished response by the diseased vasculature 
in no-option patients to an angiogenic stimulus, short exposure times to the respective growth 
factors that promote vascular stability and prevent rapid neovascular regression, and a limited 
capability to detect treatment effects due to technical limitations76.  
 
6.9. Cell delivery to promote therapeutic angiogenesis 
After disappointing results in molecular strategies for therapeutic angiogenesis in clinical 
trials, cell therapy strategies gained attention. While initially intended to replace irreversibly 
damaged cardiomyocytes, proof of substantial cardiac regeneration by cellular therapy 
remains elusive. Since the initial studies, functional improvements after cell injections have 
largely been attributed to paracrine effects, such as promoting angiogenesis. Skeletal muscle 
myoblasts were the first proposed as surrogate cells for cardiac repair448-450. After extensive 
testing in animal models proving the beneficial effects of cell transplantation after myocardial 
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infarcts451-453, initial human trials were started in 2000454. The early trials for chronic ischemic 
disease proved the feasibility of cell transplantation and some long-term engraftment of 
myoblasts455,456 was shown. It also became apparent that improving cell retention and survival 
of transplanted cells in the hostile host environment constitutes one of the major challenges. 
While patients showed improved symptoms, ejection fraction and regional 
contractility454,457,458, definite conclusions regarding the efficacy of the treatment could not be 
shown due to the lack of control groups.  
 
After myoblasts had paved the way, the field quickly moved forward focusing on bone 
marrow459-462 and endothelial progenitor cells463 for cardiac repair due to their suggested 
additional benefits. Bone marrow cells had previously been shown to contain a subpopulation 
of progenitor cells, including hematopoietic stem cells464,465, mesenchymal stem cells466 and 
multipotent adult progenitor cells467. These were hypothesized to contribute to an enhanced 
neovascularization by incorporating into the newly formed vessels and also by secreting pro-
angiogenic factors in a paracrine way. Originally believed to generate new myocardium by 
either differentiating into cardiac cells or by means of cell fusion468, hematopoietic stem cells 
and bone marrow mesenchymal stem cells are now thought to exert their effects mainly via 
their non-cardiogenic mechanisms469.  Indeed, the formation of cardiomyocytes from 
hematopoietic stem cells seems to be an extremely rare event caused by cell fusion470-473. 
Initial clinical trials for acute myocardial infarction with both bone marrow cells459,462,474 and 
cardiac progenitor cells460,475 yielded comparable results: improved contractility, perfusion and 
significantly reduced end-systolic left ventricular volumes. The outcome of the following 
larger, randomized studies was somewhat more controversial and emphasized the 
importance of choosing the right cell population. In the same issue of the New England 
Journal of Medicine, Schächinger and colleagues reported that in the setting of acute 
myocardial infarction the injection of progenitor cells isolated from bone marrow cells 
significantly improved left ventricular ejection fraction476 while Lunde et al.477 described that 
no significant difference had been found between treatment and control group after the 
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delivery of unselected bone marrow mononuclear cells. Bone marrow progenitor cell 
transplantation for patients with stable ischemic heart disease was linked to a moderate but 
significant improvement in left ventricular ejection fraction after 3 months478.  
 
This second phase of therapeutic angiogenesis trials focusing on cell therapy again 
underlined the need for large randomized placebo-controlled Phase III trials to prove the 
efficacy of this novel therapy. Amongst the important lessons learned from experimental and 
clinical cell transplantation were that an improvement in function is not synonymous with 
definite myocardial regeneration and that effects seen with cell therapy thus far likely result 
from promoting angiogenesis, reducing ventricular remodelling or mediating pro-survival 
signals468.  
 
In summary, recent evidence suggests that clinical trials to promote neovascularization and 
the recovery of ischemic tissues after injury have been hampered by the inability to create a 
stable vascular network. Developing more efficient approaches will likely depend on acquiring 
a deeper understanding of the mechanisms involved in both promoting a mature vascular 
phenotype and governing neovascular regression.   
 
6.10. Biomaterials as vehicles for prolonged and sequential growth factor 
delivery to enhance therapeutic angiogenesis 
Prolonged growth factor delivery from biomaterials holds great promise for therapeutic 
angiogenesis. In many tissues, the development of a stable neovasculature is dependent on 
continuing growth factor exposure, as single bolus injections show little to no effect partly due 
to rapid clearance from the target site or insufficient delivery479,480. Furthermore, many potent 
angiogenic growth factors induce adverse side effects. Particularly VEGF levels need to be 
highly controlled as high dosages may lead to vascular permeability, leakage and 
hypotension481,482. Repeated drug injections into remote tissues (e.g. myocardium) is also 
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technically challenging, impractical and generally considered unsafe481,483. Previously, in 
collaboration with our laboratory, Jeffrey Hubbell’s group has shown that the integration of 
integrin binding sites and VEGF into MMP-sensitive PEG hydrogels leads to the complete 
replacement of the hydrogel by newly formed blood vessels in a subcutaneous wound healing 
model, providing the first in vivo evidence that PEG hydrogels are suitable candidates to 
promote therapeutic angiogenesis in the ischemic myocardium289. In this study, VEGF121 and 
VEGF165 were bound to the PEG matrix by Michael-type addition reaction. Formation of the 
hydrogel was subsequently performed with a MMP-sensitive crosslinker-sequence that 
allowed for VEGF release upon cellular invasion, thus establishing a feedback mechanism 
between the implanted PEG matrix and the host tissue. Integration of VEGF into PEG chains 
was shown by semi-quantitative SDS-PAGE and the bioactivity of PEG-bound VEGF was 
confirmed in HUVEC proliferation assays, as matrix-bound, VEGF released from the hydrogel 
after MMP2-administration and unmodified VEGF induced identical dose-response curves.  
VEGF-functionalized PEG-peptide hydrogel matrices were then shown to promote HUVEC 
migration and to effectively stimulate vascularization in the CAM assay and after 
subcutaneous implantation into porous polyurethane discs in rats. Matrix functionality was 
thus shown by the authors to be essential to support endothelial cell survival, migration and 
angiogenesis. It is important to note that, since vascular regression is a major obstacle for 
successful therapeutic angiogenesis, no immature vessels were detected after prolonged 
delivery of VEGF165 from PEG hydrogels. This suggests that while successful long-term 
establishment may be coupled to the development of a physiological oxygen load484, 
sustained VEGF release from PEG matrices successfully prevented the rapid regression of 
newly formed vessels. Therefore delivery of VEGF-conjugated PEG hydrogels may be a 
promising strategy to induce long-term neovascularization of ischemic tissues. 
 
Some of the mechanisms that contribute to enhanced long-term neovascularization are also 
beginning to emerge. Long-term exposure to angiogenic growth factors has been 
demonstrated increase the efficacy of therapeutic angiogenesis through enhanced homing of 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 97 
progenitor cells that contribute to angiogenesis and neovascular maturation468. Subsequently, 
it was shown that beneficial effects on cardiac performance and the accompanying increase 
in neovasculature rely heavily on the continued physical incorporation and presence of pro-
angiogenic cells485. Survival of pro-angiogenic peripheral blood derived mononuclear cells 
transplanted into the heart was directly responsible for increased long-term 
neovascularization and improved cardiac function485. This adds evidence that long-term 
exposure to pro-angiogenic treatments has substantial impact on the therapeutic outcome. 
Likewise, sustained local delivery of protease-resistant stromal derived factor-1 via self-
assembling peptides was shown to drive stem-cell homing into the injured myocardial tissue, 
thereby enhancing neovascularization and cardiac function. As simultaneous release of 
VEGF and PDGF-BB from poly(lactide-co-glycolide) has been shown to significantly increase 
the vascular density and induce a more mature vasculature in vivo in comparison with 
delivering of either VEGF or PDGF alone288, the simultaneous delivery growth factors should 
also be strongly considered for therapeutic angiogenesis.  
 
While more sophisticated delivery vehicles have contributed to the continued evolvement of 
novel strategies for therapeutic angiogenesis therapies, recent findings emphasize the 
complexity of engineering a stable neovasculature in ischemic tissues. Thus, translational 
success will likely depend on simultaneously targeting a variety of vasculogenic cell 
populations and creating a local microenvironment conducive for tissue regeneration using 
smart biomaterials that interact with host tissue and help limit damage sustained from 
ischemia486. 
 
7. Hypothesis MI chapter 
Collectively, a large body of work has shown that promoting neovessel formation after 
myocardial infarction can effectively be used to limit detrimental effects of MI in animal 
models. Polymeric delivery systems that allow for sustained growth factor supplementation to 
the ischemic tissue have been demonstrated to more efficiently promote long-term 
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neovascularization and improve cardiac function after MI than injecting a single bolus of a 
growth factor. The central finding from the subcutaneous angiogenesis model study suggests 
that the growth factor dosage delivered critically regulates the development of a stable 
neovasculature. Recently developed smart hydrogels allow advanced control over growth 
factor release through modification of degradation kinetics, thus enabling prolonged growth 
factor delivery to target tissues that are less accessible, such as the heart. Amongst smart 
biomaterials, PEG hydrogels, which have previously been extensively studied in our 
laboratory, have proven their value for therapeutic angiogenesis. Enzymatically degradable 
VEGF-165-conjugated PEG hydrogels crosslinked by Michael-type addition were shown to 
promote angiogenesis and prevent vascular regression in a subcutaneous in vivo 
angiogenesis assay.  
While their use as a delivery matrix has long been described, synthetic biomaterials have 
recently gained attention as stand-alone therapies after myocardial ischemia, as the injection 
of hydrogels themselves was shown to have beneficial effects on heart function post-MI. 
Collagen, fibrin, alginate and matrigel hydrogel injections all yielded beneficial results ranging 
from increased angiogenesis to improved myocardial contractility and function388-391. 
 
Combining these recent findings, this thesis tests the following hypothesis: 
 
1. Prolonged delivery of VEGF165 dosages - that promoted long-term neovascularization in 
the subcutaneous wound healing assay – from enzymatically degradable polyethylene 
glycol hydrogels results in increased angiogenesis and the formation of a more stable 
neovasculature in the heart, resulting in enhanced functional recovery and/or improved 
heart remodelling.  
2. When used as stand alone therapy, polyethylene glycol hydrogel injections into the 
ischemic myocardium ameliorate left ventricular dysfunction and remodelling after 
myocardial infarction. 
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As a necessary step towards investigating the above, a rat myocardial ischemia model was 
established. 
 
8. Results MI chapter 
8.1. Establishment of a rat myocardial infarct model  
The aim of an initial pilot study was to show successful induction of myocardial infarcts in rats 
by ligation of the left anterior descending (LAD) coronary artery. An important technical 
objective of this study was to determine whether a correlation between a decrease in 
fractional shortening and infarct size can be achieved in our rat model. In 12 rats a 
myocardial infarction was induced by ligation of the LAD (see 10.2.5). 10 rats serving as 
control animals (sham group) underwent a thoracotomy without LAD ligation. The success of 
a ligation was confirmed by ST-elevation, which was recorded by 2-lead ECG (see Fig.30). 
Additional markers that were monitored during the surgery were the appearance of a pale 
demarcated zone and dyskinesia of the left-ventricular wall, the area typically supplied with 
blood by the left anterior descending coronary artery.  
  
 
Fig.30.  
2-lead electrocardiograms 
before (red) and after 
successful ligation of the 
left anterior descending 
coronary artery (blue) are 
shown. ST-elevation 
characteristic of 
myocardial ischemia, 
namely, was observed.  
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Left-ventricular function of the animals was assessed both at days 14 and 28 post surgery by 
transthoracic echocardiography. Left-ventricular diameters at the end of systole and diastole 
were obtained in both 2D-mode and m-mode (representative images are shown in figure)407. 
Both 2D and m-mode measurements were included to obtain the final data. Animals were 
sacrificed on day 29 and the explanted hearts were processed for histological analysis. To 
determine infarct volumes heart sections were stained with modified Masson’s trichrome.  
 
 
 
8.1.1. Echocardiographic analysis, day 14 
As early as day 14, a highly significant 17.29% decrease in fractional shortening in the 
myocardial infarction group (31.7±2.95%, n=11, p<0.001) was observed in comparison with 
sham-operated animals (shown in Fig.32).  
Fig.31. Representative echocardiographic images obtained on day 28 post surgery for 
analysis of cardiac function and ventricular remodelling. A 2D image (Fig.31A), and M-mode 
images of a large (Fig31.B) and small infarct (Fig31.C) taken on the level of the papillary 
muscle (white arrow in Fig 31.A) are shown. 
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Similar results were observed for both the 2D and M-modes as stand alone measurements 
(see Fig.33). 
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Fig.32. Echocardiographic analysis was performed on day 14. Myocardial infarction induced by 
permanent ligation of the left anterior descending coronary artery (LAD) led to a significant 
reduction in fractional shortening 14 days after surgery (*p<0.001, -17.29%). 
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8.1.2. Echocardiographic analysis, day 28 
The results obtained from echocardiographic analysis at day 28 were almost identical when 
compared to the day 14 timepoint. At 4 weeks, myocardial infarction surgery significantly 
reduced fractional shortening by 20.05% in comparison with sham-operated animals (n=11, 
p<0.001). This confirmed that the main loss of left-ventricular function in the MI group had 
occurred over the initial 2 week-period after experimental coronary artery ligation.  
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Fig.33. Independent assessment of cardiac function was performed for echocardiographic 
images acquired in 2D-mode and M-mode, respectively. No significant difference was observed 
after comparing 2D and M-mode measurements, confirming a significant reduction in fractional 
shortening after experimental myocardial infarction. 
Fig.34. Combined echocardiographic analysis for images acquired in 2D and M-Mode. Significant 
loss of cardiomyocyte contractility after LAD coronary artery ligation is confirmed at day 28 
(*p<0.001). 
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8.1.3. Histological analysis – Infarct volume 
Immediately after sacrifice, the hearts were explanted and evaluated macroscopically. 
Extensive scar formation in the left-ventricular area indicated successful LAD ligations in the 
myocardial infarction group (a representative photograph is shown in Fig.35).  
 
 
 
After fixation and staining with modified Masson’s Trichrome, histologic sections were 
photographed and analysed using Visiopharm Integrator System (VIS, as seen in Fig.36).  
Sham-operated animals looked healthy and did not show any signs of scar formation (data 
not shown). On the contrary, extensive scar formation was observed in animals subjected to 
coronary artery ligation. The average infarct volume in animals after myocardial infarction was 
22.48±3.54%. 
 
Figure.35. Macroscopic picture of a rat heart explanted 29 days after induction of myocardial 
infarction. Extensive scar formation (white) is seen in the left-ventricular region of the heart. 
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After plotting infarct size against fractional shortening for each animal that had undergone 
permanent LAD occlusion a significant correlation (p=0.023) between the volume of the 
infarcted left ventricle and the decrease in left-ventricular function was revealed (shown in 
Fig.37.) revealed. This finding confirmed successful establishment of the rat myocardial 
infarction model. 
 
Figure.36. Modified Masson’s Trichrome stains of two cross sections of infarcted rat hearts are 
shown. The micrograph includes the Visiopharm Integrator Systems (VIS) image analysis tracings 
of infarcted (in red) and non-infarcted (in green) left-ventricular circumference, which were 
subsequently used for calculations of infarct volume. 
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8.2. Pilot PEG injections 
8.2.1. Rationale 
Polyethylene glycol (PEG) hydrogels exhibit a range of properties that render them suitable 
for a variety of in situ applications409,487. They gel within a few minutes at physiological 
temperature and pH, do not require the addition of initiators, produce no by-products, have 
very low reactivity toward tissue, and are considered to be very biocompatible488.  
Furthermore physical properties of PEG hydrogels may be varied by choice of molecular 
mass, functionality and crosslinker type, and protein, carbohydrate and therapeutic agents 
may be readily coupled and released from the gels, either with or without degradation of the 
gel itself. As PEG hydrogels represent a promising class of biomaterials for myocardial tissue 
Figure.37. After analysis, parameters for cardiac function (fractional shortening) and infarct size 
were plotted against each other. Increased infarct size significantly correlated with an increased 
drop-off in cardiac contractility (p=0.023).  
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engineering, pilot experiments were designed to demonstrate that polyethylene glycol (PEG) 
hydrogels can successfully be injected and permanently implanted into infarcted rat hearts. 
One of the major concerns associated with hydrogel injections into the heart is the short time 
window after injection of the solution, before the gelling process is completed. During this 
timespan, a substantial proportion of the injected monomeric gel components may be washed 
out of the beating heart into the circulation. This may lead to the formation of foreign body 
emboli, which subsequently can cause ischemic events such as strokes.  
 
8.2.2 In vitro gel formation 
To generate stable polyethylene glycol hydrogels dithiothrietol was used to initiate gel 
formation of 20kD-8arm Vinyl sulfone-PEG-hydrogels. After the additi n of the crosslinker 
dithiothrietol (DTT), non-degradable polyethylene glycol hydrogels completely gelled within 2 
minutes in vitro.  
 
8.2.3. Surgery and in vivo injections of PEG hydrogels 
To allow for easier detection after in vivo injections, PEG hydrogel solutions were labelled 
with a covalently attached far-red fluorescent marker (described in Chapter 10.2.2). 
Experimental myocardial infarcts were then induced in 3 rats by ligation of the LAD, and 100 
µl of the non-degradable polyethylene glycol hydrogel solution were immediately injected into 
the infarcted area. As previously detected in vitro, in situ gelling of PEG hydrogels was 
completed within 2 minutes. All animals (n=3) survived the initial surgery and PEG injection, 
suggesting that in vivo gelling times were rapid enough to prevent PEG from entering the 
circulation and forming foreign body thrombi. To detect PEG retention and distribution within 
the left ventricle, the animals were sacrificed and hearts harvested 4, 24 and 48 hours post 
surgery.  
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8.2.4. Detection of PEG hydrogels 
In all animals, after 4, 24 and 48 hours, respectively, PEG hydrogels were readily detected by 
fluorescent microscopy of the attached far-red fluorescent label. The rapid gelling time likely 
aided in the retention of the hydrogel within the myocardial wall. PEG hydrogels were evenly 
distributed around the injection sites at all timepoints (see representative image in Fig.38). 
 
 
 
 
Fig.38. A covalently attached far-red fluorescent marker allows easy identification of PEG hydrogels 
on histological sections. Around the injection sites, PEG hydrogels (shown in purple) are maintained 
in the left-ventricular wall after in vivo injection for at least 48 hours.  
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8.2.5. Conclusion 
Pilot experiments confirmed successful PEG hydrogel implantation after permanent left 
anterior descending coronary artery occlusion. PEG hydrogels were detected throughout the 
left ventricle and retained within the myocardial wall for 48 hours.  
Next, the effects of polyethylene glycol hydrogels on ventricular function and architecture 
after myocardial ischemia were explored. 
 
8.3. The effects of a non-degradable polyethylene glycol hydrogel on post-
infarct left ventricular function and remodelling 
8.3.1. Rationale 
Over the last few years a number of animal studies have shown that biomaterial injections 
may attenuate left-ventricular dysfunction after ischemia. Wall and colleagues have used a 
finite element modelling approach to show that biomaterial injections into the heart help 
normalize wall stresses thereby contributing to an improvement in LV function386, with stiffer 
materials showing a greater benefit. While the materials used thus far have all been 
degradable, it has recently been proposed that an injectable polymer that is non-degradable 
may be needed for long-term beneficial effects on heart remodelling 489. To overcome 
handling problems, potential immunogenicity and limited engineerability of natural polymers 
that limit their potential for clinical application409, a synthetic, non-degradable, polyethylene 
glycol based hydrogel was chosen for this study. Polyethylene glycol’s mechanical properties 
are well suited for myocardial injections, as it ranks amongst the stiffest materials mentioned 
in Wall´s paper and remains amongst the most inert synthetic biomaterials to date490.  
The aim of the study was to determine short- and long-term effects of permanent mechanical 
reinforcement on post-infarction ventricular remodelling in an attempt to answer whether or 
not the presence of a synthetic biomaterial produces some of the same benefits as cell 
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transplantation, namely wall thickening, beneficial LV remodelling and functional 
improvement. 
 
After permanent ligation of the left anterior descending artery, PEG gel reagents were 
injected into the infarcted region and polymerised in situ. Ventricular function and heart 
dimensions were assessed at 2, 4 and 13 weeks. Histological analyses to determine post-
mortem infarct volume and scar thickness were performed at 4 and 13 weeks. 
 
8.3.2. Survival 
A total of 91 rats were used in this study. The survival in the 28-day experiment was 100 % 
(42 rats, n=10-11). In the 3-month study one rat died due to fibrillation, immediately after the 
thoracotomy was performed. The remaining 48 animals survived (97,96 %; 48 rats, n=10-14). 
The overall survival rate for the study was 98,9 %. 
 
8.3.3. Durability of PEG-gel in rat hearts 
Distribution of injected PEG-hydrogel was assessed at 4 and 13 weeks by detection through 
fluorescent microscopy of a covalently attached far-red fluorescent label. The label was easily 
detected at both time points and the hydrogels had very similar signal intensities (Figure 39). 
PEG hydrogel was found distributed throughout the infarcted region and its border zones at 4 
and 13 weeks with the amount of gel appearing to remain constant. 
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Figure.39. Assessment of polyethylene glycol (PEG) gel distribution in an infarcted rat heart. 
Representative micrographs of Alexa Fluor 660 labeled PEG (red) at (A) 4 and (B) 13 weeks. 
The white line delineates the infarcted regions. Nuclei are stained blue with DAPI. Bar 
represents 500 µm. 
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8.3.4. Echocardiographic analysis 
The fractional shortening was not significantly different between saline and PEG hydrogel 
injected hearts at 2, 4 and 13 weeks (Table 2). The dimensions of the PEG hydrogel injected 
hearts were significantly reduced at end diastole at 2 and 4 weeks as compared to the saline 
controls (Table 2, Figure 40). The increase in heart size that was induced by infarction was 
reduced by 33% at 2 weeks and 43% at 4 weeks (p≤0.05) for the PEG hydrogel injected 
heart relative to the saline control. The dimension changes at end systole showed a similar 
but non-significant trend, whereby the infarction induced increase was reduced by 22% and 
23% in the PEG gel-injected hearts at 2 and 4 weeks respectively (p=0.25 and 0.19). 
 
Weeks Parameter Sham Sham plus 
PEG 
Infarct plus 
saline 
Infarct plus 
PEG 
 
2 
FS% 48.99±1.43 47.56±1.26 34.99±1.29 36.55±2.58 
ESD 3.52±0.13 4.25±0.17δ 5.55±0.22 5.09±0.31 
EDD 6.89±0.10 8.07±0.15δ 8.51±0.19 7.98±0.18* 
 
4 
FS% 52.27±0.42 48.29±0.84δ  34.42±1.63 35.51±2.75 
ESD 3.60±0.04 4.04±0.16δ 6.07±0.30 5.49±0.31 
EDD 7.54±0.09 7.79±0.20 9.2±0.24 8.48±0.16* 
 
13 
FS% 48.35±0.61 34.73±1.24 26.48±1.53 26.11±2.53 
ESD 4.36±0.10 5.76±0.20δ 7.54±0.32 7.66±0.45 
EDD 8.44±0.14 8.81±0.16 10.20±0.26 10.24±0.30 
 
Table 2: Echocardiography at 2, 4 and 13 weeks 
 
The initial partial preservation of heart dimensions obtained by synthetic hydrogel injection 
was however lost at 13 weeks with the ESD and EDD being equivalent for both saline and 
PEG hydrogel injected hearts (Table 2, Figure 40). 
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The injection of PEG hydrogel into sham-operated hearts did not affect fractional shortening 
at 2 weeks but there was a small but significant reduction at 4 weeks relative to sham-
operated hearts with no PEG injection (Table 2). By 13 weeks, there was a further marked 
deterioration in fractional shortening associated with PEG injection in sham animals. At 2 
weeks both EDD and ESD were significantly increased relative to the sham for PEG gel 
injected hearts, but by 4 weeks only the ESD was significantly increased, a difference that 
was amplified at 13 weeks. 
 
 
 
 
Fig. 40. Polyethylene glycol (PEG) hydrogel injections reduce infarct induced diastolic dilation over 
the medium-term. The change in diastolic dimensions over time is presented as a percentage 
increase relative to sham diastolic dimensions. There was a significant reduction at 2 and 4 weeks 
(*p=0.05 and 0.02 for 2 and 4 weeks, respectively). 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 113 
8.3.5. Post-mortem infarct volume and scar thickness 
Infarct volume at 4 weeks in the saline group was 21.96±11.84 % and was not significantly 
different in the PEG hydrogel injected hearts (22.37±9.85 %). Likewise at 13 weeks the infarct 
volumes were similar with infarcts occupying 22.55% and 27.87% of the left ventricle volume 
for saline and PEG hydrogel injected hearts respectively. 
 
Animals in the PEG hydrogel injected group had a significantly thicker scar at 4 weeks 
relative to the saline injected group, 2.96 mm and 1.66 mm respectively (p<0.01). While 
saline-injected rats showed a 36% decrease in wall/scar thickness, PEG hydrogel injection 
completely prevented thinning of the scar compared to the sham group at 4 weeks (Figure 
41). At 13 weeks the scar in the PEG hydrogel group had thinned relative to the wall of the 
sham group. Though there was still a trend towards an increased scar thickness as compared 
to the saline, it was no longer significant (30% increase p=0.069). 
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Fig. 41. Polyethylene glycol (PEG) hydrogel injections preserve wall thickness in the medium-term. 
Micrographs of Masson’s trichrome-stained infarct scars of at 4 weeks (a, b) and 13 weeks (c, d) for 
saline (a, c) and PEG hydrogel injected hearts (b, d). Bar represents 2 mm. The wall thickness was 
quantified by image analysis (e). The wall thinning was prevented at 4 weeks (*P <0.01). 
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8.3.6. Inflammatory reaction  
As a non-degradable hydrogel was being delivered into heart tissue, the inflammatory reaction 
was assessed by immunohistochemical detection of macrophages. At 4 weeks there was a clear 
and pronounced macrophage response to the hydrogel that persisted out to 3 months (Figure 
42). 
 
 
Fig. 42. Inflammatory reaction to polyethylene glycol (PEG) hydrogel. Macrophages were identified 
by staining for ED-1 (red). Saline injected hearts at 4 and 13 weeks (a, c) and PEG hydrogel 
injected hearts at 4 and 13 weeks (b, d). Foreign body giant cells were identified by their clustered 
nuclei (DAPI: blue) at 13 weeks in PEG hydrogel injected hearts (arrowheads). Inset in (d) shows a 
higher magnification of the cell identified by the rightmost arrowhead clearly demonstrating the 
characteristic multiple nuclei present within the singular ED1 positive cytoplasm. The PEG hydrogel 
is visible on the micrograph (arrows) as light gray material. This identification was confirmed by 
examination of adjacent serial sections for presence of Alexa Fluor 660 label, as the label was lost 
during the immunohistochemical staining procedure (data not shown). Bar represents 100 µm. 
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The macrophages were relatively evenly distributed in the PEG hydrogel infiltrated regions. 
By 13 weeks, a low number of putative foreign body giant cells were observed on the borders 
of the hydrogel strands. 
 
8.3.7. DISCUSSION 
These studies showed for the first time that the injection of a synthetic non-degradable PEG 
based hydrogel into ischemic myocardium is feasible and leads to a retardation of post-infarct 
left-ventricular dilatation. A non-degradable form of a PEG-hydrogel gel was utilized to 
investigate whether a permanent support of the heart is needed to maintain beneficial effects 
on post-MI remodelling.  
It has been suggested previously that in order to maximize the attenuation of remodelling, 
limit deterioration of cardiac function and progression into heart failure when using injected 
polymers as a stand-alone treatment, stiffer materials should be used386,489. The proposed 
mechanism for the efficacy of such materials - that they impart an increased mechanical 
strength to the infarct, providing stress-relief for the cardiomyocytes - draws support from a 
recent clinical study: Sabatine et al. showed that high baseline levels of ST2, a marker for 
biomechanical strain, correlated significantly with higher incidences of cardiovascular death 
and heart failure after myocardial infarcts491. PEG-based hydrogels are mechanically more 
stable than natural hydrogels such as fibrin, collagen and alginate and rank amongst the 
stiffest hydrogels386. Furthermore, many of the natural biomaterials that have been used in 
similar approaches (fibrin, alginate, matrigel) are known to also enhance angiogenesis, 
making it challenging to separate effects mechanical strengthening of the infarcted wall might 
have from a paracrine effect492,493. 
 
PEG-injected hearts showed reduced adverse remodelling 2 and 4 weeks after myocardial 
infarction with a complete prevention of wall thinning and significant 33,3% and 43,3% 
reductions in end-diastolic diameter increase at 2 and 4 weeks, respectively. PEG-injected 
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hearts also showed a similar trend towards reduced end-systolic dilation. Taken together, the 
increased scar thickness and decreased heart dimensions should help lessen elevated 
cardiomyocytes stresses in accordance with Laplace´s law. Indeed at 1 month, delivery of 
PEG hydrogel resulted in comparable effects to the ACE-inhibitor Lisinopril, namely beneficial 
remodelling consisting of a significantly decreased EDV and a non-significant decrease in 
ESV, without improving the ejection fraction after ischemic myocardial injury494. However, 3 
months after the ischemic event, the remodelling caught up in the PEG-treated group. 
Luminal dimensions were virtually identical with only the wall thickness in the PEG-group 
somewhat preserved. To what degree the inflammatory reaction (foreign body reaction) at 
three months is responsible for the late adverse remodelling is not clear. The continuous 
inflammation might rather reflect the non-degradability of the material and not the material 
itself. What speaks against inflammation being the sole reason for the late remodelling in the 
PEG-treated group is that although long-term implants of non-degradable PEG did damage 
the non-infarcted heart as confirmed by a substantially decreased fractional shortening at 3 
months, the injection of PEG into sham operated hearts did not lead to increased diastolic 
dimensions at this time. 
A possible explanation for the late remodelling in the treatment group might be a delayed 
build up of cardiomyocyte stresses (in the border zone) above a threshold level. [PEG might 
act as a buffer for stresses initially – permanently but insufficiently reducing stresses. As the 
hearts grow bigger, stresses may well increase slowly, ultimately leading to apoptosis, late 
adverse remodelling and ultimately to a common endpoint in the treatment and control group]  
 
8.3.8. Conclusion 
While the experiments showed that the injection of non-degradable synthetic gel was 
effective in ameliorating pathological remodelling in the medium-term after infarction they also 
revealed that the injections were unable to prevent long-term dilation, a likely explanation 
being the inflammatory reaction caused by the non-degradability of the gels.  
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One of the major advantages of PEG hydrogels is that the engineerability afforded by this gel 
allows for controlled degradability, potentially reducing inflammation. Therefore the potential 
of degradable PEG hydrogels for myocardial therapy was investigated next. Degradable 
hydrogels may overcome the inflammatory issue whilst still providing mechanical support for 
an extended period of time.  
 
8.4. Enzymatically degradable polyethylene hydrogels for myocardial 
injection  
Enzymatically degradable PEG hydrogels are a potentially important alternative therapy to 
the non-degradable gel as they will disappear over time and may not induce as pronounced 
an inflammatory response.  The feasibility of crosslinking PEG hydrogels with enzymatically 
degradable peptides has previously been shown400.  
The main purpose of the following set of experiments was to determine whether controlling 
the degradability does allow a reduction or even lead to the prevention of the inflammation 
related to non-degradability. For these studies, hydrogel formation was achieved by Michael-
type addition reaction between 20kD-8arm-vinyl sulfone PEG macromers and the thiol groups 
of cysteine-containing MMP-sensitive peptides. An observation previously made in the 
laboratory was that PEG hydrogels crosslinked with two different matrix-metalloproteinase 
sensitive sequences, a highly degradable sequence modified from MMP-1 
(GCREGPQGIWGQERCG)400 or MMP-9 (GCREKGPRQITERCG), respectively, exhibit 
different degradation times in vitro (personal communication, Mona Bracher).  
Therefore a second aim was to determine whether these differences in degradation times 
between hydrogels crosslinked with MMP1-sensitive (MMP1s) or MMP9s-sequences [from 
here on referred to as either PEG-MMP1s or PEG-MMP9s] also persist in vivo, as these 
differences may potentially be exploited for local sustained delivery of cardioprotective 
factors. 
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A minor objective of these studies was to assess whether the gelling times of enzymatically 
degradable PEG hydrogels allowed for efficient delivery to the beating heart. A potential issue 
previously identified was the increased gelling time compared with non-degradable PEG 
hydrogels crosslinked with DTT, which may interfere with hydrogel retention in the beating 
heart.  
 
8.4.1. In vivo gelling times, retention and distribution of enzymatically degradable PEG 
hydrogels   
In vitro gelling times for the enzymatically degradable PEG hydrogels were comparable. 
MMP-1s crosslinked hydrogels gelled within 13.5 minutes, while it took MMP-9s-crosslinked 
hydrogels 11.5 minutes to gel under physiological conditions (37°C).  
 
To assess retention and distribution of PEG-MMP1s and PEG-MMP9s, 100 µl of PEG-
MMP1s or PEG-MMP9s were injected into the left ventricular region of rat hearts and 
polymerised in situ. Histological analysis of hears harvested 60 minutes after hydrogel 
injections revealed successful retention of hydrogels crosslinked with MMP-1- and MMP9-
sensitive sequences in beating rat hearts. Both MMP1s and MMP9s-crosslinked hydrogels 
were retained well within the myocardium and showed similar distributions 60 minutes after 
the injections (representative image for PEG-MMP1s is shown in Fig.43). Overall the 
enzymatically degradable hydrogels seemed to integrate better into the myocardial tissue 
than non-degradable PEG hydrogels (see Fig.43c-d). The hydrogels were dispersed over a 
larger area than non-degradable polyethylene glycol hydrogels and appeared more fibrillar in 
nature. Due to the slower gelling times of enzymatically degradable hydrogels, the possibility 
of gelling as a globule within the heart should be reduced. This in turn may explain the 
increased homogeneity in distribution between cardiomyocytes (see Fig.43c-d). 
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8.4.2. In vivo degradability of PEG-MMP1s and PEG-MMP9s hydrogels 
To assess the degradation rates of and the inflammation provoked by PEG-MMP1s and 
PEG-MMP9s, hearts were again injected with 100µl of the respective PEG hydrogels. 
Distribution of PEG-hydrogels was then assessed 60 minutes, 1, 2 and 4 weeks after 
Figure.43. Micrographs of degradable PEG-MMP1s implants 1 hour after myocardial injection. H&E 
scan showing entire cross section with extent of PEG dispersion indicated (black frame), 2x 
magnification (A). H&E 10x magnification (B). Fluorescent micrograph showing fibrillar nature (PEG 
in pink (arrows), cardiomyocytes red due to autofluorescence, Nuclei counterstained with DAPI in 
blue, 200x magnification (C). Micrograph showing even dispersion of PEG between 
cardiomyocytes, 200x magnification (D). 
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intramyocardial injection by detection through fluorescent microscopy of the covalently 
attached far-red fluorescent label (n=2 for each timepoint).  
 
Hearts harvested 60 minutes after myocardial injection showed that hydrogel distribution was 
similar for PEG-MMP1s and PEG-MMP9s, demonstrating successful in vivo delivery after 
crosslinking with either sequence (see Fig.44)  
 
 
 
After successful implantation, PEG-MMP1s degradation occurred at a much more rapid pace 
in comparison with PEG-MMP9s hydrogels (Fig.45). 7 days after intramyocardial injection a 
majority of the hydrogel had been degraded (see Fig.45a). In histological section obtained 
from hears harvested after 14 and 28 days, respectively, only traces of remaining hydrogel 
were found [Fig.45c (14 days) and Fig.45e (28 days)], suggesting that degradation is 
essentially completed between day 7 and 14 after intramyocardial injection. PEG-MMP9s 
hydrogels on the other hand were found throughout the left-ventricle at all timepoints [shown 
in Fig.45b (7 days), d (14 days), f (28 days)]. PEG distribution was similar between the 60-
minute and the 28-day timepoint suggesting that PEG-MMP9s hydrogels are stable for up the 
first month after cardiac implantation into sham-operated rat hearts. 
Fig.44. To confirm successful delivery, distribution of PEG hydrogels crosslinked with a MMP1-
sentitive (A) or a MMP-9-sensitive sequence (B) was analyzed 60 minutes after cardiac injection 
and was shown to be similar in both treatment groups. 
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Fig.45. Left-ventricular distribution of PEG-MMP1s and PEG-MMP9s 7, 14 and 28 days after 
intramyocardial injection was assessed. PEG-MMP1s hydrogels degraded faster in vivo [7 days (A), 
14 days (C), 28 days (E)] than PEG hydrogels crosslinked with a MMP9-sensitive peptide sequence 
[7 days (B), 14 days (D), 28 days (F)] 
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8.4.3. Discussion 
Differential degradation rates between PEG-MMP1s and PEG-MMP9s hydrogels had been 
expected prior to conducting these experiments. The MMP1-derived MMP1s-sequence used 
to form PEG-MMP1s hydrogels had previously been engineered to be highly degradable400. 
Furthermore in vitro experiments had revealed faster degradation rates of PEG-MMP1s 
hydrogels when compared with PEG-MMP9s hydrogels (personal communication 
M.Bracher). The current study thus confirmed these previous findings in vivo after myocardial 
injection.  
 
Since it was hypothesized that the prolonged inflammatory reaction observed in previous 
studies was correlated to the non-degradability, the next objective was to assess the 
inflammatory response triggered by enzymatically degradable PEG hydrogel at the 7-, 14- 
and 28 day-timepoints. 
 
8.4.4. Inflammatory response after cardiac injection of enzymatically degradable PEG 
hydrogels   
At day 7, the inflammation assessed by immunohistochemical analysis of ED-1, a marker for 
rat macrophages, was similar in hearts injected with PEG-MMP1s and PEG-MMP9s (see 
Fig.46A and 46.B respectively). By day 14, as PEG-MMP1s hydrogels had almost entirely 
degraded, the inflammatory response had also mostly resolved (see Fig.46C). Samples 
obtained on day 28 confirmed this trend as inflammation was remarkedly reduced after PEG-
MMP1s degradation (Fig.46E). In PEG-MMP9s hydrogels ED-1 staining revealed similar 
amounts of inflammation at all timepoints [Fig.46B (7 days), 46.D (14 days) and 46.F (28 
days)]. This result suggests that the rate of PEG degradability is linked to the degree of 
inflammation induced after myocardial injection. 
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Fig.46 Immunohistochemical analysis of ED-1+-cells was performed to determine the 
inflammatory response present 7, 14 and 28 days after injection of PEG-MMP1s and PEG-
MMP9s, respectively. In accordance with a faster degradation of PEG-MMP1s hydrogels (shown 
in Fig.45) inflammation was markedly reduced at later timepoints [7 days (A), 14 days (C), 28 
days (E)]. PEG-MMP9s hydrogels illicited an inflammatory response that remained constant over 
the course of the study [7 days (B), 14 days (D), 28 days (F)]. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 125 
8.4.5. Conclusion 
Characterization of hearts injected with both PEG-MMP1s and PEG-MMP9s hydrogels 
revealed that in situ polymerisation and retention of enzymatically degradable hydrogels 
within the beating heart is feasible. Importantly, degradation times differed between PEG 
hydrogels crosslinked with MMP1s and MMP9s, as PEG-MMP1s hydrogels had almost 
entirely degraded after 14 days, while PEG-MMP9s hydrogels remained stable for the 
duration of the study. This finding suggests that hydrogel formation with varying protease-
sensitive peptide sequences allows control over the rate of hydrogel degradation in vivo. This 
in turn could be exploited to modulate the release of bioactive molecules for therapeutic 
angiogenesis. 
Furthermore, these experiments revealed that the inflammation observed after cardiac PEG 
hydrogel injection is linked to their degradation rate, as the induced inflammatory response 
resolved faster after injection of quickly degrading PEG-MMP1s hydrogels. 
 
Since it was hypothesized that the prolonged inflammatory reaction observed in previous 
studies with DTT-crosslinked PEG hydrogels was a result of the non-degradability leading to 
a reduction in cardiac function, the next objective was to investigate the biocompatibility of 
enzymatically degradable polyethylene hydrogels (PEG-MMP1s and PEG-MMP9s) after 
intramyocardial injection into healthy hearts.   
 
8.5. Biocompatibility of enzymatically crosslinked PEG-hydrogels in rat 
hearts 
To determine the biocompatibility of PEG hydrogels cross-linked with either the MMP1 or 
MMP9-sensitive peptide sequence, 100 µl of PEG hydrogels was injected into the heart after 
a thoracotomy (n=8). Saline injected rat hearts served as control animals (n=8). 
Echocardiographic analysis was performed 2 and 4 weeks post surgery. The animals were 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 126 
sacrificed on day 29 and histological analysis to investigate a potential inflammatory reaction 
was performed.   
 
8.5.1. Survival 
A total of 24 rats (n=8) were used in this study. All animals survived for the duration of the 
study period.  
 
8.5.2. Echocardiographic analysis 
Left-ventricular function was assessed at days 14 and 28. After 2 weeks, animals injected 
with polyethylene hydrogels crosslinked with either an MMP1-sensitive or an MMP9-sensitive 
peptide sequence had an ejection fraction of 43.01±2.58% and 47.16±0.49%, respectively, 
and did not differ significantly from saline-injected control animals (46.3±1.03%, n=8, NS, see 
Fig.47).  
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Fig.47. Echocardiographic evaluation of cardiac function was performed 14 days after 
intramyocardial injection of enzymatically degradable PEG hydrogels into sham-operated 
hearts. No significant changes were observed after treatment with PEG-MMP1s or PEG-
MMP9s in comparison with saline controls (*p>0.05). 
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Myocardial contractility was again evaluated 4 weeks after PEG-MMP1s and PEG-MMP9s 
injections into the heart. As seen on day 14, no adverse effects on left-ventricular function 
resulted from injection of enzymatically degradable PEG hydrogels (n=8, p>0.05, see Fig.48). 
Fractional shortening after PEG-MMP1s injections was 44.18±2.47% at the 4 week-timepoint, 
while animals injected with PEG-MMP9s had an ejection fraction of 47.15±1.19%.  These 
results were not significantly different in comparison with saline-injected controls 
(46.49±0.94%). 
    
 
 
8.5.3. Histological analysis – Masson’s Trichrome 
To determine, whether injections of PEG-MMP1s and PEG-MMP9s is associated with scar 
formation within the left-ventricular wall, hearts sections obtained after sacrifice on day 29 
were stained with modified Masson’s Trichrome. No differences with saline-injected control 
hearts were observed. Neither the faster degrading PEG-MMP1s hydrogels nor the more 
stable PEG-MMP1s hydrogels induced scar formation 4 weeks after intramyocardial injection, 
confirming a superior biocompatibility in comparison with PEG-DTT hydrogels (see Fig.49).  
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Fig.48. Graph shows results from echocardiographic analysis of cardiac function on day 28. 
Injections of PEG-MMP1s and PEG-MMP9s did not adversely affect cardiac contractility at this 
timepoint (*p>0.05 vs saline injected controls).  
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8.5.4. Inflammation (not shown, see Fig.46) 
Immunohistochemical staining for macrophages in hearts injected with PEG-MMP1s and 
PEG-MMP1s was performed to determine the extent of inflammation at day 29. As found in 
the previous study (see.Fig.46), the injection of MMP9s-crosslinked hydrogels caused a more 
pronounced inflammatory reaction in comparison with the faster degrading MMP1s-
crosslinked gels at day 29.  
 
Fig.49. Masson’s Trichrome images of sham-operated hearts injected with saline (A), PEG-MMP1s 
(B), PEG-MMP9s (C), and non-degradable PEG-DTT (D) are shown. At day 29, no traces of scar 
formation are found around the inj ction sites of enzymatically degradable PEG hydrogels while 
PEG-DTT injections resulted in extensive scarring of the LV at this timepoint.     
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8.5.5. Conclusion 
Myocardial injections of enzymatically crosslinked PEG-MMP1s and PEG-MMP9s hydrogels 
had no adverse effects on ventricular function at days 14 and 28. On the contrary, after 
injection of DTT-crosslinked hydrogels, a slight, but significant decrease in myocardial 
contractility had been observed on day 28 in comparison with saline controls (see Table 2, 
8.3.4.). 
When investigating the amount of inflammation present at day 29, an increased inflammatory 
reaction directed against PEG-MMP9s hydrogels was observed in comparison with PEG-
MMP1s or saline injected hearts. Yet, this did not have an effect on myocardial performance 
(see Fig.48). Time constraints did not allow for additional long-term experiments to definitively 
exclude an adverse effect of PEG-MMP9s hydrogels on cardiac function at a later timepoint. 
However, the significant reduction seen after injection of the highly degradable PEG-MMP1s 
suggests, that once degradation of the gels sets in, the inflammation present around the 
hydrogels quickly resolves. Collectively these results indicate that degradable polyethylene 
glycol hydrogels are more suitable for intramyocardial injections in comparison with non-
degradable PEG-hydrogels and present a promising platform for in vivo targeted delivery of 
bioactive molecules. Whether transient support by PEG-MMP1s and PEG-MMP9s hydrogels 
is sufficient to ameliorate left ventricular remodelling after myocardial infarction, though, is 
unknown. Thus, the effects of enzymatically degradable PEG-MMP1s and PEG-MMP9s 
hydrogels on post-infarct left-ventricular function and remodelling were tested next. 
 
8.6. Effects of enzymatically-degradable polyethylene glycol hydrogels on 
post-infarct left ventricular function and remodelling 
8.6.1. Rationale 
After confirming that myocardial injections of enzymatically-degradable polyethylene glycol 
hydrogels do not have adverse effects left-ventricular function up to 28 days after myocardial 
injection, the next objective was to test whether a transient support of the left ventricle after 
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myocardial infarction is sufficient to ameliorate infarction-associated left ventricular remodelling 
and whether the implantation of degradable hydrogels has beneficial effects on heart function 
post MI. 
 
Immediately after permanent ligation of the left anterior descending artery, PEG-MMP1s or PEG-
MMP9s hydrogels were injected into the infarcted region and polymerised in situ. Ventricular 
function and heart dimensions were assessed at 2 and 4 weeks. Histological analysis to 
determine post-mortem infarct volume and scar thickness was performed subsequent to sacrifice 
of the animals at day 29. 
8.6.2. Survival 
A total of 35 rats were operated for this study. Two animals died within 30 minutes of the 
surgery. An additional animal died 3 weeks post operation. The overall survival rate for the 
study was 91.43% (32 rats, n=9-12).  
 
8.6.3. Echocardiographic analysis 
Echocardiographic analysis did not reveal any significant differences between the treatment 
and control groups at both days 14 and 28. Saline injected animals had a fractional 
shortening of 31.71±1.78% at day 14 (n=10), which was similar to animals treated with either 
PEG-MMP1s (31.86±1.89%, n=11, p=0.95) or PEG-MMP9s (30.26±1.8, n=12, p=0.58), 
respectively (see. Fig.50).  
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Ventricular function slightly decreased in all groups between days 14 and 28. At day 28 the 
fractional shortening of saline injected animals was 28.98±1.95% (n=9) and did not differ 
significantly from animals treated with either PEG-MMP1s (29.81±1.99%, n=11, p=0.77) or 
PEG-MMP9s (28.43±1.95, n=12, p=0.85), respectively. 
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Fig.50. Echocardiographic analysis of cardiac function was performed 14 days after experimental 
myocardial infarction. Injections of ezymatically degradable PEG-MMP1s or PEG-MMP9s hydrogels 
did not improve fractional shortening in comparison with saline-injected controls (p>0.05). 
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8.6.3.1.	  Heart	  dimensions	  	  
To determine whether enzymatically degradable PEG hydrogels affect post-infarct heart 
remodelling, left-ventricular end-systolic (ESD) and end-diastolic (EDD) dimensions were 
measured using echocardiography at 14 and 28 days. 14 days after experimental myocardial 
infarction ESD was 574.35±31.72µm in saline-injected hearts (n=10). PEG-MMP1s and PEG-
MMP9s injections did not significantly change ESD in comparison with controls at this time 
and were 573.97±31.49µm (n=11) and 581.71±26.90µm (n=12), respectively (see Fig.52). 
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Fig.51. Cardiac contractility was again assessed 28 days after MI. Neither PEG-MMP1s nor PEG-
MMP9s significantly affected fractional shortening at this timepoint (*p>0.05 compared to saline). 
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EDD measured 14 days after injection of saline (836.50±28.41µm, n=10), PEG-MMP1s 
(836.20±25.21µm, n=11) or PEG-MMP9s (830.39±19.13µm, n=12), respectively, were almost 
identical and did not statistically differ (p>0.05, shown in Fig.53).  
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Fig.52. 14 days after having undergone experimental myocardial infarction, end-systolic diameters 
were measured during echocardiographic evaluation to determine post-infarct left ventricular 
remodelling. No significant effects were seen after injection of either PEG-MMP1s or PEG-MMP9s 
(*p>0.05 vs. saline controls), respectively. 
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As seen on day 14, left ventricular diameters were not significantly different 28 days after 
intramyocardial injection between the three treatment groups. ESD was 625.15±36.62µm 
(n=9), 623.53±34.69µm (n=11), and 634.70±38.31µm (n=12) after administration of saline, 
PEG-MMP1s and PEG-MMP9s (see Fig.54). 
 
 
  
 
 
At day 28, left ventricular diameter at the end of diastole was 888.06±28.49µm (n=9), 
881.83±26.13µm (n=11), and 879.81±28.18µm (n=12) hearts injected with saline, PEG-
MMP1s and PEG-MMP9s, respectively (see Fig.55). 
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Fig.53. Echocardiographic measurement of end-diastolic diameters revealed no significant 
differences between hearts injected with saline, PEG-MMP1s and PEG-MMP9s (*p>0.05, 
compared to saline) 14 days after myocardial infarction.  
Fig. 54. Graph shows end-systolic diameters 28 days after myocardial infarction. A significant 
difference after saline, PEG-MMP1s or PEG-MMP9s-delivery was not seen (*p>0.05 vs. saline). 
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8.6.4. Post-mortem scar thickness and infarct volume 
To determine whether the injection of PEG-MMP1s or PEG-MMP9s leads to successful 
prevention of left ventricular wall thinning or a reduction in infarct volume, heart sections were 
stained with Masson’s Trichrome.  
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Fig.55. No significant difference in end-diastolic diameter as measured by echocardiography was found 
(*p>0.05 vs. saline controls) between the three treatment groups at day 28 after MI.   
Fig. 56. Masson’s Trichrome staining of histological sections from hearts explanted on day 28 was 
performed to assess myocardial infarct scar thickness. Representative images for hearts treated 
with saline (A), PEG-MMP1s (B) and PEG-MMP9s (C) are shown. 
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Image analysis revealed that the average thickness of the scar spanning the left ventricular 
wall after MI was 907.75±80.02µm in hearts injected with saline. Injections of both 
enzymatically degradable PEG-hydrogels resulted in a non-significant decrease in wall 
thinning after myocardial infarction (see Fig.56+57). Scars stemming from MI were 17.6% 
thicker after PEG-MMP1s hydrogel injections on day 28 and were measured at 
1067.90±131.92µm (p=0.36 vs. saline). PEG-MMP9s injections preserved the thickness of 
the left-ventricular wall best. There was a strong trend towards a significant increase in scar 
thickness in comparison with saline injected control hearts (p=0.16), as the treatment of PEG-
MMP9s resulted in an average scar thickness of 1126.73±108.32µm (a 24.12% increase over 
saline controls, see Fig.57). The fact that PEG-MMP9s injections resulted in the biggest 
increase in scar thickness/lowest decrease in wall thickness post MI is in accordance with the 
previous finding that these hydrogels were more stable and degraded slower after 
intramyocardial injections in comparison with PEG hydrogels crosslinked with the MMP1-
sensitive sequence. 
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Fig.57. Quantification of scar thickness revealed no significant differences in scar thickness 
between treatment groups and saline injected controls. A trend towards decreased wall thinning 
was observed after injection of slower degrading PEG-MMP9s hydrogels (p=0.16).   
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A potential effect of enzymatically degradable PEG-hydrogels on limiting the extent of the 
myocardial infarct was investigated next. Infarct volume in hearts treated with saline was 
27.85±2.37% 28 days after permanent LAD occlusion. In comparison, infarct volumes 
measured after PEG-MMP1s and PEG-MMP9s injections were 26.75±3.55% and 33.23%, 
respectively and not significantly different (see Fig.58). While there appears to be a trend 
towards increased infarct volumes in PEG-MMP9s injected hearts, this likely represents an 
artefact due to the increased wall thickness present after treatment in this group (p=0.18 vs. 
saline, p=0.16 vs. PEG-MMP1s).  
 
   
 
 
8.6.5. Discussion 
While the injection of non-degradable polyethylene glycol hydrogels significantly slowed down 
heart remodelling over the first 4 weeks after myocardial infarction, enzymatically degradable 
polyethylene glycol hydrogels were not effective in ameliorating post-infarction left ventricular 
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Fig.58. Quantification of infarct volume was performed on heart sections stained with Masson 
Trichrome is shown. On day 28, no significant differences were seen after treatment of infarcted 
hearts with saline, PEG-MMP1s or PEG-MMP9s, respectively. 
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remodelling during this period of time. The results of this study thus confirm that degradable 
PEG-MMP1s and PEG-MMP9s hydrogels used in this study are not an effective alternative to 
non-degradable polyethylene glycol hydrogels. Currently a lack of long-term data exists 
determining whether beneficial effects seen after biomaterial injections persist over extended 
periods of time495. Collectively the data obtained after injection of non-degradable DTT-
crosslinked and enzymatically degradable PEG-MMP1s and PEG-MMP9s hydrogels suggest 
that permanent support is necessary to maintain beneficial effects on cardiac remodelling. 
Yet, many degradable natural biomaterials such as fibrin and collagen have been previously 
reported to limit infarct size, cardiac remodelling and to promote cardiac function up to 5 
weeks after MI388,390,393. A number of potential explanations for this finding exist, including 
differences in MI model (chronic MI vs. ischemia-reperfusion), differences in infarct size, and 
timing and volume of biomaterial injections. In part the differential outcome may also be a 
result of the pro-angiogenic potential of natural biomaterials393. A comprehensive comparison 
between natural and synthetic biomaterials using standardised protocols would yield valuable 
information to gain a better understanding into the mechanisms underlying beneficial effects 
on post-MI remodelling after biomaterial injections. A shortcoming of the current study is the 
lack of data on ventricular remodelling prior to the 2-week time-point. Thus it remains unclear 
whether the degradable hydrogels used in this study retarded LV remodelling at any point 
prior to 2 weeks. Consequently, no definitive conclusion can be drawn as to whether 
mechanical support by hydrogels exerts its main beneficial effects within the first minutes 
after myocardial infarction or whether ventricular remodelling proceeds after rapid 
degradation of the hydrogel. As gelling times in non-degradable hydrogels were shorter, an 
increased benefit would be expected, if immediate support after coronary occlusion is the 
most crucial variable. While slower gelling times allow for a more homogeneous distribution of 
the enzymatically degradable hydrogels, this may also result in inferior mechanical 
characteristics of degradable hydrogels in comparison with non-degradable hydrogels. 
Therefore it is possible to hypothesize that insufficient stress relief for surviving 
cardiomyocytes provided by degradable hydrogels in the first minutes to hours after 
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myocardial infarction explains the different outcomes. Additional studies to determine 
mechanical characteristics of hydrogels crosslinked with enzymatically degradable peptide 
sequences in comparison with DTT (to form non-degradable hydrogels) should be performed 
in the future. Alternatively, if lack of initial mechanical support is not the underlying 
mechanism for the negative result of this study, an early benefit could have been lost after 
partial degradation of the enzymatically degradable hydrogels. One of the main benefits after 
injection of non-degradable PEG hydrogels, a prevention of wall thinning, was somewhat 
preserved after injection of the more slowly degrading PEG-MMP9s hydrogels, as a 24.12% 
increase in scar thickness was observed on day 28 in comparison with saline controls 
(p=0.16). This points towards hydrogel degradability being the main reason responsible for 
the lack of positive effects of post-infarct heart remodelling. As - due to the limited 
regenerative potential of the myocardium - degrading hydrogels are mainly replaced by scar 
tissue, rapid degradation of the enzymatically polyethylene hydrogels may not allow sufficient 
time for proper scar formation thereby eradicating an initial benefit.  
 
8.6.6. Conclusion 
Enzymatically degradable hydrogels did not effectively reduce LV remodelling after 
myocardial infarction. Even after injection of PEG-MMP9s hydrogels, which degrade more 
slowly in vivo, only a non-significant increase in scar thickness compared with saline injected 
controls was seen. Importantly, though, it was shown that the host inflammatory response 
after myocardial injection was dramatically reduced as hydrogel degradation progressed, 
suggesting that no adverse long-term effects result from local delivery of enzymatically 
degradable PEG-hydrogels to the myocardium. Thus, these synthetic hydrogels still have a 
great potential for use as slow delivery matrix for therapeutic angiogenesis.  
Consequently, the potential of enzymatically degradable PEG hydrogels to act as long-term 
delivery matrix to promote therapeutic angiogenesis after MI, was tested next. As an 
increased scar thickness and slower degradation in vivo (over 4 weeks instead of 7-14 days 
with PEG-MMP1s) was observed after PEG-MMP9s hydrogel injections, it was hypothesized 
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that PEG-MMP9s hydrogels may be more suitable for sustained delivery of angiogenic 
growth factors such as VEGF than PEG-MMP1s hydrogels, while still exerting a limited 
beneficial effect on wall stress reduction. Therefore PEG-MMP9s hydrogels were chosen for 
the following experiment.  
 
8.7. Targeted delivery of VEGF from enzymatically degradable PEG-MMP9s 
hydrogels to promote therapeutic angiogenesis after myocardial infarction 
8.7.1. Rationale 
Myocardial infarction remains one of the pathologies hypothesized to be most effectively 
treated via therapeutic angiogenesis. More effective therapeutic angi genesis regimens 
centering on the prolonged targeted delivery of growth factors from polymeric delivery 
systems to promote long-term neovascularization have recently been developed. The 
increased long-term benefit is hypothesized to stem from overcoming rapid neovascular 
regression by promoting neovascular stability. PEG hydrogels are amongst a group of 
synthetic biomaterials that allow feedback dependent release of bound biologics. The 
chemistry utilized in forming PEG hydrogels employed in the previously described studies, 
Michael-type addition reaction, also allows for the covalent attachment of growth factors and 
other bioactive moieties409. In concert with Jeff Hubbell’s laboratory, our group has previously 
shown that these synthetic hydrogels can effectively be used to release bioactive VEGF as 
they degrade, promoting angiogenesis and preventing vascular regression in vivo289. In 
addition, previous studies showed that when injected as stand-alone treatment after 
myocardial infarction, PEG hydrogels ameliorated post-infarct left ventricular remodelling. 
Therefore, this type of gel may not only be used to provide mechanical strength for the critical 
early stages of the infarct, but also to deliver paracrine type signals in a well-defined manner.  
 
The objective of the following study was to test whether a synergistic beneficial effect can be 
achieved by providing initial mechanical support for the ischemic heart in combination with 
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sustained delivery of the pro-angiogenic growth factor VEGF. PEG hydrogels crosslinked with 
the MMP9-sensitive peptide sequence showed a slower degradation rate in vivo compared to 
hydrogels crosslinked with the MMP1-sensitive peptide. Furthermore, when injected after MI, 
a strong trend towards better preventing wall thinning was seen after PEG-MMP9s delivery.  
It was therefore hypothesized that PEG-MMP9s hydrogels would provide extended 
mechanical support in comparison with MMP1s-crosslinked hydrogels while also allowing 
extended release of vascular endothelial growth factor.  
In the long-term angiogenesis study performed in the subcutaneous wound-healing model, 
the medium dosage of VEGF (150ng/day for 42 days) promoted vascular stability up to 80 
days after termination of growth factor delivery. Earlier experiments showed that when 
injected immediately following permanent LAD occlusion, PEG-MMP9s hydrogels had almost 
entirely degraded 4 weeks after myocardial infarction. Accordingly, to test whether the VEGF 
dosage that most efficiently increased the neovasculature at 4 months in our subcutaneous 
angiogenesis model would impart functional benefit in the setting of MI, a total amount of 
4.675µg of VEGF was delivered per intramyocardial injection for this study, corresponding to 
150ng/day over a period of 31 days.  
 
8.7.2. Procedure and VEGF dosage  
After permanent ligation of the left anterior descending artery, rats were randomly selected to 
receive 100 µl injections of saline, 4.675µg VEGF as a single bolus injection, 10% PEG-
MMP9s or 100µl of 4.675µg VEGF incorporated into 10% PEG-MMP9s. Ventricular function 
and heart dimensions were assessed at 1, 2, 4 and 10 weeks. Histological analysis to 
determine post-mortem infarct volume, scar thickness and vascular density was performed 
subsequent to sacrifice of the animals after 10 weeks.  
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8.7.3. Survival 
A total of 62 rats were operated on for this study. 6 animals died within 48 hours of the 
surgical procedure, resulting in an overall survival rate of 90,3 % (n=10-13 per experimental 
group).  
 
8.7.4. Echocardiographic analysis 
8.7.4.1.	  Cardiac	  function	  
To assess potential benefits on cardiac function, echocardiographic analysis was performed 
at 1, 2, 4 and 10 weeks. Compared to sham-operated animals (47.94±0.66%) a significant 
drop-off in fractional shortening was seen in all groups that underwent permanent LAD 
occlusion as early as 1 week after surgery (saline, PEG-MMP9s, VEGF, PEG-
MMP9s+VEGF; p<0.05 vs. sham). Fractional shortening was 26.94±1.66, 23.65±1.79, 
27.77±2.07 and 26.2±2.8 after treatment with saline, PEG-MMP9s, VEGF and PEG-MMP9s-
VEGF, respectively; no significant difference between the treatment groups was seen at this 
timepoint (see Fig.59).  
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Echocardiographic evaluation at the later timepoints, at 2, 4 and 10 weeks, respectively, also 
did not reveal any significant differences between the treatment groups (see Fig.59, Table 3). 
Neither single bolus nor prolonged delivery of vascular endothelial growth factor via PEG 
hydrogels led to an improved functional recovery from myocardial ischemia (see table). 
Interestingly, single bolus injections of VEGF, and not prolonged delivery of VEGF from PEG-
MMP9s hydrogels, showed a non-significant trend towards increased fractional shortening in 
comparison with saline injected control hearts at 2, 4, and 10 weeks (p=0.16 at 2 weeks, 
p=0.14 at 4 weeks, p=0.22 at 10 weeks vs. saline). A trend towards increased cardiac 
function seen subsequent to PEG-MMP9s treatment at 1 week (p=0.19 vs. saline), but was 
lost over the course of week 2 (p=0.96 vs. saline at the 2-week-timepoint). 
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Fig.59. The effects of single bolus and prolonged delivery of VEGF on cardiac function were 
evaluated using echocardiographic analysis of fractional shortening 1, 2, 4, and 10 weeks after 
experimental myocardial infarction. Significant differences between treatment groups were not 
found. 
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Weeks 1 2 4 10 
Sham (n=10) 47.94±0.66 49.38±0.74 48.25±0.85 45.35±0.8 
Saline (13) 26.94±1.66 22.85±2.09 20.79±1.84 20.41±1.77 
PEG-MMP9s (11) 23.65±1.79 22.72±1.75 22.07±2.08 21.17±1.79 
VEGF (11) 27.77±2.07 27.67±2.69 25.37±2.54 23.8±2.12 
PEGMMP9s – 
VEGF (11) 26.2±2.8 23.22±2.76 21±3.12 19.75±2.75 
 
Table 3. Ejection fraction measured by echocardiography 1, 2, 4, and 10 weeks after MI. 
 
8.7.4.2.	  Left-­‐ventricular	  remodelling	  
To determine whether single bolus or prolonged delivery of VEGF has beneficial effects on 
post-infarct remodelling, left ventricular end-systolic and end-diastolic diameters were 
measured, 1, 2, 4, and 10 weeks after MI. Over the course of the study, a steady increase in 
both left-ventricular end-systolic and end-diastolic diameter was observed (shown in Fig.60-
61).  
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Fig.60. Echocardiographic measurements of left-ventricular diameters were taken 1, 2, 4, and 10 
weeks after experimental MI. At the 10-week-timepoint, a strong, non-significant trend towards 
increased left-ventricular dimensions at the end of systole was seen when comparing single bolus 
VEGF injections (purple) with PEG-MMP9s-VEGF injections (turquoise), p=0.07. 
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Subsequent to myocardial infarction, a significant increase in both ESD and EDD occurred in 
the saline, PEG-MMP9s, VEGF and PEG-MMP9s-VEGF groups (p<0.05, see Fig.60-61). Up 
to 4 weeks after MI, ventricular dimensions between the experimental treatment groups 
remained similar.  
 
ESD	  (in	  µm)	   	  	   	  	   	  	   	  	  
Weeks 1 2 4 10 
Sham (n=10) 410.13±10.02 391.38±8.37 419.24±10.19 475.65±10.77 
Saline (13) 609.04±22.29 689.05±27.25 771.56±30.52 839.29±31.66 
PEG-MMP9s (11) 831.41±39.63 711.56±34.20 768.88±40.92 831.41±39.63 
VEGF (11) 594.78±26.41 648.55±37.09 717.09±42.84 769.80±43.40 
PEGMMP9s – VEGF 
(11) 641.88±38.98 707.52±48.42 799.80±58.37 912.66±60.77 
 
Table 4. Left-ventricular end-systolic diameters measured by echocardiography. 
 
While ESD in the VEGF, PEG-MMP9s and PEG-MMP9s-VEGF groups measured at 10 weeks 
did not significantly differ from saline-injected controls (VEGF vs. saline p=0.2; PEG-MMP9s-
VEGF vs. saline p=0.27), a strong trend towards an increase was measured when comparing 
VEGF and PEG-MMP9s-VEGF treatments (VEGF: 769.80±43.40µm; PEG-MMP9s-VEGF: 
912.66±60.77; p=0.07; see Fig.60, table 4). 
 
Analysis of EDD at the 10-week-timepoint revealed a significant increase in the PEG-MMP9s-
VEGF group when compared to hearts injected with a single VEGF bolus (see Fig. 61, table 
5, p=0.03) and a trend when compared with saline-injected controls (p=0.12). Interestingly, at 
this time, a non-significant reduction in EDD was observed after administration of VEGF as a 
single bolus when compared to saline-controls (p=0.17) 
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EDD	  (in	  µm)	   	  	   	  	   	  	   	  	  
Weeks 1 2 4 10 
Sham (n=10) 787.06±12.11 772.86±10.91 809.42±8.79 869.87±9.93 
Saline (13) 831.12±16.90 890.00±14.90 970.40±20.45 1050.66±20.06 
PEG-MMP9s (11) 1049.08±26.43 915.93±25.53 979.74±27.63 1049.08±26.43 
VEGF (11) 813.69±13.79 882.02±18.43 942.32±27.26 1000.14±30.36 
PEGMMP9s – VEGF 
(11) 863.14±21.89 910.79±30.94 998.67±37.09 1125.89±44.20 
 
Table 5. Left-ventricular end-diastolic diameters measured by echocardiography 1, 2, 4, and 10 weeks 
after MI. 
 
8.7.5. Post-mortem infarct volume and scar thickness 
To evaluate the effects of VEGF delivery on the extent of the infarcted left ventricular area, 
image analysis of Masson’s Trichrome stained sections was performed at 10 weeks.  
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Fig.61. Post-infarct remodelling was assessed via echocardiography at 1, 2, 4, and 10 weeks. 10 
weeks after MI, a significant increase in EDD was observed in hearts injected with PEG-MMP9s-
VEGF (turquoise) when compared with single bolus VEGF injections (purple), *p=0.03.  
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No scar formation was observed in sham-operated animals. In saline-injected animals, infarct 
volume was 26.22±3.48% of the left-ventricle. PEG-MMP9s, VEGF and PEG-MMP9s-VEGF 
treatment resulted in infarct volumes of 27.5±2.36, 19.06±2.87, and 30.6±3.4%, respectively 
(see Fig.62).  
 
In comparison with saline-injected control, neither VEGF bolus injections, PEG-MMP9s 
injections nor local PEG-MMP9s-VEGF delivery, led to significant changes in infarct volume 
at week 10. Nevertheless, a trend towards a reduction in infarct volume was observed in 
VEGF bolus-injected animals (p=0.23 VEGF vs. saline). When prolonged VEGF delivery was 
compared with single bolus VEGF injections, though, a significantly reduced infarct volume 
was found in the latter group (p=0.04, see Fig.62). 
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Fig.62. Morphometric analysis of infarct volume is shown. A significantly reduced infarct volume 
was observed after single bolus VEGF administration in comparison with PEG-MMP9s-VEGF 
treatment (*p=0.04).  
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To determine whether PEG-MMP9s, single bolus VEGF or PEG-MMP9s-VEGF effectively 
prevent left ventricular wall thinning after MI, the thickness of the MI scar was measured.  
 
 
Scar thickness 10 weeks post-MI did not significantly differ between the treatment groups and 
the saline injected control animals (see Fig.63). Surprisingly, when comparing scar thickness 
after PEG-MMP9s (495.37±29.26µm) and single bolus VEGF treatment (521.23±52.55µm) 
with combined PEG-MMP9s-VEGF delivery (445.51±16.97µm) trends towards an increase in 
scar thickness were seen (PEG-MMP9s vs. PEG-MMP9s-VEGF p=0.16; VEGF vs. PEG-
MMP9s-VEGF p=0.19). 
 
8.7.6. Vascularization area and vessel density in the LV infarct area 
Quantification of vWF+-vessels was carried out to assess the effects of prolonged VEGF 
delivery on long-term neovascularization. Vessel density, as vessels per mm2, and 
vascularization area, as a percentage of the infarcted left ventricle, were measured (Fig.64). 
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Fig.63. The potential to prevent wall thinning subsequent to MI was determined by measuring the 
thickness of the infarct scar 10 weeks after treatment. Significant differences were not observed 
between the groups.  
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No statistically significant long-term effects of single bolus or prolonged VEGF delivery on 
neovascularization were seen 10 weeks after experimental myocardial infarction. 
Vascularization area was 5.13±0.59, 5.18±0.86, 4.98±0.65 and 5.28±0.53% after 
administration of saline, PEG-MMP9s, VEGF and PEG-MMP9s-VEGF, respectively (see 
Fig.65). 
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Fig.64. Immunoflurescent staining for vWF+-vessels 10 weeks after MI was performed to 
evaluate vascularization of the left ventricle. Images were acquired at 80x magnification (A, B), 
before automated image analysis with VIS was carried out.    
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A non-significant increase in vessel density was seen in all treatment groups in comparison 
with saline-injected control hearts (see Fig.66). The strongest trend towards an increase in 
vessel density at 10 weeks was seen after prolonged delivery of VEGF (p=0.16 PEG-MMP9s-
VEGF vs. saline-injected heart, p=0.34 PEG-MMP9s vs. saline, p=0.54 VEGF vs. saline). 
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Fig.65. Immunofluorescent staining for vWF was performed to quantify the vascularization area 10 
weeks after MI. No significant differences were seen between treatment groups and saline-injected 
controls. 
Fig.66. Capillary density was assessed by immunofluorescent staining of vWF. 10 weeks after 
experimental myocardial infarction, non-significant increases were observed after treatment with 
PEG-MMP9s, VEGF and PEG-MMP9s-VEGF.  
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8.7.7. Discussion + Conclusion 
In the current study, the potential of sustained VEGF-delivery from enzymatically degradable 
PEG hydrogels for the stimulation of therapeutic angiogenesis in the setting of MI was tested. 
Previous work had shown that PEG hydrogels successfully ameliorate left-ventricular 
remodelling post-MI and that these smart hydrogels can be used to successfully promote 
angiogenesis in vivo. By combining the mechanical support provided by PEG hydrogels with 
the sustained delivery of VEGF to establish a stable vascular network, a synergistic beneficial 
effect on post-MI remodelling and cardiac function was expected. The only positive result 
seen after PEG-MMP9s-VEGF administration, though, was a statistically non-significant 
increase in capillary density 10 weeks after MI. Further, single bolus administration of VEGF 
appeared to be the superior treatment option, as adverse left-ventricular remodelling was 
reduced in comparison with the PEG-MMP9s-VEGF group, a significantly smaller infarct 
volume was observed and cardiac function was better preserved over the course of the 10-
week study. As successful in-vitro release of bioactive VEGF from PEG hydrogels and in vivo 
functionality was previously shown in a collaborative effort with Jeff Hubbell’s laboratory289, 
further experiments to characterize in vivo-release in the heart were not pursued due to their 
technically challenging nature. While insufficiently high VEGF levels may have contributed to 
the negative results of the study, it is impossible to exclude a potential increased pro-
angiogenic effect induced by prolonged VEGF delivery earlier during the study, due to the 
lack of additional time-points to assess neovascularization. Nevertheless, with the current 
protocol, no improvement in long-term neovascularization was seen 10 weeks after MI. As 
the single bolus delivery of VEGF repeatedly outperformed treatment with PEG-MMP9s and 
PEG-MMP9s-VEGF, the suitability of these hydrogels for targeted delivery to the myocardium 
after MI has to be questioned, despite the fact that a detailed comparison between PEG-
MMP9s treatment groups and saline-injected controls up to 10 weeks suggests no adverse 
long-term effects after cardiac injection of enzymatically degradable hydrogels.   
As the continued inflammatory reaction against non-degradable PEG hydrogels limits their 
usefulness as in vivo therapy, future experiments need to identify the ideal crosslinking 
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chemistry (e.g. using multiple different protease-sensitive peptide sequences) that strikes a 
balance between optimal mechanical support and growth factor release for the ischemic 
heart, while ensuring sufficient degradability to prevent prolonged inflammation that 
potentially damages the heart.  
 
9. CONCLUSION 
 
9.1. THERAPEUTIC ANGIOGENESIS 
In recent years enhancing neovascularization in ischemic tissues has emerged as a novel 
therapeutic concept. While many pro-angiogenic factors have been identified, the instability of 
growth factor-induced neovasculature remains a major obstacle that has yet to be overcome. A 
novel in vivo angiogenesis assay was designed as a part of this thesis that allows delivery of 
defined dosages of pro-angiogenic growth factors into a scaffold of well-defined porosity and the 
complete termination thereof, thereby allowing investigations into the stability and mural cell 
investment of newly created vessels. While a number of growth factors tested in this assay 
significantly increased angiogenesis (PlGF, BDNF), VEGF165 emerged as the most potent pro-
angiogenic factor tested. Subsequent experiments revealed that depending on dosage and 
duration of VEGF165 delivery, a single growth factor is sufficient to create a long-term stable 
vasculature for therapeutic angiogenesis. The medium dosage of VEGF165 tested (150ng/day for 
42 days) significantly enhanced neovascularization up to 80 days after termination of VEGF165 
delivery, and this increased vessel stability was shown to correlate with an increase in mural cell 
investiture. With increased incidence as time went on, the continuous delivery of VEGF165 at 10-
fold higher concentrations (1500ng/day) was shown to lead to rapid vascular regression in the 
presence of VEGF as early as 20 days after the initiation of pro-angiogenic therapy. This finding 
was taken advantage of to establish an assay that allows for the identification of underlying 
mechanisms contributing to the regression of VEGF165-induced neovasculature. As early as day 
2 after discontinuation of VEGF165-delivery (at 1500ng/day), perfusion of the newly created 
vessels highly diminished and was followed by neovascular regression. A number of strategies 
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were tested to increase neovessel stability based on previous reports in the literature. Neither 
SDF-1, inhibition of MMPs, nor simultaneous delivery of stabilizing growth factors successfully 
prevented the regression of VEGF165-induced vessels. Finally a gene array was performed to 
identify future targets implicated in the regulation of VEGF165-induced vessel stability revealing 
serpin F1, CXCL2, PEDF, and inhibitors of DNA binding as potential candidates. 
 
9.2. PEG HYDROGELS FOR MI THERAPY 
Smart hydrogels represent a novel class of biomaterials that have been identified as 
promising technologies for in vivo tissue engineering. Previous work has demonstrated that 
feedback-dependent release of therapeutic proteins from bioactive biomaterials can 
successfully promote angiogenesis and enhance tissue regeneration289,496. Collectively, the 
work described in the second part of this thesis presents the first steps to establish PEG 
hydrogel implantation as a novel therapy for myocardial ischemia. Pilot experiments 
confirmed successful PEG hydrogel delivery and retention after permanent left anterior 
descending coronary artery occlusion. As stand-alone therapy, the injection of non-
degradable PEG hydrogels was shown to effectively limit pathological remodelling in the early 
stages after MI. Most likely due to an enhanced inflammation elicited by non-degradable 
hydrogels, though, the injections were unable to prevent long-term left ventricular dilation. 
Subsequently the potential of enzymatically degradable PEG hydrogels for myocardial 
therapy was assessed. Cardiac injections of PEG-MMP1s and PEG-MMP9s hydrogels were 
shown to have no detrimental effects on cardiac function as opposed to non-degradable 
hydrogels. Breakdown of the degradable hydrogels in vivo resulted in a rapid resolution of the 
inflammatory response present after initial hydrogel injection. However, unlike non-
degradable PEG hydrogels, local injections of PEG-MMP1s and PEG-MMP9s into the heart 
did not effectively retard LV remodelling after myocardial infarction. Finally, as the long-term 
goal remains the simultaneous exploitation of mechanical support provided by PEG hydrogels 
and sustained local delivery of therapeutics, the potential of enzymatically degradable PEG 
hydrogels to locally promote long-term neovascularization after MI was tested. According to 
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the successful establishment of a long-term stable vasculature in the subcutaneous in vivo 
assay and previous characterization of PEG-MMP9s degradation, an amount of VEGF 
sufficient to result in the release of 150ng/day was attached to the PEG gel. While the 
outcome of this study was negative, as no significant increase in vascularization was seen 10 
weeks after MI, these experiments confirmed the potential usefulness of enzymatically 
degradable PEG gels for cardiac therapy, as no detrimental effects on cardiac function were 
observed up to 10 weeks after injection.  
 
To fully explore the potential of bioactive PEG hydrogels, future studies will be needed to 
deepen our understanding of the mechanisms that underlie the beneficial effects on cardiac 
remodelling seen after injection of non-degradable PEG hydrogels. The timing of hydrogel 
injection (hours, days, weeks after MI) may for instance be a crucial variable that determines 
the successful outcome of this therapy. Additionally to establish PEG hydrogels as a 
technological platform to promote therapeutic angiogenesis, the ideal crosslinking conditions 
need to be identified to optimize hydrogel degradation and release kinetics of the attached 
biologics. 
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10. MATERIALS & METHODS 
10.1. ANGIOGENESIS 
10.1.1. Porous polyurethane scaffold fabrication 
Porous polyurethane tubes were produced as described earlier 497. Briefly, the interstices in 
an annular column of spherical gelatin beads (150-180µm sieve size), contained between a 
glass tube (3.7x8.0x150mm: IDxODxLength) and a central stainless steel mandrel 
(2.7x175mm), were infiltrated with a polyurethane solution (20% in N-methylpyrrolidone 
(Sigma-Aldrich, Steinheim, Germany) and subsequently demolded.  The polyurethane was 
precipitated by immersion in ethanol (96%, 24h, RT), the porogens extracted by extensive 
washing in deionized water (60 ºC, 5 days), and the resulting structures dried and cut to 
19mm lengths. 
 
Each device (shown in Figure 1) was assembled from a porous PU tube (2.4x3.4x19mm, 
150µm pores with 70µm interconnecting windows), an ePTFE barrier (1.8x2.4x19mm, 
20±4µm internodal distance, (Zeus Inc., Orangeburg, SC, USA) to prevent cell penetration 
into the lumen, a distal PTFE plug (1.2x1.8x3mm), and a polyethylene (PE/4 and PE/8 
(Scientific Commodities Inc., Lak  Havasu City, AZ, USA) feeder tube assembly, tied down 
with 4/0 silk ligatures. 
 
10.1.2. Production of human VEGF165 in E. coli  
The cDNA of human VEGF165 was cloned into the expression plasmid pRSET T7 (Novagen, 
Madison, WI, USA) between restriction sites Nde1 and BamHI. The pRSET-VEGF165 was 
introduced into the E.coli expression host BL21 (DE3) pLysS. Once the transformed bacteria 
had reached an OD600 of 0.8, isopropyl-β-D1-thiogalactopyranoside was added to 1 mM to 
induce protein expression for 3 hrs. The bacterial cells were pelleted, frozen at –20°C and 
then resuspended in a tenth of the original culture volume in 50 mM Tris, PH 7.5, 150 mM 
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NaCl, 5 mM EDTA, followed by incubation with lysozyme at 0.1 mg/ml suspension for 20 min 
at room temperature. Benzonaze (Merck KGA, Darmstadt, Germany) was then added at 50 
units/ml suspension, and incubated overnight at 4°C. Inclusion bodies were then collected by 
centrifugation at 30 000g for 30 min and then washed in 4 M urea, 20 mM Tris, pH 8.0, 150 
mM NaCl, 2 mM EDTA overnight at 4°C. They were then solubilised in 8 M urea, 20 mM Tris, 
pH 8.0, 150 mM NaCl, 10 mM dithiothreitol at 4°C. The supernatant was then dialysed 
sequentially for 24 hrs against 6, 4 and 2 M urea in 20 mM Tris, pH 8.0, 150 mM NaCl, 2mM 
EDTA at 4°C. The monomeric proteins were then dimerized over a period of 48 hrs at 4°C in 
the presence of oxidised and reduced glutathione (Sigma-Aldrich, Steinheim, Germany) at 
0.5 and 5 mM respectively. The dimerized solution was then dialysed against 20 mM Tris, pH 
8.0, 150 mM NaCl, 2mM EDTA at 4°C and passed over a heparin agarose column 
(Applichem, Darmstadt, Germany). The column was washed with 150 mM NaCl, 20 mM Tris 
pH 8.0, and the bound VEGF eluted with 0.75 M NaCl, 20 mM Tris, pH 8.0. The eluted VEGF 
was then dialysed against 150 mM NaCl, 20 mM Tris, pH 8.0. 
 
10.1.3. In vivo angiogenesis assay 
Osmotic pumps (Alzet, Cupertino, CA, USA) with a nominal pump rate of 0.25 µl/hr were filled 
under sterile conditions with the respective growth factor, growth factor combination or PBS. 
The nominal pump rate was used to calculate the dosage per day. After sterilizing the tubular 
polyurethane devices with 70% ethanol (Sigma, Steinheim, Germany), they were flushed with 
10 ml of 99.7% ethanol to make them permeable and subsequently attached to the osmotic 
pump. The whole construct was then put into distilled water and placed into an incubator for 
24 (Alzet 1002 model) or 48 (2004 model) hours at 37oC. Animals were anaesthetized using 
100 µl of a ketamine (64,3 mg/ml) and xylazine (7,14 mg/ml) mix i.m. and 100 µl i.m. of 
buprenorphine (Temgesic®, Schering-Plough LTD, Woodmead, SA). Two 1cm skin incisions 
were made in the dorsal paramedian region of the skin and two tissue pockets were 
dissected bluntly. The entire construct was then placed into the pocket before the skin was 
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closed up using a 4-0 Prolene suture (Ethicon, Johnson&Johnson, Halfway House, SA). 
Pump exchanges and removal were performed under anaesthesia. After pump removal the 
catheter tubing was sealed using a LT 200 liga clip (Ethicon) before the skin incision was 
closed as described above. The rats were sacrificed using carbon dioxide and the devices 
explanted at the end of the study period. For a comprehensive list of the detailed 
experimental protocol see table 6. 
 
TIMELINE for osmotic pump experiments 
Experiment Construct 
implant 
Pump 
change 
Pump 
explant 
Graft explant 
5 0 N/A 5 5 
10 0 N/A 10 10 
10+1 0 N/A 10 11 
10+2 0 N/A 10 12 
10+4 0 N/A 10 14 
10+10 0 N/A 10 20 
10+10 0 10  20 
10+20 0 N/A 10 30 
20 0 N/A 20 20 
30 0 N/A 30 30 
42 0 N/A 42 42 
42+80 0 N/A 42 122 
Day 
 
Table 6. Timetable shows different experimental protocols for the assessment of angiogenesis in the 
neovascularization devices. Time of pump exchange, pump explant and neovascularization device 
harvest was measured from time of subcutaneous implantation (=day 0). 
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The animal study protocol had been approved in writing by the University of Cape Town 
Animal Ethics Committee. All animal studies were performed in accordance with the National 
Health Institute (NIH, Bethesda, MD USA) guidelines. 
 
10.1.4. Vascular perfusion with Lycopersicon esculentum 
Patency and blood flow were assessed in the various implants by perfusion of the vasculature 
with lycopersicon esculentum lectin, which was essentially done as previously described498.  
In brief, prior to explantation of the device, the rat was anaesthetized with a 400µl 
intramuscular injection of ketamine/xylazine. The animal was then placed onto a heating pad, 
a skin incision was made above the groin, the femoral vein was visualised and dissected 
under a Leica MS 5 microscope (Leica, Wetzlar, Germany) and 500 µl of biotinylated l. 
esculentum lectin (1 mg/ml, Vector Laboratories, Burlingame, CA, USA) in 0.9% NaCl were 
injected into the vein. After two minutes of perfusion, the chest was opened and the 
vasculature was perfusion fixated with 250 ml 1% paraformaldehyde (Saarchem, 
Kruegersdorp, South Africa) in PBS at 37°C at 120 mmHg via an 18-gauge cannula inserted 
into the ascending aorta through the left ventricle. The right atrium was incised to allow for the 
exsanguination of the animal while the circulatory system was perfused. The device was 
explanted and placed in zinc fixative (2.8 mM calcium acetate (Merck KGA, Darmstadt, 
Germany), 2.3 mM zinc acetate (Merck KGA, Darmstadt, Germany), 3.7 mM zinc chloride 
(Sigma-Aldrich, Steinheim, Germany) in 0.1 M Tris. HCl pH 6.75 (Sigma-Aldrich, Steinheim, 
Germany)499 for 24 hours.   
 
10.1.5. VEGF Stability 
To determine the stability of VEGF over the maximum period of delivery, VEGF (250 µg/ml 
PBS) was incubated at 37°C for 42 days. The concentration of VEGF remaining after 
incubation was quantified using a human VEGF ELISA (Catalog Number: DY293, R&D, 
Minneapolis, MN, USA) as per manufacturer’s instructions. In order to measure the amount of 
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VEGF in an implanted device, constructs were explanted at days 10 and 42. They were then 
cut in half and rotated at 50 rpm in 2 ml of a protease-inhibitor mix (1µg/ml leupeptin, 25µM 
benzamidine, 1 mM EGTA, 1mM phenylmethylsulfonyl fluoride, 1µg/ml aprotinin in PBS) for 1 
hour @ 4°C and the VEGF content was assayed with a human VEGF ELISA. 
Briefly, after the capture antibody was diluted to the working concentration in PBS, a 96-well 
microplate was immediately coated with 100 µl per well of the diluted antibody. The plate was 
then sealed and incubated overnight. The next morning, each well was aspirated and washed 
three times with 400 µl the freshly made up wash buffer. After the final wash remaining wash 
buffer was removed by inverting the plate and blotting it against a clean paper towel. 300 µl of 
block buffer was added to each well, the plate was sealed and incubated at room temperature 
for 1 hour. Again, each well was aspirated, washed three times with 400µl wash buffer and 
after the third wash the remaining wash buffer was removed by inverting the plate and 
blotting it against a clean paper towel. Subsequently, 100 µl of sample or standard diluted in 
reagent diluent, was added per well, the plate was covered with an adhesive strip and 
incubated for 2 hours at room temperature. Yet again, the wells were aspirated, washed three 
times and remaining buffer removed. After adding 100 µl of the detection antibody, diluted in 
reagent diluent, to each well, the sealed plated was incubated for 2 hours at room 
temperature. The aspiration/wash step was repeated and 100 µl of the working dilution of 
Streptavidin-HRP was added to each well. The plate was covered and incubated for 20 
minutes at room temperature and careful attention was paid to avoid placing the plate in 
direct light. After another aspiration/ wash step, 100 µl of substrate solution were added to 
each well and in a light-protected place, the plate was incubated for 20 minutes at room 
temperature. Next, 50 µl of stop solution (H2SO4) was added to each well and the plate was 
gently tapped to ensure thorough mixing. The optical density of each well was measured 
immediately using a Benchmark® Microplate Reader (Biorad, Japan) set to 450 nm. 
Wavelength correction was set to 540 nm to correct for optical imperfections in the plate. 
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The bioactivity of the incubated VEGF was assessed in an endothelial cell proliferation assay. 
Briefly, human saphenous vein endothelial cells (passage 2) were cultured at 2000 cells/cm2 
in MCDB131 medium (Sigma-Aldrich, Steinheim, Germany), 2% fetal calf serum (Invitrogen, 
Carlsbad USA) and 1 ng/ml VEGF for 2 days. The number of cells was then quantified using 
a Cell Titre Glo assay (Promega, Madison, USA) as per manufacturer’s instructions. The 
number of cells determined for the incubated VEGF was compared to cells cultured in 
MCDB131, 2% FCS plus/minus fresh 1 ng/ml VEGF.  
Briefly, CellTiter-Glo® Buffer and lyophilized CellTiter-Glo® Substrate were allowed to 
equilibrate to room temperature prior to use. To form the CellTiter-Glo® Reagent CellTiter-
Glo® Buffer was added to CellTiter-Glo® Substrate to reconstitute the lyophilized 
enzyme/substrate mixture and vortexed to obtain a homogeneous solution. The cultured 
human saphenous vein endothelial cells were transferred onto opaque-walled multiwell 
plates, covered with 100µl culture medium per well. To obtain a value for background 
luminescence, control wells containing medium without cells were prepared. Plate and its 
contents were allowed to equilibrate to room temperature for approximately 30 minutes 
before adding a volume (100 µl) of CellTiter-Glo® Reagent equal to the volume of cell culture 
medium present in each well. Contents were then mixed for 2 minutes on an orbital shaker to 
induce cell lysis and the plate was allowed to incubate at room temperature for further 10 
minutes to stabilize the signal, before luminescence was recorded. 
 
10.1.6. HISTOLOGY 
10.1.6.1.	  Lectin	  
Sections fixed in 4% paraformaldehyde were dewaxed in xylene. To remove the 
polyurethane, sections were incubated with cyclohexanone (2x 30 min). Sections were 
cleared in alcohol baths, thoroughly washed in H2O and then placed in TBS for 10 minutes. 
Lectin was detected by overnight incubation at 4°C with a 1:3500 dilution of Cy3 conjugated 
streptavidin (Jacksons Immunoresearch, West Grove, PA, USA). 
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The next morning, after a wash in TBS (2x10 min @ RT), sections were counterstained with 
DAPI using Vectashield® mounting medium (Vector Laboratories, Burlingame, CA).   
 
10.1.6.2.	  H&E	  
Histological slides were dewaxed using Xylene or Trimethylpentane (for PU) before the 
sections were cleared in alcohol baths, thoroughly washed in H2O and placed in TBS. The 
sections were then incubated in Haematoxylin for 5 minutes. After a 5 wash in running tap 
water, the slides were placed in Eosin for 30 seconds, dipped in distilled water, dehydrated 
through the alcohols, before being mounted with Entellan (Merck, Darmstadt, Germany). 
 
10.1.6.3.	  CD31	  	  
PU-grafts were fixed in zinc-fixative for 24 hours before being processed through graded 
alcohols and embedded in wax. 5 µm sections were cut onto uncoated slides and incubated 
at 37°C overnight. Sections were then dewaxed using 4 changes of  2,2,4 tri-methylpentane 
and 2 changes of cyclohexanone before being taken through graded alcohol to water. After 
rinsing for 10 min with 0.1% tween in PBS the primary antibody mouse anti-rat from RDI-
RTCD31 (RDI Research Diagnostics Inc., Flanders, NJ) was applied at a 1:50 dilution in 1 % 
BSA in PBS for 40 minutes. Sections were rinsed twice for 10 minutes each with 0.1 % tween 
in PBS prior to using the alkaline phosphatase Biocare Medical kit. Sections were incubated 
with the Rodent body for 30 minutes, followed by two 10-minute washes with TBS. The 
Mouse on Rat alkaline phosphatase polymer was subsequently added for 30 min, followed by 
2 washes with 0.1 % tween in PBS. Finally, sections were incubated with the substrate 
BCIP/NBT DAKO (DAKO, A/S, Glostrup, Denmark) until colour development was complete. 
After a rinse with running tap water, the sections were dehydrated, cleared in 2,2,4 
trimethylpentane, and mounted with Entellan (Merck, Darmstadt, Germany). 
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10.1.6.4.	  CD31/Desmin	  (fluorescent)	  
After fixation in zinc fixative, all samples were processed through graded alcohol and xylene 
(tissue processor), and then embedded in paraffin wax. 3 µm thick cross-sections from the 
mid-region of the device were dewaxed with xylene. To remove the polyurethane, sections 
were incubated with cyclohexanone (2x 30 min). Sections were cleared in alcohol baths, 
thoroughly washed in H2O and then placed in TBS. To reduce background staining, sections 
were incubated with Rodent Block (Biocare Medical) for 1 hour. Pericytes and their 
associated vessels were detected by incubation with a 1:400 dilution of rabbit polyclonal anti-
desmin antibody (Abcam, Cambridge UK) and a 1:25 dilution of mouse anti-rat CD31 primary 
antibody (RDI Research Diagnostics Inc., Flanders, NJ, USA) in 1% bovine serum albumin 
(BSA, Jacksons Immunoresearch, West Grove, PA, USA)/PBS for 2 hours at room 
temperature (RT). Next, sections were incubated with a 1:250 dilution of a biotinylated 
donkey anti-mouse IgG antibody (Rockland, Gilbertsville, PA, USA) for 30 minutes. 
Thereafter, the former was detected by incubating with a 1:3500 dilution of Cy3 conjugated 
streptavidin (Jacksons Immunoresearch, West Grove, PA, USA) and the anti-desmin 
antibody was detected with a 1:50 dilution of an Alexa 488 conjugated goat anti-rabbit IgG 
antibody (Invitrogen, Carlsbad, CA, USA) for 2 hours at RT. After a wash in TBS, sections 
were counterstained with DAPI using Vectashield® mounting medium (Vector Laboratories, 
Burlingame, CA).   
 
10.1.7. Image analysis of immunostained sections for quantitative assaying of 
neovascularization 
CD31-stained samples were loaded into a Nikon Coolscope (Nikon Corp., Tokyo, Japan), and 
an image of the complete cross-section was acquired at a 100x magnification. All of the 
ensuing analysis was performed with Visiopharm Integrated Systems (VIS) (Visiopharm A/S, 
Hørsholm, Denmark). Briefly, the software was trained to automatically detect CD31 positive 
structures; all analyses were assessed by an observer for accuracy and, if necessary, 
manually corrected. Vessel area and cross-sectional tissue ingrowth area of the graft were 
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calculated and the vascular density was obtained by dividing vessel area through cross-
sectional area. The average vessel diameter was calculated from the average vessel area 
with the assumption of vessel circularity.  
 
4 random images were acquired with a Nikon 90i fluorescence microscope (Nikon Corp., 
Tokyo, Japan) at 200 X magnification of each desmin/Cd31 stained cross-section. The 
interface length between desmin positive cells and CD31 positive vessels was calculated for 
those desmin positive cells that had greater than 15% of their circumference in direct contact 
with a vessel using VIS. The total of all interface lengths was divided by the total of all vessel 
circumferences to obtain vessel coverage. 
 
10.1.8. Rat angiogenesis RT2 Profiler PCR Array 
10.1.8.1.	  RNA	  Isolation	  (Preparation	  &	  Quality	  Control)	  
RNA was isolated using a RNeasy® Plus kit from Qiagen (Qiagen N.V., Venlo, The 
Netherlands) as per manufacturer´s instructions. Briefly, a 2,5 mm section of the frozen PU-
graft with approximately 20-30g of tissue was placed in liquid nitrogen, then disrupted and 
homogenized using a pestle and mortar. Careful attention was being paid to not allow the 
sample to thaw by repeatedly adding small amounts of liquid nitrogen. The tissue powder was 
then transferred to an empty 2ml microcentrifuge tube, the remaining liquid nitrogen was 
allowed to evaporate and 600 µl of RLT-buffer was immediately added. After vortexing 
thoroughly, the lysate was pipetted into a QIAshredder spin column placed in a 2ml collection 
tube and centrifuged for 2 minutes at 13200 RPM. The lysate was centrifuged for another 3 
minutes at 13200 RPM before the supernatant was carefully removed by pipetting and 
transferred to a gDNA Eliminator spin column placed in a 2 ml collection tube. After 
centrifugation for 30 seconds at 10600 RPM, the column was discarded and the flow-through 
saved. An equal volume of 70% ethanol was added to the flow-through and mixed well by 
pipetting, before the sample was transferred to an RNeasy spin column placed in a 2ml 
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collection tube. After a 15 second centrifugation at 10600 RPM, the flow-through was 
discarded. Then 700 µl of RW1 Buffer was added to the RNeasy spin column and centrifuged 
for 15 seconds at 10600 RPM to wash the spin column membrane. Again, the flow-through 
was discarded. 500 µl of Buffer RPE was added to the RNeasy spin column and centrifuged 
for 2 minutes at 10600 RPM, thereby washing the spin column membrane, once again. The 
RNeasy spin column was subsequently placed into a new 2 ml collection tube and 
centrifuged at 13200 RPM for 1 minute to eliminate any possible carryover of Buffer RPE. 
After that the RNeasy spin column was transferred into a new 1.5 ml collection tube, 30 µl of 
RNAse-free water was added to the spin column membrane and centrifuged for 1 minute at 
10600 RPM. Since we expected a RNA yield of more than 30 µg, we repeated the last step, 
adding another 30 µl of RNAse-free water to the spin column membrane before centrifuging 
for 1 minute at 10600 RPM. The eluate was then aliquoted, snap frozen and stored at -80°C 
until experiments were carried out. RNA quality control was assessed at the Centre for 
Proteomic and Genomic Research (CPGR) at the University of Cape Town. 
 
10.1.8.2.	  RT2	  First	  Strand	  cDNA	  Synthesis	  
Genomic DNA Elimination mixture was prepared by adding 2.0 µl GE (5x gDNA Elimination 
Buffer) and RNAse free H2O to 0.5 µg of total RNA for a final volume of 10 µl. The contents 
were gently mixed with a pipettor and briefly centrifuged. Samples were then incubated at 
42°C for 5 minutes and immediately thereafter chilled on ice for 1 minute.   
10 µl of RT Cocktail (1 reaction: 4 µl BC3 (5x RT Buffer 3) + 1 µl P2 (Primer & External 
Control Mix) + 2µl RE3 (RT Enzyme Mix 3) + 3 µl RNase free H2O) was added to each 10µl 
Genomic DNA Elimination mixture and mixed well with a pipettor. Samples were then 
incubated at 42°C for exactly 15 minutes, after which the reaction was immediately stopped 
by heating at 95°C for 5 minutes. 91 µl of double distilled water (ddH2O) were subsequently 
added to each 20 µl of cDNA synthesis reaction. The finished First Strand cDNA Synthesis 
Reaction was kept on ice until Real-Time PCR was performed. 
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10.1.8.3.	  Quantitative	  Real-­‐Time	  Polymerase	  Chain	  Reaction	  
The experimental cocktail was prepared by mixing 102 µl of the First Strand cDNA Synthesis 
Reaction, 550 µl of 2x SuperArray RT2 qPCR Master Mix and 448 µl ddH2 for a total volume 
of 1100 µl. Samples were kept on ice. Samples were loaded using an automated liquid 
handling system at the CPGR and quantitative real-time PCR was performed using an ABI 
7900HT. 
 
10.2. MYOCARDIAL INFARCTION 
10.2.1. PEG derivatization 
Vinyl sulfone derivatized polyethylene glycol was prepared by methods similar to those 
employed by Lutolf et al.408.  Briefly, a 5% polyethylene glycol (20kDa, 8-arm, hydroxyl-
terminated: 20PEG-8OH, Shearwater/Nektar) solution in dry dichloromethane (DCM) was 
reacted with 5x molar excess of NaH followed by 50x molar excess of divinyl sulfone (DVS) 
under inert atmosphere for 48hr.  After neutralization of the remaining NaH with glacial acetic 
acid and removal of the precipitated NaOAc salt through centrifugation and vacuum filtration, 
reduction of the volume by rotary evaporation, and precipitation in 10X excess cold diethyl 
ether (DEE), the product was dried (RT, 24hr, reduced pressure).  Purification of the product 
(20PEG-8VS) was achieved through 3x re-precipitation from DCM in DEE and drying. PEG-
[O-(CH2)2-SO2-CHa-CHcisHtrans]8. Yield = 65%. 1H NMR, 400MHz, CDCl3, δH 6.1 (Hcis), 6.4 
(Htrans), 6.8 (Ha).  Complete conversion was shown by the absence of the –CH2-OH peak in 
the 13C spectrum of the derivatized product (62ppm in the unmodified PEG-OH) and a 97% 
conversion calculated from integration of the 1H peaks. 
 
10.2.2. Labelling and formation of non-degradable PEG hydrogels 
40ng of Alexa Fluor 660 C2 maleimide (Invitrogen, Carlsblad, California) was added to 50µl 
of 12mg/ml dithiothrietol (DTT, Sigma-Aldrich, Steinheim, Germany) in phosphate buffered 
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saline (PBS 0.15M, pH=7.4) and reacted for 30 minutes at 37°C. Gels of 10% (m/v) nominal 
concentration were prepared by dissolving 10mg of 20PEG-8VS in 50 µl PBS, and then 
adding 50 µl of the above labelled DTT solution, vortex mixing, immediately aspirating the 
admixture into a syringe, and injecting the contents into the myocardium. 
 
10.2.3. Labelling and formation of MMP-1/MMP-9 degradable PEG hydrogels 
10mg of 20PEG-8VS were dissolved in 50 µl PBS before adding 40ng of Alexa Fluor 660 
C2 maleimide (Invitrogen, Carlsblad, California). After reacting for 30 minutes at 37°C, gels of 
10% (m/v) nominal concentration were prepared by adding 50µl of a peptide crosslinker 
sequence (MMP-1s or MMP9s), sensitive to cleavage by either MMP-1 
(GCREGPQGIWGQERCG; 3.45mg/gel) or MMP-9 (GCREKGPRQITERCG; 3.65mg/gel). 
After mixing, the admixture was immediately aspirated into a syringe, and the contents were 
injected into the myocardium. 
 
10.2.4. Attachment of Growth factors to the PEG hydrogel (PEGylation of VEGF)  
To allow attachment of the respective growth factors, 20kDaPEG-8arm vinylsulfone was 
dissolved in PBS containing recombinant VEGF and incubated at 37°C for 30 minutes. 
Formation of growth factor containing PEG hydrogels was performed using a peptide 
crosslinker sequence sensitive to cleavage by MMP-9 (GCREKGPRQITERCG; 3.65mg/gel), 
as described above. 
 
10.2.5. Induction of myocardial infarction and injection of PEG hydrogels 
Myocardial infarction was produced in male Wistar rats weighing approximately 180-220g as 
previously described249. Briefly, rats were anaesthetized with a 5% isoflurane (Safeline 
Pharmaceuticals (PTY) LTD, Johannesburg, RSA) /oxygen mix, placed on a rodent work 
stand (Braintree Scientific Inc., Braintree, MA, USA) and the vocal cords were visualized 
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using a Welch Allyn LI ION Otoscope equipped with a specially designed and molded, 
autoclavable intubation speculum (Braintree Scientific Inc.). After tracheal intubation with an 
16 G i.v. indwelling cannula (Braun, Melsungen, Germany), the animals were placed on a 
heated Deltaphase® operating board (Braintree Scientific Inc.). During the surgery, animals 
were ventilated at 110 BPM with a small animal ventilator (Harvard apparatus, Holliston, MA, 
USA) and the anaesthesia was maintained with 1,5% isoflurane/oxygen. A 2 cm skin incision 
was made above the 4th intercostal space. With a cotton earbud the pectoral muscles were 
dissected bluntly and the hearts were exposed via left thoracotomy. An eyelid retractor was 
used to retract the ribs and ensured optimal vision of the operating field. Following a 
pericardiotomy, a myocardial infarct was induced by permanently ligating the left anterior 
descending (LAD) artery 2 mm below the left atrial appendix with a 6-0 prolene suture. MI 
was confirmed by ECG, colour change and dyskinesis of the left ventricular wall. After 
successful ligation animals were randomized to either receive 100 µl injections of treatment or 
control. For the sham operation only a thoracotomy and pericardiotomy were performed. Via 
2-3 injections a total of 100µl of treatment/control was delivered to the infarct area within 2 
minutes of coronary artery ligation. 4-0 silk sutures (Ethicon) were used to close ribs, muscle 
layer and the skin. For analgesia, i.m. buprenorphine (Temgesic ®, Schering-Plough LTD, 
Woodmead, RSA) was given during the first 48 hours after surgery. At the end of the study 
period, animals were anaesthetized with a mix of 100 µl Pentobarbitol and 200 µl Heparin 
(1000 I.U. per ml). The abdominal cavity was opened, the tip of the heart visualized, the 
needle was advanced through the diaphragm into the left ventricle and the animals were 
sacrificed by injecting 500 µl saturated KCl (Sigma-Aldrich, Steinheim, Germany), thereby 
arresting the heart in diastole. 
 
The animal study protocol had been approved in writing by the University of Cape Town 
Animal Ethics Committee. All animal studies were performed in accordance with the National 
Institutes of Health (NIH, Bethesda, MD USA) guidelines. 
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10.2.6. Echocardiography 
A 5%isoflurane/oxygen mix was used for the induction of the anaesthesia. The rats were 
placed on a Deltaphase® operating board in a left lateral decubitus position. Anaesthesia was 
maintained with mixture of 1,5% isoflurane/oxygen. Images acquired with a Siemens Acuson 
Sequoia 512 Ultrasound system and a 15L8 transducer  (both Siemens, Berlin, Germany) 
were analysed at the time of acquisition. Short-axis 2D and m-mode measurements of the left 
ventricular diameters were taken at the level of the papillary muscle and all measurements 
were averaged over 3 consecutive cardiac cycles. 
Left ventricular fractional shortening (in percent) was calculated as following: (EDD-
ESD)/EDD * 100, where EDD is end-diastolic diameter and ESD end-systolic diameter. 
Depending on the experimental protocol, echocardiography was performed at 7, 14, 28 days, 
10 weeks and 3 months after experimental myocardial infarction by an examiner blinded to 
the treatment groups. 
 
10.2.7. Infarct size measurement 
Explanted hearts were flushed with 10 ml 1% paraformaldehyde, fixed in 4% 
paraformaldehyde (Sigma-Aldrich) for 24 hours, cut into 4 equally sized parts and embedded 
in paraffin. After obtaining a 3µm section, the 4 parts were trimmed and a second 3µm 
section was cut 250 µm deeper. All 8 sections were stained with Masson´s Trichrome stain, 
and then captured using a Nikon E1000M (Nikon, Tokyo, Japan) with a 0,5x magnification 
lens. The infarct size derived from midline length measurements was calculated by dividing 
the sum of midline infarct lengths, acquired with Visiopharm Integrator Systems (Visiopharm, 
Hørsholm, Denmark), from all sections by the sum of midline circumferences from all sections 
and multiplying by 100, as previously described500. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 169 
10.2.8. Scar Thickness 
Scar thickness measurements were taken in 1 mm intervals from all 8 Masson’s Trichrome 
sections. The measurements were then added and divided by the number of measurements 
taken for every single sample to calculate the average thickness of the scar. For sham-
operated animals, the thickness of the wall was measured in the corresponding region and 
quantified in similar fashion. 
 
10.2.9. HISTOLOGY 
10.2.9.1.	  PEG-­‐Alexa	  fluor	  660	  detection	  
3 µm myocardial tissue sections were dewaxed, hydrated and mounted ith DAPI. Stitched 
images were acquired with a Nikon 90i fluorescence microscope. 
	  
10.2.9.2.	  Modified	  Masson’s	  Trichrome	  stain	  
After fixation in 4% paraformaldehyde (Sigma-Aldrich, Steinheim, Germany), all samples 
were processed through graded alcohol and then embedded in paraffin wax.  
3 µm tissue sections were heat fixed on a hotplate at 60°C, dewaxed with xylene and taken 
through alcohol followed by a wash in running tap water.  The sections were then flooded with 
0.5% acid fuchsin (5 min) (Merck, Gauteng, South Africa), followed by 1% phosphomolybdic 
acid (5 min) (Sigma-Aldrich, Steinheim, Germany) to remove excess acid fuchsin. A 2% light 
green (2 min) (Sigma-Aldrich, Steinheim, Germany) solution was used as a counter-stain.  
 
10.2.9.3.	  ED1	  (anti-­‐rat	  cd68)	  	  
3 µm myocardial tissue sections were dewaxed, hydrated and pre-treated with a ready to use 
proteinase k solution (Dako, California, USA) for 10 minutes. After washing in TBS for 5 
minutes, sections were blocked with 1% bovine serum albumin/or rodent block (BSA, 
Jacksons Immunoresearch, West Grove, PA, USA) for 20 minutes and then incubated with a 
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1:100 dilution of mouse anti rat ED1/CD68 primary antibody (Serotec, Kidlington, Oxford, UK) 
in 1% BSA in PBS for 1 hour. Sections were again washed in TBS for 5 minutes and 
subsequently the primary antibody was detected by incubating with a 1:1000 (1:500 after 
freezing with glycerol) of a CY3 donkey anti-mouse IgG antibody (Jackson Immuno Research 
Lab, West Grove, USA) for 1-2 hours. During the incubation period with the secondary 
antibody and the following 5-minute wash in TBS, slides were kept in the dark. Slides were 
finally counterstained and mounted with DAPI (Vector laboratories, Burlingame, CA) and the 
coverslip was sealed with nail polish. Images were acquired with a Nikon 90i fluorescence 
microscope (Nikon Corp., Tokyo, Japan) 
 
10.2.9.4.	  Von	  Willebrand	  Factor	  
Cross-sections were dewaxed in xylene (3x), cleared in alcohol (3x) and washed with H2O. 
After a 20 minute incubation step (at 37°C) with proteinase K (Dako, Glostrup, Denmark), 
sections were washed with H2O and placed in TBS. Next, slides were incubated with 10% 
goat serum for 15 minutes at RT, before being incubated with a 1:400 dilution of primary 
rabbit anti-rat von Willebrand factor antibody (ab6994, ABCAM, Cambridge, UK) in 1 % BSA 
in PBS overnight at 4°C. The next morning, sections were washed in TBS, and the primary 
antibody was detected by a 2 hour 30 minute incubation with a 1:500 dilution of Cy3 donkey 
anti-rabbit antibody (Jacksons Immunoresearch, West Grove, PA, USA). After a wash in TBS 
(in the dark), sections were counterstained with DAPI (Vectashield® mounting medium, 
Vector Laboratories, Burlingame, CA). 
10.2.9.4.1.	  Quantification	  of	  vascularisation	  area	  and	  vessel	  density	  in	  infarcted	  hearts	  
4 random images were acquired with a Nikon 90i fluorescence microscope (Nikon Corp., Tokyo, 
Japan) at 80x magnification within clearly infarcted regions on the vWF stained cross-sections. 
The images were analysed with Visiopharm Integrated Systems (VIS) (Visiopharm A/S, 
Hørsholm, Denmark). Briefly, the software was trained to recognise vWF+-structures after pre-
processing steps that had enhanced the contrast of these structures relative to the surrounding 
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tissue. Vascularisation area was calculated as a percentage of the cardiac tissue present in the 4 
images. Similarly vessel density was calculated as the number of vessels per mm2 of infarcted 
cardiac tissue cross-section. 
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